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The hypoxia inducible factors (HIF1α, HIF2α, HIF1β) promote transcription of 
genes that regulate glycolysis and cell survival and growth. Sprouty2 (Spry2) is a 
modulator of receptor tyrosine kinase signaling and inhibits cell proliferation via different 
mechanisms. Because of the seemingly opposite actions of the HIF and Spry2 on cellular 
processes, we hypothesized that Spry2 decreases the protein levels of HIF1α, HIF2α and 
HIF1β by recruiting an ubiquitin ligase in the proximity of the HIF subunits resulting in 
their ubiquitylation and degradation. Focusing on HIF1α as a prototypical alpha subunit, 
in a variety of tumor derived cell lines, Spry2 decreases the protein levels of HIF1α. We 
showed that this decrease is caused by Spry2 increasing the ubiquitylation and 
proteosomal degradation of HIF1α by enhancing the amount of pVHL bound to HIF1α. 
Spry2 also decreases in the mRNA levels of the HIF1α-regulated genes (e.g. glycolysis). 
Along the same lines, we demonstrated Spry2 decreases the HIF1α-sensitive glucose 
uptake in cells.  
 Spry2 also reduces the protein levels of HIF1β or Aryl Hydrocarbon Receptor 
Nuclear Translocator (ARNT) by enhancing proteosomal degradation of ARNT. Spry2 
also associates with ARNT. We showed that Nedd4-1, an ubiquitin ligase, regulates 
ARNT and participates in the ability of Spry2 to regulate the protein levels of ARNT. As 
a functional readout, we demonstrate that Spry2 reduces the mRNA levels of the 
ARNT/Aryl hydrocarbon receptor (AhR) regulated gene cytochrome P450 1A1 
(CYP1A1), which regulates metabolism of environmental toxins. Together, these data 
v 
suggest that Spry2 via Nedd4-1 enhances the proteosomal degradation of ARNT 
decreasing the mRNA levels of ARNT/AhR regulated genes. 
Overall, my dissertation work has unveiled a novel paradigm by which Spry2 
enhances the degradation of proteins that regulate gene transcription by associating with 
the target protein and E3 ligase that ubiquitylates the target protein. Also, we have shown 
a new role for Spry2 in modulating biological processes regulated by these transcription 
factors, such as glucose uptake and expression of xenobiotic metabolism gene. These 
novel mechanisms could contribute towards the tumor suppressive actions of Spry2. My 
studies concerning regulation of CYP1A1 by Spry2 also has major implications in drug 
metabolism and toxicology. 
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 Sprouty proteins were first discovered in drosophila from a genetic screen that 
revealed excess tracheal branching in drosophila embryos (1). The identity of the missing 
gene in these embryos led to it being designated as Sprouty (Spry) because of the 
increased “sprouting” of the tracheal branching (1). Since tracheal branching is under the 
control of fibroblast growth factor receptor (FGFR) signaling, Spry was implicated as an 
inhibitor of FGFR and later the signaling of other receptor tyrosine kinases (RTKs), such 
as the epidermal growth factor receptor (EGFR) (1,2). In mammals, four Spry (Spry1-
Spry4) isoforms have been identified that are all transcribed from different genes (1,3). 
Of the Spry isoforms, Spry2 is ubiquitously expressed, most studied, and the focus of this 
dissertation. In general, Spry2 also inhibits RTK signaling, with the exception of 
epidermal growth factor receptor (EGFR), via sequestering Grb2 or Raf and inhibiting 
extracellular regulated kinases (ERK) activation or by enhancing the levels and activity 
of phosphatase and tensin homolog (PTEN) to inhibit AKT activation (4-10).  
It is now well known that RTK signaling is prevalent in development and 
tumorigenesis. Due to the ability of Spry2 to regulate RTK signaling, the impact of Spry2 
in development and tumorigenesis has been investigated. Specifically, Spry2 has been 
shown to regulate tracheal/lung, limb, and craniofacial development, as well as 
angiogenesis (1,11-13). Additionally, Spry2 levels are lost or decreased in cancers of the 
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liver, lung, breast, and prostate, which are correlated to poor patient prognosis 
implicating Spry2 as a tumor suppressor (14-21). 
 During development and tumorigenesis, a hypoxic environment can form when 
cells proliferate more rapidly than new vessels can be formed by angiogenesis (reviewed 
in (22)). Cells adapt to hypoxia via the upregulation of the transcription factors the 
hypoxia inducible factors (HIFs) (23-28). HIFs are composed of an oxygen-regulated 
alpha subunit (HIF1α & HIF2α) and a beta subunit (HIF1β), which is also referred to as 
aryl hydrocarbon receptor nuclear translocator (ARNT). In normoxia, the alpha subunits 
are hydroxylated by prolyl hydroxylase domain proteins (PHDs) (29,30). The hydroxy-
prolyl residues provide a binding site for von Hippel-Lindau protein (pVHL) and 
associated E3 ubiquitin ligase, resulting in the ubiquitylation and proteosomal 
degradation of HIF1α and HIF2α in normoxia (31-34). In hypoxia, because of decreased 
oxygen levels, PHD-mediated prolyl hydroxylation is attenuated, but not entirely 
inhibited, allowing for the alpha subunits to become stabilized and translocate into the 
nucleus. The alpha subunit, as a heterodimer with ARNT, binds to hypoxia response 
elements (HREs) located on the promoter of a variety of genes. HIFs have been shown to 
regulate genes involved in angiogenesis, proliferation, metabolism, and drug resistance 
(reviewed in (35-37)). Due to the fact many of these processes are needed to promote 
tumorigenesis and because elevated HIF1α levels have been correlated to poor patient 
prognosis, HIFs are implicated as tumor promoters (reviewed in (22,38,39)). 
 While ARNT functions as the dimerization partner for HIFα, ARNT also 
dimerizes with other transcription factors such as Aryl Hydrocarbon Receptor (AhR) 
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(40), estrogen receptor α (ERα) and ERβ (41,42), SIM1 (43,44), and SRC-1 (45,46) to 
regulate a large variety of genes. In fact, the first dimerization partner identified for 
ARNT was AhR (40). AhR resides primarily in the cytoplasm and upon ligand binding 
translocates to the nucleus where it will bind ARNT (47-51). The heterodimer then binds 
to xenobiotic response elements located in the promoter of a variety of genes such as 
those involved in Phase I and Phase II drug metabolism (51,52). Although the regulation 
of the dimerization partners for ARNT has been well studied, the regulation of ARNT has 
been sorely understudied. Along the same lines, AhR, HIF1α, and HIF2α have been 
implicated as tumor promoters, but the somewhat limited previous research on ARNT 
suggests ARNT has a tumor-promoting role in the early stages of tumor growth and a 
tumor-suppressing role in the late stages (53-58). 
Main Hypothesis 
 The working hypothesis proposed for this dissertation is: In hypoxia, Spry2 
enhances the degradation of HIF1α, HIF2α and ARNT protein levels via increasing the 
ubiquitylation of these protein by ubiquitin ligases, thereby decreasing transcription of 
their target genes. For clarity, the specific aims and chapters in this dissertation are 
separated as they relate to HIF1α/2α and ARNT. To test the aforementioned hypothesis, 
the following specific aims were investigated: 
HIF1α and HIF2α 
Specific Aim 1: To determine whether Spry2 regulates the protein levels of HIF1α and 
HIF2α, as well as the transcript levels of HIF1α/HIF2α target genes. 
The following experiments were performed to investigate Aim 1. 
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A) Using Western blot analyses, changes in HIF1α and HIF2α protein levels were 
monitored when Spry2 expression was silenced with siRNA in human hepatoma 
cell line HuH7. Using HIF1α, as the prototype of the HIFα’s, the ability of 
endogenous Spry2 to regulate HIF1α protein levels were also monitored in a 
variety of cancer cell lines: human hepatoma, Hep3B; human lung cancer, A549; 
human breast cancer, MCF7 and MBA-MD-231; human cervical cancer, HeLa, 
and HEK293T. 
B) Using quantitative Real Time PCR, changes in the mRNA levels of the HIF1α-
regulated genes phosphoglycerate kinase 1 (PGK1) and glucose transporter 1 
(Glut1) and HIF2α-regulated gene Erythropoietin (EPO) were monitored with and 
without silencing of endogenous Spry2. 
C) The functional impact of Spry2-mediated regulation of HIF1α levels was 
investigated by monitoring HIF1α-sensitive glucose uptake. 
Specific Aim 2: To elucidate the mechanism by which Spry2 regulates HIF1α protein 
levels. 
The following experiments were performed to investigate Aim 2. 
A) The ability of Spry2 to regulate HIF1α protein stability was determined by 
inhibiting protein translation with cycloheximide and measuring the half-life of 
HIF1α with and without silencing of Spry2 expression. It was also determined if 
the proteosomal inhibitor Bortezomib abrogated the ability of Spry2 to regulate 
HIF1α protein levels.  
B) It was determined whether endogenous Spry2 regulated ubiquitylation of HIF1α. 
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C) The presence of Spry2 and HIF1α in the same protein complex was determined 
using coimmunoprecipitation, co-localization and proximity ligation assay.  
D) By utilizing siRNAs and a mutant form of Sprouty2, the ubiquitin ligase involved 
in Spry2-mediated regulation of HIF1α was determined to be pVHL.  
ARNT 
Specific Aim 1: To determine whether Spry2 regulates the protein levels of ARNT, as 
well as the transcript levels of target genes regulated by these proteins. 
The following experiments were performed to investigate Aim 1. 
A) Using Western blot analyses, changes in ARNT protein levels were monitored 
when Spry2 expression was silenced with siRNA in variety of cancer cell lines: 
human hepatoma, HuH7 and Hep3B; human lung cancer, A549; human breast 
cancer, MCF7 and MBA-MD-231; and HEK293T. 
B) Using quantitative Real Time PCR, changes in the mRNA levels of the 
ARNT/AhR-regulated gene cytochrome p450 1A1 (CYP1A1) were monitored. 
Specific Aim 2: To elucidate the mechanism by which Spry2 regulates ARNT protein 
levels. 
The following experiments were performed to investigate Aim 2. 
A) The ability of Spry2 to regulate ARNT protein stability was determined by 
inhibiting protein translation with cycloheximide and measuring the half-life of 
ARNT with and without the silencing of Spry2 expression. It was also determined 
if the proteosomal inhibitor MG132 abrogated the ability of Spry2 to regulate 
ARNT protein levels. 
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B) The presence of Spry2 and ARNT in the same protein complex was determined 
using coimmunoprecipitation. 
C) The ubiquitin ligase involved in Spry2-mediated regulation of ARNT was 
investigated by silencing pVHL, c-Cbl, and Nedd4-1 with siRNAs. 
 
Outcomes and Significance 
Our studies unveiled a novel mechanism by which Spry2 enhances the 
degradation of HIF1α and HIF2α protein levels in a pVHL-dependent manner. 
Furthermore, HIF1α- and HIF2α- regulated genes were enhanced when the expression of 
endogenous Spry2 was silenced implying that when Spry2 levels are lost or decreased in 
cancers, then HIF1α and HIF2α proteins levels and the transcription of the genes they 
regulate would be elevated. Aside from RTK inhibition, this would provide another 
mechanism by which Spry2 functions as a tumor suppressor. We also for the first time 
demonstrate that the expression of Spry2 reduces HIF1α-sensitive glucose uptake 
implicating Spry2 as a regulator of glycolysis.  
As stated earlier, previous research on ARNT regulation is lacking. Therefore, the 
enhanced proteosomal degradation of ARNT by Spry2 is one of the few mechanisms 
demonstrated to regulate ARNT levels. To date, no known ubiquitin ligase for ARNT has 
been identified. In this study, we, for the first time, demonstrate that the ubiquitin ligase 
Nedd4-1 regulates ARNT protein levels, since silencing Nedd4-1 elevates ARNT protein 
levels. Because ARNT is capable of dimerizing with many transcription factors, the 
impact of this regulation can be quite extensive. For instance, in this study the mRNA 
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levels of the metabolic enzyme CYP1A1 were elevated by Spry2 silencing implying 
Spry2 may have an impact on drug metabolism. Overall, the studies in this dissertation 
establish the novel regulation of HIF1α, HIF2α and ARNT by Spry2, which would, at the 







Receptor Tyrosine Kinases 
 One of the key ways environmental information is transmitted into cells is 
through Receptor Tyrosine Kinases (RTKs). RTK are composed of an extracellular 
ligand binding region, a single transmembrane domain, and cytoplasmic protein tyrosine 
kinase domains (reviewed in (59)). Growth factors such as fibroblast growth factor 
(FGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), etc. bind 
to the extracellular ligand-binding region of a receptor that is already dimerized or causes 
the receptor to dimerize, resulting in a receptor conformational change that activates the 
cytoplasmic tyrosine kinase domain (59,60). The kinase domain of one receptor 
monomer in the dimer phosphorylates tyrosine residues on the cytoplasmic tail of the 
other monomer in the complex (59). This process, referred to as autophosphorylation, 
further changes receptor conformation to fully activate the receptor. The phosphorylated 
tyrosine residues provide loci for SRC homology-2 (SH2) or phosphotyrosine-binding 
(PTB) domains to bind to the receptor and initiate downstream signaling processes that 
ultimately culminate in variety of changes to cellular processes (61-63). For example, the 
SH2 domains of Grb2 bind to phosphorylated tyrosine residues on EGFR. The SH3 
domains of Grb2 permit its association with the Ras GTP/GDP exchange factor son of 
sevenless (SOS), which is brought in proximity of Ras resulting in Ras activation (64). 
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Ras then stimulates the mitogen activated protein kinase (MAPK) cascade resulting in 
enhanced cell proliferation, survival, and migration (Fig. 1).  
Another example of a signaling pathway that RTKs can initiate is AKT activation. 
Previous research demonstrated that phosphatidylinositol-3 kinase (PI3K) can complex 
with the tyrosine phosphorylated RTK and become activated in three different ways. 
First, PI3K can directly bind to the phosphorylated RTK via the regulatory p85 subunit 
and the phospho-YXXM motif on the RTK resulting in the activation of the catalytic 
subunit of PI3K, p110 (65). Second, the p85 subunit of PI3K can bind to GAB, the 
scaffolding protein for GRB2, which is bound to the phosphorylated RTK (62). Third, 
independent of p85 activation, activated Ras can activate the p110 subunit of PI3K (66). 
Any of these mechanisms result in the activation of PI3K, which can then phosphorylate 
phosphatidylinositol-3,4,-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-
trisphosphate (PIP3). PIP3 can bind to proteins containing pleckstrin homology (PH) 
domains such as phosphoinositide-dependent kinase 1 (PDK1) and AKT. Upon binding 
PIP3, PDK1 becomes activated and phosphorylates AKT on T308 initiating AKT 
activation (reviewed in (67)). AKT is fully activated after phosphorylation on S473 by 
mammalian target of rapamycin 2 (mTORC2). The active AKT phosphorylates its 
downstream targets resulting in enhanced cell proliferation, survival, and migration (68) 
(Fig. 1). 
RTK signaling is attenuated by a variety of negative feedback mechanisms. One 




Figure 1: Simplified schematic of two RTK signaling pathways. 
RTKs are activated when a growth factor binds to the extracellular region of the 
receptor. This induces the receptor to trans-phosphorylate the monomers on tyrosine 
residues thereby providing docking sites for downstream signaling molecules such as 
Grb2 and PI3K resulting in the activation of ERK1/2 and AKT. Both of these signaling 
pathways, via multiple mechanisms, promote cell proliferation, survival, and migration. 
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(PTP) that dephosphorylate RTKs removing the docking site for downstream signaling 
proteins (69) (Fig. 2A). On the other hand, receptor activated kinases can also attenuate 
RTK activity by phosphorylating residues that result in receptor inhibition (59,70) (Fig. 
2B). Along the same lines, RTK signaling can be attenuated through disrupting the 
MAPK cascade protein-protein interactions through phosphorylation or sequestration of 
signaling components (71,72) (Fig. 2B). The signal from an active RTK can be 
terminated via internalization of the receptor followed by lysosomal degradation (73,74) 
(Fig. 2C). Initially, it was believed that internalization of RTKs would terminate their 
signaling, but several studies have since shown that RTKs can continue to signal at 
endosomes (reviewed in (75-77)). Finally, a slower negative feedback mechanism occurs 
through the enhanced transcription of RTK negative regulators (78) (Fig. 2D). One such 
negative regulator of RTK signaling that this dissertation focuses on is Sprouty2. 
Sprouty2 is the most well studied among its family members and disrupts RTK signaling 
via sequestration of signaling components as discussed later.  
While all RTKs share commonalities in the molecular mechanisms for activation 
and inhibition, the details of each mechanism of activation and inhibition for a specific 
RTK is markedly different. Understanding RTK signaling pathways and mechanisms of 
inhibition is underscored by the fact RTKs are involved in critical processes, such as 
normal growth, development and reparative processes (79,80). Furthermore, any genetic 
changes or alteration of abundance, activity, or distribution of RTKs results in a variety 
of pathologies including cancer, cardiovascular disease, and developmental disorders. 






Figure 2: RTK negative feedback mechanisms.  
A) PTPs dephosphorylate RTKs removing the docking site for downstream signaling 
proteins. B) Kinases phosphorylate RTKs on inhibitory sites. MAPK phosphorylate 
proteins upstream disrupting the interactions between the signaling components. C) 
RTK is internalized and degraded by the lysosome terminating the signal. D) Enhanced 




Sprouty Discovery, Isoforms and Expression 
Sprouty (Spry) was first discovered in a drosophila genetic screen to understand 
the molecular basis of organogenesis. Spry was given its name due to mutations in the 
dSpry gene resulting in excessive branching or “sprouting” of the drosophila trachea. It 
was found that dSpry gene encoded for a novel inhibitor of the RTK, fibroblast growth 
factor receptor (FGFR) (1). Along the same lines, others investigated if dSpry could 
inhibit other RTKs. When dSpry is overexpressed in drosophila tissues in which 
epidermal growth factor receptor (EGFR) is required for patterning, such as wing veins 
and ovarian follicle cells, the phenotype in these tissues resembles the EGFR loss of 
function phenotype suggesting dSpry can also inhibit EGFR (2). The fact that dSpry 
could inhibit both FGFR and EGFR led to the hypothesis that dSpry was acting on a 
downstream signaling point common to both receptors rather than directly binding to the 
receptor or blocking the binding of the ligand since both receptors were divergent in their 
extracellular similarities (2). This hypothesis was supported by the work done by Casci, 
T., et al. whereby they showed that dSpry associates with the inner cell membrane and 
binds to two components of the Ras pathway, Drk and Gap1 (84). Also, Reich, A. et al. 
observed dSpry can inhibit both FGF and EGF signaling; however, the authors 
hypothesized that dSpry would be acting at the level of Raf or downstream of it (85). 
This controversy about the site at which Spry proteins act in RTK signaling pathway 
carries over into the mammalian Spry as discussed later. Overall, this work suggested that 
dSpry2 could be a widespread inhibitor of RTK signaling.  
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 The role of dSpry as an RTK inhibitor is evolutionary conserved in the 
mammalian homologues. Four mammalian Spry isoforms have since been identified 
Spry1-Spry4 due to their sequence similarity to dSpry. Three homologs (Spry1, Spry2, 
Spry3) were identified by searching the human Expressed Sequence Tag database (1) and 
the fourth homolog, Spry4, was identified by searching the Expression Sequence Tag 
database from GenBank for murine Spry homologues (3). The four human isoforms are 
transcribed from four different genes located on chromosomes 4q28.1 (Spry1), 13q31.1 
(Spry2), Xq28/Yq12 (Spry3), and 5q31.3 (Spry4). All of the mammalian Spry protein 
homologs are shorter than dSpry, but contain a conserved cysteine rich C-terminus that is 
similar to dSpry; however, their N-terminus is more variable (25-37% identity match) (1). 
Figure 3 shows a schematic of the domains and motifs on Spry2, as a prototype of the 
Spry proteins. 
In order to maintain tight regulation on signaling pathways, often the activation of 
a particular pathway results in the expression or activation of the inhibitor of that 
pathway. Spry is an example of this principle. During development, Spry isoforms are 
found localized to “centers of FGF signaling” leading to the discovery that growth factors 
regulate the expression of Spry isoforms (3,13,86-88). Specifically, it has been shown 
that expression of Spry2 and Spry4 can be induced by EGF, FGF, and PDGF, as well as, 
ERK activation (7,12,89,90). Ding et al. analyzed the Spry2 promoter for other 
transcription factor sites and found the cis-acting elements AP2, CREB, SP1, and Ets-1 
were located in the proximal promoter of Spry2. The binding of these transcription 
factors was confirmed using an electrophorectic mobility shift assay (91). In adults, 





Figure 3: Schematic of domains and motifs on Spry2.  
Spry2 is a 315 amino acid protein with a cysteine rich and PxxPxR domain containing C-
terminus. The N-terminus contains the Cbl Tyrosine Kinase binding motif that binds to 
the ubiquitin ligase c-Cbl and the Serine-Rich motif that contains the two serines that can 
be phosphorylated by Mnk1 as discussed later. 
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level. Expression levels of mRNA for each Spry isoform can be found at the following 
websites: www.biogps.org, www.gtexportal.org, and cgap.nci.nih.gov. In terms of protein 
levels, Spry1, Spry2, and Spry4 are ubiquitously expressed, while Spry3 expression is 
restricted to the brain and testis. My studies utilize Spry2 as the prototypic protein in this 
family and, therefore, the remainder of this section will focus on Spry2. 
Regulation of Spry2 activity: Interacting Partners and Post Translational 
Modifications 
 Early on, it was observed that dSpry proteins were localized to the plasma 
membrane, and the cysteine rich C-terminus of dSpry2 was necessary for this 
translocation (1,84). The conservation of this cysteine rich C-terminus among all the Spry 
isoforms led to the hypothesis that upon growth factor stimulation Spry2 becomes 
localized to the plasma membrane where it would exert its inhibitory effects. Indeed, in a 
variety of cell lines, the cysteine rich C-terminus of Spry2 was required for Spry2 to 
translocate from the microtubules to the plasma membrane ruffles upon growth factor 
stimulation, and mutation or deletion of this region abrogates the ability of Spry2 to 
translocate to the membrane and inhibit RTK signaling (92-95).  
Three different mechanisms of translocation of Spry2 have been postulated. First, 
since Spry2 is capable of binding to phosphatidylinositol 4,5-bisphosphate PIP2 via its C-
terminus, it has been suggested that the interaction of Spry2 and PIP2 is responsible for 
Spry2 localizating to the plasma membrane (94). Second, in human umbilical endothelial 
cells (HUVECs), the C-terminus of Spry2 undergoes palmitoylation, which may play a 
role in membrane localization (12). However, whether the palmitoylation of Spry2 is 
altered with growth factor treatment was not investigated. The final possible mechanism 
17 
 
is that Spry2 translocates to the plasma membrane after serine phosphorylation and 
associates with caveolin-1 (12). Interestingly, in this study the authors showed that the 
association of Spry2 and caveolin-1 was not altered by growth factor stimulation, and 
Spry2 was capable of inhibiting ERK1/2 phosphorylation independent of caveolin-1 
while other Spry isoforms were not (96). Overall, the precise mechanism by which Spry2 
translocates to the plasma membrane may vary depending on the cell type, growth factor 
type and may even vary for the other Spry isoforms. 
Once at the plasma membrane, Spry2 inhibits RTK signaling by associating with 
RTK adaptor proteins, such as Grb2 or Raf, thereby sequestering them away from the 
signaling complex (Fig. 4). However, the precise adaptor protein Spry2 associates with to 
modulate RTK signaling has been controversial. As stated earlier, dSpry2 was shown to 
inhibit a point at or above Ras/Raf1 activation and could bind Drk, which is homologous 
to mammalian Grb2 and Gap1, a Ras GTPase-activating protein (84). However, three 
early studies demonstrated that Spry2 and Spry4 bind to Raf1 (4-6) (Fig. 4). One recent 
study also showed Spry2 associates with Raf1, but instead of inhibiting Raf1 kinase 
activity Spry2 acts as a scaffold to aid in association of regulators with Raf1 (97). On the 
other hand, Gross et al. were not able to observe an interaction between Spry2 and Raf1 
(7).  
Instead, in agreement with the study investigating dSpry2 (84), Gross et al. and 
others have shown that Spry2 can associate with Grb2 (Fig. 4) and the association is 
enhanced with growth factor stimulation that increases the phosphorylation of Spry2 on 
Tyr55, which is required for Spry2 to inhibit FGFR signaling (discussed later) (4,7-9). 





Figure 4: Points where Spry2 inhibits RTK signaling. 
Spry2 inhibits RTK signaling by binding to and sequestering away either Grb2 or Raf 
preventing ERK activation. Alternatively, Spry2 can inhibit the activation of AKT by 
RTKs by increasing the levels and activity of the phosphatase, PTEN. Either method of 
inhibition results in decreased cell proliferation, survival, and migration. 
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Spry2 (59-64 and 303-307) (9). While this interaction is constitutive, growth factor 
signaling enhances the interaction of Grb2 and Spry2 (9). One possible mechanism for 
Spry2 inhibition of Grb2 is that upon growth factor stimulation a cryptic PxxPxR motif 
(proline rich motif 303-307) is exposed in the C-terminus of Spry2, which then binds to 
N-terminal SH3 domain of Grb2 thereby preventing Grb2 from associating with SOS (8). 
Kinases Implicated in the Regulation and Function of Spry2 
Using electron capture dissociation, 15 phosphorylation sites were identified on 
Spry2, however only the function of four has been determined. A recent study identified 
the serine/threonine kinase, casein kinase 1 (CK1) as being a key regulator of the ability 
of Spry2 to interact with Grb2. The authors showed that CK1 binds to Spry2 in a 
phosphorylation-dependent manner, but the residue that is phosphorylated on Spry2 was 
not identified. Additionally, phosphorylation of Spry2 by CK1 makes Spry2 a more 
potent inhibitor of FGFR signaling by enhancing the ability of Spry2 to interact with 
Grb2. Since both CK1 and PP2A (discussed later) activate Spry2 through 
phosphorylation and dephosphorylation respectively, the authors proposed that CK1 
functions in concert with PP2A to achieve a balance of posttranslational modifications on 
Spry2 to activate it (98). 
In addition to CK1, other kinases have been shown to interact with or regulate 
Spry2. It was observed that Spry2 migrates as multiple bands on SDS-polyacrylamide 
gels. While one of the bands may be due to palmitoylation, studies by Impagnatiello et al. 
demonstrated that treatment of cell lysates with phosphatases caused the slower migrating 
Spry bands to disappear providing evidence of Spry2 phosphorylation (12). Initially, Tyr 
55 on Spry2 as a site of phosphorylation by Src family kinases in response to growth 
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factors (95,99,100). Intriguingly, Tyr 55 is conserved in other Spry isoforms, suggesting 
it has a critical role in Spry regulation. Furthermore, phosphorylation of Tyr 55 is 
necessary for Spry2 to inhibit FGFR signaling (90,95,100). Substitution of Tyr55 with 
Phe or Ala generates a dominant negative form of Spry2, however, the precise 
mechanism by which Spry2 Y55F (or Y55A) acts as a dominant negative is not clear 
(90,95,100). In a review, Mason et al. proposed that the dominant negative acts by 
mislocalization, sequestration of the wild type Spry2 or altering interactions with Spry-
binding partners (101). In particular, they suggest that Spry monomers or oligomers must 
be phosphorylated to recruit co-factors and the presence of a Spry2 that cannot be 
phosphorylated disrupts the complex (101). The fact that Spry2 Y55F still migrated as 
multiple bands suggested that other phosphorylation sites existed. 
While investigating Spry2 ubiquitylation, DaSilva et al. demonstrated that Spry2 
is phosphorylated on Ser 112 and Ser 121 by mitogen-activated protein kinase-interacting 
kinase 1 (Mnk1) kinase and these phosphorylated residues regulate the phosphorylation 
of Tyr 55 (102). In a later study, using siRNAs to silence Mnk1 and Mnk2, Edwin et al. 
demonstrated that Ser112 and Ser121 are phosphorylated by Mnk2 and not Mnk1 (103). 
Nevertheless, substitution of these Ser residues with Ala (Spry2 S112A/S121A) 
eliminated the slower migrating bands demonstrating those bands were due to 
phosphorylation of serine 112 and 121. Additionally, Spry2 S112A/S121A was degraded 
faster due to an increase in Tyr 55 phosphorylation of the mutant and association with c-
Cbl (discussed later) (102). 
While many kinases enhance the ability of Spry2 to inhibit RTK signaling, others 
kinases negatively regulate it. Dual-specificity tyrosine phosphorylated and regulated 
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kinase 1A (DYRK1A) can interact with and phosphorylate Spry2 at Thr 75 (104). 
Substitution of Thr 75 with Ala enhances the ability of Spry2 to inhibit ERK1/2 
activation in response to overexpressing FGFR, suggesting the phosphorylation of Thr 75 
attenuates the ability of Spry2 to inhibit RTK signaling (104). Additionally, the recent 
report by Yim et al. suggested that CK1 and DYRK1A compete for the same site on 
Spry2, and because CK1 and DYRK1A have opposing actions on Spry2, their 
competition for the same site may form a switching mechanism to regulate Spry2 actions 
on RTK signaling (98). Likewise, testicular protein kinase 1 (TESK1) was found to 
inhibit Spry2 by interacting with and localizing Spry2 to vesicular compartments thereby 
preventing Spry2 from binding to Grb2 (105). TESK1 also prevented Spry2 from binding 
to the catalytic subunit of PP2A, which activates Spry2 through dephosphorylation 
(discussed later) (105).  Overall, Spry2 associates with many kinases that alter the 
stability of Spry2 and the ability of Spry2 to regulate RTK signaling. 
Phosphatases Implicated in the Regulation and Function of Spry2 
The actions of Spry2 are also either mediated or regulated by phosphatases. 
Yigzaw et al. demonstrated Spry2 increased the soluble amount of protein tyrosine 
phosphatase 1B (PTP1B) without altering the total PTP1B levels (106). Since PTP1B has 
been implicated in regulation of proteins involved with cell migration (reviewed in 
(107)), this provides a mechanism via which Spry2 can inhibit migration. Indeed, the 
expression of a dominant negative PTP1B only attenuated the ability of Spry2 to inhibit 
cell migration, but not the ability of Spry2 to inhibit cell proliferation (106). It is 
important to note that an interaction between PTP1B and Spry2 or a mechanism by which 
Spry2 regulates PTP1B soluble levels has not been identified. 
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While searching for other phosphatases that Spry2 can regulate, Edwin et al. 
discovered that Spry2 elevated the protein and mRNA levels of phosphatase and tensin 
homolog (PTEN), while decreasing the stability of PTEN and enhancing its activity (10). 
Spry2 increases the activity of PTEN by dephosphorylation of Ser residues on PTEN; this 
also decreases the stability of PTEN (10). The precise mechanism how Spry2 modulates 
PTEN phosphorylation is unknown. Nonetheless, the anti-proliferative actions of Spry2 
and its ability to inhibit AKT activation were demonstrated to be through activation of 
PTEN, since in cells lacking PTEN Spry2 could not inhibit cell proliferation (10). 
Upon FGF treatment of cells a small region on Spry2 (amino acids 50-60) 
encompassing Y55 interacts with protein phosphatase 2A (PP2A) (8). Because 
phosphorylation of Y55 provides a binding site for c-Cbl (discussed later)(108), PP2A 
may compete with c-Cbl for binding to Tyr 55 when it is phosphorylated, and therefore 
protect Spry2 from degradation via c-Cbl ubiquitylation pathway or alter RTK signaling 
via disrupting interactions between Spry2 and c-Cbl (discussed later) (8). As indicated 
previously, PP2A enhances Spry2 activity by dephosphorylating the inhibitory 
phosphorylation of Ser 112 and 121 (8). The effect Spry2 has on PP2A activity was 
unclear until recently when Patel et al. demonstrated that PP2A had elevated activity in 
Spry2 deficient cells suggesting that Spry2 inhibits PP2A activity (109). 
When Src homology 2-containing phosphotyrosine phosphatase (SHP2) was 
overexpressed, it resulted in dephosphorylation of Spry2 both in vivo and in vitro on 
phosphotyrosines resulting in a reduction in the association of Spry2 with Grb2 (110). 
This provided a possible mechanism by which SHP2 could enhance RTK signaling. More 
recently, it was shown that SHP2 positively regulates Spry2 transcription via Ras 
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signaling and negatively regulates Spry2 activity via dephosphorylating Spry2, although 
the residue was not identified (111). Additionally, Okur et al. demonstrated that 
intersectin1 (ITSN1) recruits SHP2 to Spry2 by binding to Spry2 at one of the proline 
rich regions (aa 303-307)(112). This enhances dephosphorylation of Spry2 on Tyr 55 and 
disrupts the inhibitory effect Spry2 had on c-Cbl resulting in enhanced EGFR 
ubiquitylation (112). To conclude, a majority of the phosphatases that interact with Spry2 
enhance the ability of Spry2 to inhibit RTK signaling. 
Ubiquitin Ligases Implicated in Regulation and Function of Spry2 
 To date Spry2 has been shown to interact with four ubiquitin E3 ligases: c-Cbl, 
SIAH2, Nedd4-1, and pVHL/associated E3 ligase. As mentioned in the sections above, c-
Casitas B-lineage Lymphoma (c-Cbl) interacts with Spry2 following phosphorylation of 
Spry2 on Y55 (100,108,113). c-Cbl is a Really Interesting New Gene (RING) domain 
containing E3 ubiquitin ligase that ubiquitylates RTKs and initiates their endocytosis 
and/or lysosomal/proteosomal degradation (114,115). Because of the high affinity 
interaction between Spry2 and c-Cbl, Spry2 can sequester c-Cbl away from EGFR, 
thereby protecting EGFR from ubiquitylation, endocytosis and degradation (116,117). As 
discussed above, recently it has been demonstrated that ITSN1 can enhance c-Cbl activity 
by recruiting SHP2 to the Cbl/Spry2 complex, causing c-Cbl to be released from Spry2 
thereby enhancing ubiquitylation of EGFR (112,118). 
Similar to c-Cbl, Seven-in-Absentia homolog 2 (SIAH2) binds to the N-terminus 
of Spry2. However, this interaction is independent of Y55 on Spry2 being 
phosphorylated, and the precise binding site on Spry2 is not known (119). SIAH2 binds 
to Spry2 via its RING finger domain (119). Overexpression of SIAH2 results in enhanced 
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Spry2 degradation without a change in Spry2 ubiquitylation, perhaps suggesting SIAH2 
is indirectly altering Spry2 degradation (119). Additionally, Qi et al. showed the 
expression of a dominant negative SIAH2 stabilized Spry2, suggesting SIAH2 was 
enhancing Spry2 degradation (120). To conclude, the precise mechanism by which 
SIAH2 regulates Spry2 protein levels is unknown. 
 The Homologous to the E6-AP Carboxyl Terminus (HECT) domain containing 
ubiquitin E3 ligase Neuronal Precursor Cell Expressed, Developmentally Down-
Regulated 4 (Nedd4) also regulates Spry2 protein levels. Nedd4 has two isoforms Nedd4-
1 and Nedd4-2. The WW domain of Nedd4-1 interacts with a region surrounding 
phosphorylated Ser 112 and Ser 121 on Spry2. Both overexpressed and endogenous 
Nedd4-1 can polyubiquitylate and enhance the degradation of Spry2 with a resultant 
increase in ERK1/2 activation in response to growth factors (103). Also, Nedd4 silencing 
in the human hepatoma cell line, HuH7, reduced the ubiquitylation and degradation of 
Spry2 (18). Intriguingly, in a subset of hepatocellular carcinoma (HCC) samples that had 
lower Spry2 protein levels, Nedd4 levels were elevated providing a possible explanation 
for the observed reduction in Spry2 levels (18).  
 Most recently, it was observed that Spry2 protein levels were elevated by hypoxia 
(121). Previous research has shown that prolyl hydroxylase domain proteins (PHDs) 
hydroxylate proteins on proline residues, and the ubiquitin ligase von Hippel-Lindau 
protein (pVHL) and associated E3 ubiquitin ligase bind to these hydroxy-proline 
residues, ubiquitylate and degrade the hydroxylated proteins (29,33,122,123). The 
activities of the PHDs are attenuated by hypoxia allowing the proteins that they and 
pVHL target to become stabilized in hypoxia (124). This mechanism could explain how 
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Spry2 became stabilized in hypoxia. Indeed, silencing of PHD1 and PHD3 elevated 
Spry2 protein levels, while overexpressing all three PHDs decreased Spry2 levels (121). 
Using mass spectrometry, three potential hydroxylation sites were identified: Pro 18, Pro 
144 and Pro 160. These hydroxylated residues bind pVHL since mutation of these 
residues decreased pVHL binding to Spry2 and enhanced Spry2 stability (121). Similar to 
what was observed for Nedd4-1, a subset of HCC samples that had lower Spry2 levels, 
also had elevated pVHL levels providing a possible explanation for the decreased Spry2 
levels (125). To conclude, currently there are four ubiquitin ligases capable of associating 
with and enhancing the degradation of Spry2. 
 Processes Spry2 Regulates 
 Overall, Spry2 inhibits cellular proliferation and migration in response to a wide 
range of growth factors in a variety of cell lines (Table 1). As will be discussed later, this 
has implications in cancer where Spry2 levels are decreased. Due to the anti-proliferative 
actions of Spry2, the effect of Spry2 on apoptosis has also been investigated. In adrenal 
cortex adenocarcinoma cells (SW13), silencing of Spry2 eliminated the anti-apoptotic 
actions of serum measured by DNA fragmentation and decreased phosphorylation of the 
pro-apoptotic factor BAD. It was found that Spry2 mediated the anti-apoptotic actions of 
serum via c-Cbl (126). It is important to note that only when comparing serum treated 
cells Spry2 was inhibiting apoptosis, indicating serum was required for Spry2 to inhibit 
apoptosis. A similar finding was observed in Ras-transformed human fibroblasts, such 
that, Spry2 inhibits UV induced apoptosis by regulating AKT, HDM2 and p53 (127). 
Consistent with the pro-survival actions of Spry2, the expression of Spry2 prevented the 




Table 1:  Spry2 effect on proliferation and migration 
Ref. Cell line Growth  
Factor 
Effect 




 proliferation via C-terminus 
(12) HUVECs EGF 
FGF 
VEGF 
 proliferation & differentiation 
(7) NIH3T3 
PC12 
serum  proliferation & DNA synthesis 
(129) IEC6 Serum  proliferation & migration 
(130) HUVEC HGF  proliferation, migration, & 
anchorage independent growth 




 proliferation & migration 
(10) MEFs EGF proliferation via PTEN 
(132) Neuroblastoma 
cell line TGW 
GDNF proliferation 
(133) Colon cancer 
HCT116 






-  proliferation & anchorage 
independent growth 
Table 1: Spry2 effect on proliferation and migration.  
The table lists the references for the studies showing changes in proliferation and/or 
migration with Spry2 expression and in what cell line and with what growth factor the 




On the other hand, there have been a couple of reports that Spry2 enhances apoptosis. In 
mature neurons, overexpressing Spry2 increased neuronal cell death while inhibition of 
Spry2 increased neuronal cell survival (135). Additionally, in colon cancer cell lines, 
Spry2 promoted apoptosis as measured via Annexin V staining (133). To conclude, Spry2 
often inhibits RTK signaling leading to inhibition of proliferation and migration, however 
not in every cell line or with every RTK. Furthermore, Spry2 inhibits apoptosis in most 
cell lines, but again not always. For this reason, Spry2 is designated a modulator of RTK 
signaling rather than an inhibitor. 
Spry2 in Cancers 
 As described above, Spry2 is most often an inhibitor of RTK signaling. Since 
RTK signaling is excessive in cancer, the levels and impact of Spry2 in cancer has been 
investigated. Table 2 summarizes the change in Spry2 levels in different cancers, the 
method they used to detect the change and the number of patient samples measured. 
Breast Cancer 
Previous research has indicated that Spry2 levels are decreased in breast cancer 
(14). While the authors in this study do not conclude this, from the cDNA microarray 
studies, it looks like Erb2 is upregulated in those cancers that have decreased Spry2 
levels (14). Additionally, in keeping with the notion that Spry proteins act as tumor 
suppressors, Spry2 is an independent prognostic marker for breast cancer and can serve 
as a marker for therapeutic efficacy for trastuzumab, the HER2 targeting RTK inhibitor, 
which has efficacy in the treatment of early and metastatic breast cancer (19). 
Interestingly, the decrease in Spry2 levels in breast cancer is not due to loss of 
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Cancer Type Change in 
Spry2 Levels 





Breast Decreased microarray Global 
Cancer Map database 
& patients protein and 
mRNA levels 
n/a (14) 
Breast Decreased independent meta-
analysis 
1107 (19) 
Colon Increased Protein and mRNA 
levels 
10 (136) 





Colon Increased Immunofluorescence 
Protein levels 
34 (138) 





Colon Increased in 
KRAS mutant 
tumors 







Colon Decreased mRNA qRT-PCR 67 (141) 
Colon  Decrease  microarray Global 
Cancer Map database 
n/a (14) 




HCC Decrease qRT-PCR 31 (16) 
HCC Decrease IHC 240 (142) 
HCC Decrease qRT-PCR and IHC 39 (14) 
NSCLC Decrease microarray Global 
Cancer Map database 
n/a (14) 
NSCLC Decrease qRT-PCR and IHC 25 (21) 
Prostate Decrease qPCR 9 (143) 
Prostate Decrease Microarray and qRT-
PCR 
49 (20) 
Prostate Decrease Tissue microarray 202 (144) 
Prostate Decrease  IHC 244 (109) 
Prostate Decrease microarray Global 
Cancer Map database 
n/a (14) 
Table 2: Spry2 levels in cancers.  
The table able lists the type of cancer, direction of change for Spry2 levels, the method of 




heterozygosity or epigenetic changes such as SPRY2 promoter hypermethylation or 
histone hypoacetylation (14). One possible explanation for the loss of Spry2 in breast 
cancer is the upregulation of microRNAs (miRs) that target Spry2. More recently, Li et 
al. showed that SPRY2 is the target of the miR-23a/24-2/27a cluster, which is upregulated 
in breast carcinomas (145). Additionally, two independent studies looking at tissue 
microarray data sets confirmed that miR-21 is increased in breast cancer (146,147) and 
high miR-21 levels were correlated with unfavorable high tumor grade and negative 
hormone receptor status (148). Interestingly, miR-21 targets Spry2 in cardiac myocytes, 
but there are no reports on regulation of Spry2 by miR-21 in breast cancer cells (149). 
Therefore, in breast carcinomas, perhaps upregulation of the miRs -21 and/or -23a/24/27a 
could account for the downregulation of Spry2.  
The role of Spry2 in breast cancer has been investigated. Either decreasing Spry2 
levels through siRNA or decreasing Spry2 activity through a dominant negative Spry2 
Y55F resulted in increased proliferation, anchorage-independent growth, cell migration 
and invasion, as well as, the formation of larger tumors in mice (14,145). All of these 
effects are thought to be due to the ability of the Spry proteins to regulate MAPK 
signaling and suggests that Spry2 may act as a tumor suppressor in breast carcinomas. 
Aside from the ability of Spry2 to alter MAPK signaling, our lab has shown that Spry2 
exerts its anti-proliferative actions through elevation of PTEN protein levels and activity 
(10). Incidentally, Faratian et al. found that breast tumors that expressed both PTEN and 




 There have been conflicting reports on the direction of change in the levels of 
Spry2 and the impact Spry2 has in colorectal cancer (CRC) (14,136-141). A review by 
Frey et al. suggested that the differences in the changes in Spry2 might be due to the 
growth factor repertoire activated in the specific tumor or tumor model (150). One group, 
showing elevation in Spry2 levels, suggests that Spry2 enhances tumor migration and 
invasion by elevating c-MET levels (136). The same group recently showed that while 
Spry2 inhibition reduces EGFR-induced MAPK activation, the resulting ERK/AKT 
activation is insufficient to drive CRC cell proliferation. Instead, Spry2 reduction results 
in p21WAF/CIP1 upregulation and inhibition of the cell cycle providing a tumor promoting 
role for Spry2 in CRC (151).  
Consistent with this, another group shows that Spry2 levels are higher in high-
grade tumors (138). The authors also show a tumorigenic role for Spry2 in CRC cell lines 
by promoting the epithelial to mesenchymal transition (EMT) through upregulation of the 
EMT inducer zinc finger E-box-binding homeobox (ZEB1) (138). They proposed two 
mechanisms by which ZEB1 is upregulated by Spry2. First, Spry2 enhances EGF-
induced AKT activation elevating the transcription factor ETS-1, which increases ZEB1 
levels (152). Second, Spry2 reduces miR-200 and miR-150 that target ZEB1 (152). ZEB1 
induces EMT by repressing the transcription of genes encoding cell to matrix and cell-to-
cell adhesion proteins, such as e-cadherin (152). A previous study demonstrated that 
Spry2 represses e-cadherin via ZEB1 (138). Recently, the same group described another 
possible mechanism that, in part, explains how Spry2 represses e-cadherin via a 
combination of miR194-5p downregulation and AKT2 upregulation (137). Altogether 
they provide evidence that Spry2 promotes migration and EMT in CRC.  
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Two possible mechanisms for Spry2 upregulation in CRC involved e-cadherin 
and Wnt/β-catenin. It was found that Spry2 and e-cadherin repress the expression of each 
other in CRC cell lines and their levels are inversely correlated in human CRC samples. 
Therefore, Spry, through repression of e-cadherin, might enhance its own expression 
levels. In another study, it was demonstrated that Wnt/β-catenin and FOXO3a induce the 
transcription of the SPRY2 promoter (139). Since Wnt/β-catenin pathway has been 
shown to be activated and an initiating event in many CRC’s (153), it supports the 
proposal that Spry2 is elevated and oncogenic in CRC’s.    
Contradicting what has been described so far, two different groups have observed 
a decrease in Spry2 mRNA levels (14,141). Feng et al. observed lower levels of Spry2 in 
the advanced stages of CRC and correlated it to an increase in miR-21 levels, which as 
discussed before, has been shown to target Spry2 (141,149). The decrease in Spry2 levels 
resulted in a decrease in cell proliferation and migration due to elevated PTEN levels 
decreasing AKT/MAPK signaling (141). In other studies, they demonstrated that Spry2 
increased CRC cell sensitivity to gefitinib, fluorouracil and metformin (133,154). Further 
studies are needed to elucidate the reasons for these discrepancies in Spry2 levels and 
function in CRC. 
Hepatocellular Carcinoma 
In hepatocellular carcinoma (HCC), it has been reported by three different groups 
that Spry2 levels are decreased (16,17,142). Additionally, those patients with Spry2 
negative tumors had worse survival rates and increased recurrence (142). Spry2 negative 
tumors had more malignant phenotypes with enhanced vascular invasion, advanced 
tumor stages and enhanced metastatic potential (142). Furthermore, Spry2 is an 
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independent predictor of post-operative recurrence of HCC (142). Often there is 
activation of the Ras/ERK pathways in human HCC without mutations to Ras family 
members. Since Spry2 is a well-characterized inhibitor of ERK activation, perhaps the 
loss of Spry2 in HCC can partially account for aberrant RTK signaling in HCC. 
A variety of mechanisms are attributed to decreasing Spry2 levels in HCC. Spry2 
has a large CpG island encompassing the 5’ UTR, first exon and intron. Since CpG 
islands have been shown to be hypermethylated (155), the authors monitored epigenetic 
alterations to SPRY2 promoter and found evidence of both SPRY2 promoter 
hypermethylation and loss of heterozygosity (18). However, Fong et al. did not reproduce 
this finding (15). Additionally, in samples that had high Spry2 mRNA levels but low 
protein levels, Nedd4 was upregulated (18). Since Nedd4 targets Spry2 for degradation 
(discussed under Ubiquitin Ligase), this could provide an explanation as to how Spry2 
levels were decreased. One area of interest that no one has investigated is if any miR’s 
regulate Spry2 levels and are upregulated in HCC. 
Lee et al. studied the in vivo impact of Spry2 in HCC through the expression of a 
dominant negative Spry2 Y55F through hydrodynamic injection into the liver preventing 
the need to generate transgenic mice or xenografts (17). The expression of a 
constitutively active β-catenin (ΔN90-β-catenin) or overexpression of c-Met cooperates 
with the expression of Spry2 Y55F to promote liver cancer formation in mice thereby 
providing, as stated above, a possible mechanism for aberrant RTK signaling in the 
absence of Ras/Raf mutations (17,18). Additionally, opposite to what was observed for 
CRC, Spry2 expression inhibited c-MET-induced MAPK signaling (18). Recently, the 
same group demonstrated that the expression of the dominant negative Spry2 Y55F 
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accelerated AKT driven hepatocarcinogenesis in a mouse resulting in tumors that had 
enhanced proliferative capacity and glycolysis (156). Interestingly, PKM2 levels were 
increased in these tumors (156). It is important to note that while loss of Spry2 being able 
to bind to Raf, Grb2 and c-Cbl enhanced liver cancer formation, the complete loss of all 
of Spry2 functions through the use of a conditional knockout using Spry2 flox/flox and Alb-
Cre may have a more profound effect on liver cancer formation. 
Lung Cancer 
Lung cancer can be broken into two broad categories, small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). Spry2 appears to play a larger role in 
the latter. Spry2 mRNA and protein levels were decreased in NSCLC samples compared 
to that of normal lung (14,21). More recently, Acunzo et al. described a possible reason 
for this downregulation is due to the targeting of Spry2 by miR-27a, which has been 
shown to be upregulated in lung cancer (157,158) and has been previously shown to 
target Spry2 in pancreatic cancer (159). Recently, miR-21 was implicated in reducing 
Spry2 levels in lung cancer. It was shown that nickel accumulates in the lungs of never 
smokers and is correlated with high miR-21 levels and decreased Spry2 levels perhaps 
due to miR-21 targeting Spry2 (160). 
 Spry2 has been shown to have a variety of functions in suppressing lung cancer. 
K-ras is often mutated in lung cancer and serves as a negative prognostic marker 
(161,162). The impact of K-ras mutations in NSCLC has been reviewed elsewhere (163). 
Spry2 is upregulated in tumors from mice expressing a latent K-rasG12D allele (164). Most 
importantly, when Spry2 is knocked out in combination with the mutation in K-ras, the 
mice form both a greater number of and larger tumors, suggesting that Spry2 is acting as 
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a tumor suppressor in these K-ras driven tumors (164). Furthermore, this suggests that 
tumors that have both a mutated K-ras and decreased expression of Spry2 would be far 
more severe than either by itself. Supporting this, a previous study demonstrated that 
Spry2 overexpression in mice lungs produced fewer and smaller urethane-induced lung 
tumors (165).  
 In a small proportion NSCLC, activating mutations are found in EGFR that confer 
sensitivity to EGFR inhibitors gefitinib and erlotinib(166-168). Understanding how these 
mutations impact the normal physiology of the receptor is critical. Spry2 attenuates wild 
type and mutant EGFR ubiquitylation and endocytosis by binding to and sequester away 
the ubiquitin ligase c-Cbl in a variety of cell lines (99,117,169,170). Walsh et al. and 
Acunzo et al. also showed that Spry2 silencing decreased the protein levels of wild type 
EGFR independent of the enhanced endocytosis (157,170). In fact, contrary to what was 
previously published, Walsh et al. propose that Spry2 regulates EGFR endocytosis 
primarily through regulating its levels rather than its association with c-Cbl (171). Similar 
to EGFR, Acunzo et al. demonstrated that Spry2 silencing decreased c-MET protein 
levels, which supports the work by Holgren et al. demonstrating in CRC cells Spry2 
expression increases c-MET levels (136,157). Taken together, this previous research 
suggests that Spry2 expression directly relates to EGFR and c-MET expression in 
NSCLC cell lines. However, no one to my knowledge has investigated if this correlation 
holds true in human tumor samples. 
Prostate Cancer 
 Spry2 levels were significantly decreased in prostate cancer (20,143,144). As 
discussed under Hepatocellular Carcinoma, Spry2 has a large CpG island at the 5’ end 
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that can be hypermethylated. One study found Spry2 levels are decreased in prostate 
cancer due to hypermethylation and, partially, loss of heterozygosity (143), while another 
study did not see any evidence of hypermethylation with decreased Spry2 levels (20). As 
prostate cancer progresses, it transitions from androgen dependent to androgen 
independent, which decreases the prognosis for the patient (172). Spry2 levels were 
found to be lower in androgen independent prostate cancer cell lines (173). Furthermore, 
it was found that patients that had low Spry2 levels and high HER2 had worse outcomes 
(144). 
 The loss of Spry2 enhanced prostate cancer cell proliferation and migration via 
enhanced PI3K/AKT and p38 MAPK signaling resulting in increased internalization and 
signaling of EGFR/HER2 at early endosomes (144). The activation of AKT was PTEN 
dependent as was shown previously (10,144). Similar to what was observed in NSCLC, 
Spry2 reduced levels of EGFR independent of endocytosis (144,157,170). Intriguingly, 
Spry2 interaction with c-Cbl was not investigated, which has previously been implicated 
in regulating EGFR endocytosis (99,117,169,170). The authors hypothesized that prostate 
cancer with low Spry2 and PTEN levels and high HER2 would be particularly 
susceptible to PI3K/AKT inhibitors (144). 
 Interestingly, when Spry1 and Spry2 are knocked out of the prostates of mice, 
prostatic intraepithelial neoplasia (PIN), a precancerous condition, was observed 
(174,175). However, loss of Spry2 alone was insufficient to drive tumorigenesis (109) 
demonstrating some redundancy in the roles of the different Spry proteins. The loss of 
Spry2, in addition to PTEN inactivation, increased the occurrence of PIN, tumorigenesis, 
metastasis and RTK activation in the prostate epithelium (109,175). PTEN has been 
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shown to be a critical tumor suppressor in prostate cancer (176,177). Interestingly, 
overexpression of Spry2 reduced PIN occurrence due to PTEN loss-of-function (175). 
Patel et al. delineated a mechanism for this enhanced tumorigenesis when Spry2 and 
PTEN are lost (109). Any enhanced cell proliferation from loss of Spry2 is abrogated by 
PP2A cell cycle arrest, which ultimately needs PTEN to arrest the cell cycle (109). 
Therefore, the combination Spry2 and PTEN loss bypassed the PP2A checkpoint 
allowing for the Spry2 and PTEN loss to synergize in driving murine prostate 
tumorigenesis (109). Supporting this, Spry2 expression levels were strongly correlated 
with PTEN and PP2A in human prostate cancer samples (109). It is of note that the 
authors of this most recent study reproduced the earlier findings that loss of Spry2 
increase PTEN phosphorylation without altering PTEN levels (10,109).  
 In conclusion, Spry2 is generally an inhibitor of RTK signaling that can interact 
with and be modified by a variety of kinases, phosphatases and ubiquitin ligases and has 
a role in cancers of the breast, lung, liver and prostate. 
Hypoxia Inducible Factors 
Oxygen is one of the most abundant elements on earth and makes up 21% of the 
air we breath. Eukaryotic life forms utilize oxygen as the terminal electron acceptor in 
mitochondrial metabolism generating cellular energy in the form of adenosine 
triphosphate (ATP). This emphasizes the importance of maintaining the oxygen supply in 
every cell in an organism because without oxygen, a eukaryote’s ability to produce 
energy is greatly hindered. However, it is important to note that oxygen is a highly 
reactive element and reactive oxygen species can be extremely toxic. Therefore, there 
must be a balance between the supply and consumption of oxygen in cells. When the 
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supply of oxygen is limited, it results in the formation of a hypoxic environment. In order 
to survive and adapt to hypoxia, a organism or cell must alter a variety of physiological 
and cellular processes (reviewed in (178)). 
 Hypoxia can be caused by a variety of factors including pathophysiological 
conditions such as cancer, sleep apnea, atherosclerosis and ischemic diseases (stroke), as 
well as physiological processes such as embryonic development (179,180). Even in an 
adult mammal, the partial pressure of oxygen in mammalian tissues ranges from 100 
mmHg (13.2% O2) to 8 mmHg (1.1% O2) (181). In order to survive and adapt to hypoxic 
environments, the transcription factors, hypoxia inducible factors (HIFs) are upregulated 
in cells.  
HIF discovery 
HIF1 was first discovered in 1992 by Semenza and Wang, who identified a 
nuclear factor induced by hypoxia via de novo protein synthesis that was binding to the 3’ 
flanking sequence of the human erythropoietin (EPO) gene (24). They designated this 
nuclear factor hypoxia inducible factor 1 or HIF1 (24). Since HIF1 caused the hypoxic 
induction of genes in non-EPO producing cells, HIF1 became known as a general 
regulator of cellular responses to hypoxia (25).  
Upon purifying HIF1, it was discovered that HIF1 primarily existed as a 
heterodimer of an alpha (HIF1α) and beta (HIF1β) subunit (27). The dimer binds to 
hypoxia response elements (HRE) with the sequence 5’-RCGTG-3’ (R = A/G) in the 
promoter of a variety of genes as discussed later (24,182). When performing a database 
search of the two peptide sequences of HIF1β, it was determined that HIF1β was 
previously identified as aryl hydrocarbon receptor nuclear translocator (ARNT), which 
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functions as a heterodimer with aryl hydrocarbon receptor (AhR) as the dioxin receptor 
(discussed further in this chapter under ARNT) (28,183). Both HIF1α and HIF1β contain 
basic helix-loop-helix Per ARNT Sim (bHLH-PAS) domains, which allow for DNA-
binding and dimerization (28). While looking for new members of the bHLH-PAS 
domain family, endothelial PAS domain protein 1 (EPAS1) was discovered, which had 
48% sequence similarity to HIF1α, was activated by hypoxia and could bind to HREs 
(184,185). EPAS1 became known as HIF2α, another oxygen regulated subunit that can 
bind to ARNT. Although the two HIFα’s have some overlap in the genes they regulate, 
there are distinct genes regulated solely by one or the other (186-188). 
 A third alpha subunit of HIF (HIF3α) exists, but it is different from the other 
alpha subunits. HIF3α was not examined in this study, however it will be briefly 
introduced. What is known about HIF3α has been concisely reviewed in (189). To date, 
there are at least 10 transcript variants of HIF3α, but only 8 may encode proteins (189-
192). Each variant is composed of different combinations of domains from the other two 
alpha subunits, and the only thing all HIF3α variants have in common is that they lack the 
C-terminal transactivation domain (TAD) (reviewed in (189)). Along the same lines, 
oxygen levels regulate some, but not all variants by targeting them for proteosomal 
degradation by von Hippel-Lindau protein (pVHL) (discussed below) (192). Unique to 
HIF3α, it was shown that the transcript levels of HIF3α are regulated by hypoxia and 
sometimes by HIF1α, while HIF1/2α transcript levels are not (193-196). Finally, the 
function of HIF3α was thought to be inhibiting HIF1α and HIF2α transcriptional activity 
by sequestering either ARNT or the alpha subunits (190,197), but that doesn’t seem to 





Figure 5: Schematic of HIF1α, HIF2α, and ARNT structure.  
The domains in HIF1α, HIF2α and ARNT are depicted. Nuclear localization signal 
(NLS) allows the protein to enter the nucleus. The beta helix-loop-helix (bHLH) domain 
is involved in HIF binding to DNA. Per-ARNT-SIM (PAS) domains are involved in the 
alpha subunits dimerizing with ARNT. Oxygen dependent domain (ODD) on HIF1α and 
HIF2α contains the prolines that are hydroxylated by PHD that allows pVHL to associate 
with HIFα resulting in HIFα degradation. Transactivation domains (TAD) allow HIF to 
induce transcription of genes. The asparagine that is hydroxylated by FIH is indicated on 




target genes (198,199). While there are multiples alpha subunits of HIF, HIF1α and the 
regulation of HIF1α by Spry2 will be the one of the main points of this dissertation.  
HIF Structure and Function 
 A schematic of HIFα and ARNT structure is shown in Figure 5. As stated earlier, 
HIF1α, HIF2α and ARNT all have bHLH-PAS domains. The bHLH domain is involved 
in HIF1α, HIF2α and ARNT binding DNA, while the PAS domain is needed for the 
alpha subunit to dimerize with ARNT (28,123,200). Both the alpha subunits and ARNT 
have nuclear localization signals (NLS) and transactivation domains (TAD), however the 
alpha subunits have two TADs, one on the N-terminus and the other on the C-terminus 
(201-204). The alpha subunits also have oxygen dependent domains (ODD) that contain 
the prolines that are hydroxylated as discussed below in HIF1α protein regulation. 
 As has been stated before and evident from the domains HIF contains, HIF 
functions as a transcription factor to allow cells to adapt to hypoxia. Recently, HIF target 
genes throughout the entire genome were identified using chromatin immunoprecipitation 
coupled to next-generation high-throughput sequencing (205,206). Over 500 putative 
sites were identified, of which over 400 had HREs (205,206). Over 100 of those sites 
were induced 2-fold by hypoxia (205). Interestingly, more strict sequence requirements 
for HREs were not identified outside of the core 5’-RCGTG-3’ (R = A/G) perhaps 
indicating the presence of epigenetic modifications regulating HIF binding to an HRE 
(206). Of note, there was a portion (~ 17%) of targets that were enhanced by knocking 
out HIF1α suggesting HIF represses some genes (205). Furthermore, about one third of 
the HIF-binding sites identified were located in introns. The authors proposed HIF 
generates non-coding transcripts that are not miR’s whose function is unknown and 
41 
 
needed further analyses (205). Further investigation into the types of genes that HIF 
regulates is discussed in HIFs in Cancer below. 
HIF1α protein regulation 
 HIF1α has been shown to interact with and be regulated by a very large number of 
proteins. Of note, previous research has shown that ERK1/2 and AKT regulate HIF1α. 
Specifically, studies showed that ERK1, via direct phosphorylation of the C-terminus of 
HIF1α, regulates the transcriptional activity of HIF1α without altering the protein levels 
(207-209). On the other hand, AKT is involved in enhancing the translation of HIF1α 
protein (210,211). Since this dissertation focuses on enhancing HIF1α degradation, the 
focus of this review will be on the proteins known to enhance HIF1α degradation. The 
table below summarizes the proteins known to enhance HIF1α degradation to date (Table 
3).  
Degradation via von Hippel-Lindau Protein 
 Now it is well understood that oxygen causes degradation of the alpha subunits of 
HIF thereby preventing the transcription of the genes HIF regulates. Understanding this 
process began by observing that HIF1α protein levels were reduced by ubiquitylation and 
proteosomal degradation in normoxia, but degradation was attenuated in hypoxia (212-
215). It was discovered that von Hippel-Lindau protein (pVHL) was involved since 
patients with renal clear cell carcinoma, who have a somatic mutation in the pVHL gene, 
have elevated HIF1α levels (33). pVHL is part of an E3 ubiquitin ligase complex 
composed of Cullin-2, elongin B and elongin C (216). The interaction of HIF1α with 





Effector Regulator O2 Dep. Ref 
PHD OS9 Y (217) 
PHD RUNX Y (218) 
pVHL MCM7 Y (219) 
pVHL SSAT2 Y (220) 
PHD, pVHL LIMD1, RHOBTB3 Y (221) 
RACK1, HSP90 Calcineurin, SSAT1 N (222-
225) 
CHIP, HSP70  N (226) 
HAF  N (227) 
SHARP1  N (228) 
p53, MDM2   N (229) 
HSC70, LAMP2, CHIP 
(lysosomal) 
CDK1, CDK2 N (230,231) 
Table 3: Proteins known to cause HIF1α degradation. 
The table lists the effector proteins that alter HIF1α protein levels and any regulator 
proteins that have been shown to alter HIF1α levels via the effector proteins. The 
reference for the regulation is listed as well. Y and N denote yes and no, respectively. 




needing to be hydroxylated which is an oxygen-dependent reaction (29,30). It was in C. 
elegans that the enzyme responsible for hydroxylating the prolines on HIF1α was 
discovered to be EGL-9, which has three mammalians homologs called prolyl 
hydroxylase domain proteins (PHD) 1, PHD2, and PHD3 (233). All three mammalian 
PHD’s are capable of hydroxylating HIF1α and HIF2α in vitro, and since PHD activity is 
attenuated with hypoxia, PHDs act as oxygen sensors for HIFα (233). A schematic 
representation of HIF regulation by PHDs and pVHL in normoxia and hypoxia is shown 
in Figure 6. 
HIFα transcriptional inhibition by FIH 
 In addition to normoxia resulting in degradation of HIFα protein, the activity of 
HIFα TADs is also inhibited in normoxia via factor inhibiting HIF (FIH), but the 
mechanism isn’t clear (234). It was hypothesized that FIH interacting with pVHL and 
histone deacetylases (HDACs) inhibited the transcriptional activity of HIF (234). Later, it 
was determined that asparagine hydroxylation at N803 for HIF1α and N851 for HIF2α 
was inhibiting the TAD and transcriptional activity of HIF; FIH is the asparagine 
hydroxylase responsible for this hydroxylation (235-237). Specifically, asparagine 
hydroxylation inhibits the transcriptional activity of HIFα by preventing HIFα from 
associating with the co-activator p300 (236,237). 
Hydroxylation-dependent proteins that enhance HIF1α degradation 
 Other studies have shown that some proteins can enhance HIF1α hydroxylation-
dependent degradation via protein-protein interactions that stabilize the association of 
HIF1α with pVHL or PHD (Table 3). For example, Amplified in Osteosarcoma 9 (OS9) 





Figure 6: Schematic of regulation of HIFα by PHD and pVHL in normoxia and 
hypoxia. 
HIFα binds to and is hydroxylated by PHDs in normoxia. Then pVHL and its associated 
E3 ubiquitin ligase binds to the hydroxy-prolyl residues resulting in the ubiquitylation 
and proteosomal degradation of HIFα in normoxia. However, in hypoxia, due to the fact 
PHDs need free molecular oxygen to hydroxylate proteins, the activity of PHDs is 
inhibited, but not entirely lost. This prevents pVHL from binding to, ubiquitylating and 
degrading HIFα. The stabilized HIFα subunits can then translocate into the nucleus, 
dimerize with ARNT, bind to HREs and regulate the transcription of a variety of genes. 
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by increasing the association of PHD2 with HIF1α (217,218). Importantly, RUNX3 
reduced not only the normoxic, but also the hypoxic levels of HIF1α (218). This study 
and others have shown that not only are PHD levels elevated in hypoxia, but also there is 
still PHD activity in hypoxia (218,233,238). Furthermore, studies have shown that the 
partial hydroxylation of either proline 402 or 564 can cause pVHL to associate with 
HIF1α and induce its degradation (238,239).  
On the other hand, minichromosome maintenance complex component 7 (MCM7) 
and spermidine/spermine N1-acetyltransferase 2 (SSAT2) enhanced pVHL-mediated 
ubiquitylation of HIF1α (219,220). Both proteins stabilize the interaction between pVHL 
with elongin C thereby promoting HIF1α ubiquitylation, however HIF1α must be 
hydroxylated (219,220). Previously, the tumor suppressor LIM domain-containing 
protein 1 (LIMD1) was shown to create a complex with PHD and pVHL to create an 
efficient HIF1α degradation complex that functions in both hypoxia and normoxia (240). 
More recently, it was shown that LIMD1 and Rho-related BTB domain-containing 
protein 3 (RHOBTB3), an atypical RHO family member, forms a complex with HIF1α, 
PHD2 and pVHL to promote HIF1α hydroxylation, ubiquitylation, and degradation 
(221). Hypoxia diminishes the formation of this degradation complex allowing for HIF1α 
to be stabilized (221). 
Hydroxylation-Independent Proteins that Enhance HIF1α Degradation 
 Many proteins have been implicated in enhancing HIF1α degradation in an 
oxygen (hydroxylation) independent, proteosomal-dependent manner. Previous research 
has shown HIF1α is targeted for proteosomal degradation by heat shock protein 90 
(HSP90), especially in the absence of pVHL, such as in renal clear cell carcinoma 
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(225,241). Related to that, receptor of activated protein kinase C (RACK1) competes 
with HSP90 for binding to HIF1α, yet RACK1 also promotes HIF1α degradation (224). 
Essentially, RACK1 takes the place of pVHL by simultaneously associating with both 
elongin C and non-prolyl hydroxylated HIF1α presumably resulting in the assembly of 
the rest of the E3 ubiquitin ligase complex causing the ubiquitylation and degradation 
HIF1α (224). Intriguingly, RACK1 and HIF1α association is regulated by calcineurin and 
calcium, since RACK1 needs to be phosphorylated to dimerize and induce HIF1α 
degradation (223). Calcineurin, the calcium and calmodulin dependent serine/threonine 
phosphatase, dephosphorylates RACK1, thereby preventing RACK1 dimerization and 
protecting HIF1α from ubiquitylation and degradation (223). Therefore, via this 
mechanism, elevation in intracellular calcium levels should stabilize HIF1α. 
Additionally, SSAT1 binds to RACK1 and HIF1α thereby promoting the degradation of 
HIF1α (222) 
Another heat shock protein, HSP70, has also been implicated in enhancing HIF1α 
degradation. During prolonged hypoxia, HSP70 and carboxyl terminus of Hsc70-
interacting protein (CHIP) enhance the proteosomal degradation of HIF1α (226). One 
group identified another ubiquitin ligase capable of ubiquitylating HIF1α (227). In 
hypoxia and normoxia, a novel E3 ubiquitin ligase, hypoxia associated factor (HAF), was 
shown to degrade HIF1α (227). On the other hand, SHARP1 enhances HIF1α 
degradation completely independent of ubiquitin ligases by presenting HIF1α directly to 
the proteosome (228). Finally, recently HIF1α has been shown to be degraded by 
chaperone-mediated autophagy involving HSC70 and lysosome-associated membrane 
glycoprotein 2 (LAMP-2A) (230,231). 
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HIF in Cancer 
A hypoxic environment develops when a tumor proliferates rapidly with 
angiogenesis unable to keep up pace to provide the tumor cells with blood and oxygen. 
As discussed above, this results in upregulation of HIF1α and HIF2α and the genes they 
regulate. Previous research has determined that elevated HIF1α levels are correlated with 
poor patient prognosis in a variety of cancers, such as colorectal, liver, lung, breast, 
ovarian and pancreatic (reviewed (22,38,39)). Elevated HIF1α levels decreases prognosis 
due to the types of genes that HIF1α regulates. Previous research has shown HIF 
regulates genes that are involved in all major carcinogenic processes: proliferation, 
apoptosis, angiogenesis, invasion, metastasis, metabolism and therapy resistance (242-
244). Since the work in this dissertation focuses on the impact of HIF1α in glycolysis, it 
will be the focus of this review. 
Regulation of Glycolysis by HIF1α in Cancer 
 Rapidly proliferating cells need energy in the form of ATP to be generated rapidly 
and biosynthesis of macromolecules to build new cells. To meet this demand, cells 
mainly use ATP generated from enhanced aerobic glycolysis rather than oxidative 
phosphorylation even in the presence of oxygen, a process referred to as the Warburg 
Effect (245). Aerobic glycolysis involves converting glucose into lactate (Fig. 7) rather 
than shuttling pyruvate into the tricarboxylic acid (TCA) cycle. One advantage glycolysis 
gives cancers cells is that it allows for shunting of carbon to other key biosynthetic 
pathways (246). Since glycolysis generates less ATP than oxidative phosphorylation per 
glucose molecule, glycolysis must be greatly enhanced to meet the energy needs. 





Figure 7: HIF1α impact on glycolysis. 
The process of glycolysis is shown whereby glucose is converted into lactate resulting in 
the production of 4 ATP molecules. HIF1α elevates the transcription of the glucose 




can occur in hypoxia, while the main source of ATP in normal aerobic metabolism, the 
electron transport chain, uses oxygen as the terminal carrier and therefore cannot function 
in hypoxia. This allows tumors to continue to produce ATP even during hypoxia.  
Previous research has shown that HIF1α plays a critical role in upregulating 
glycolysis (Fig. 7). At the very beginning of glycolysis, glucose is transported into the 
cell. HIF1α enhances this process by upregulating the glucose transporter 1 (GLUT1) and 
GLUT3 (247,248). Glucose is then phosphorylated, not only trapping the glucose 
molecule in the cell, but the phosphorylation of glucose maintains low glucose levels in 
the cell thus promoting glucose transport. This irreversible reaction is catalyzed by the 
rate-limiting enzyme hexokinase (HK), which is also regulated by HIF1α (249). The 
other irreversible step in glycolysis, converting fructose-6-phosphate into fructose -1,6-
bisphosphate, is also enhanced by HIF1α, since this step is catalyzed by phosphofructose 
kinase (PFK) and HIF1α has been shown to increase the transcription of the liver isoform 
of PFKL(182). Additionally, HIF1α enhances the levels of PFK-2, which generates 
fructose-2,6-bisphosphate, an allosteric activator of PFK (250,251). HIF1α also regulates 
aldolase (ALDO), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
phosphoglycerate kinase 1(PGK1) and enolase (ENO) (182,252-254). 
HIF1α also has a large impact at the end of glycolysis by upregulating both the 
rate limiting enzyme pyruvate kinase 1 (PKM1), which generates pyruvate from 
phosphoenolpyruvate, and pyruvate dehydrogenase kinase 1 (PDK1), which inhibits 
pyruvate dehydrogenase, thereby preventing conversion of pyruvate to acetyl coA for the 
TCA cycle (182,255-257). Additionally, HIF1α upregulates lactate dehydrogenase and 
50 
 
enhances the conversion of pyruvate into lactate and monocarboxylate transporter 4 
(MCT4), which transports lactate out of the cell (252,258-260). 
 Interestingly, while both PKM1 and PKM2 are upregulated in tumors and by 
HIF1α, PKM2 is inactive due to phosphorylation and only PKM1 can promote glycolysis 
(261,262). A couple theories have been proposed to explain why PKM2 is inactive. First, 
it has been proposed that inactive PKM2 allows glycolysis to slow down, facilitating 
carbohydrate metabolites entering other pathways to generate building blocks for the 
proliferating cells, or, secondly, inactive PKM2 provides a switch from glycolysis back to 
oxidative phosphorylation (261-263). Recently, it has been shown that PKM2 can also 
function as a coactivator for HIF1α after PHD3 hydroxylates PKM2, providing another 
possible reason for PKM2 to be inactivated (257). 
 To conclude, HIF is a heterodimeric transcription factor composed of an oxygen-
regulated alpha subunit and a beta subunit that controls the transcription of a variety of 
genes that allows cells to survive and adapt to hypoxia. The regulation of HIF1α and its 
impact in promoting cancer has been well studied. 
ARNT 
ARNT Discovery and Structure 
 As described under HIF discovery, ARNT was first identified as the dimerization 
partner for AhR, a ligand activated bHLH-PAS transcription factor, prior to its 
identification as the dimerization partner for HIF (40). As shown in Figure 5, ARNT is 
composed of a NLS to enter the nucleus, a bHLH domain to bind DNA, two PAS 
domains to allow ARNT to dimerize with other proteins, and a TAD to aid in regulating 
transcription of genes (264). A second ARNT, ARNT2, which is encoded by a different 
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gene, was identified that has a very similar structure and sequence to ARNT, but the 
expression is mostly limited to the brain (265). ARNT2 dimerizes with single-minded 
homologue 1 (SIM1) and neuronal PAS domain-containing protein 4 (NPAS4) to 
regulate a variety of neuronal functions and development (266,267). The focus of this 
dissertation, and therefore this review, is only on ARNT. 
ARNT Function 
As stated previously, ARNT participates in multiple distinct signaling cascades. 
ARNT has been shown to bind to HIF1/2α (27), AhR (40), ERα (41), ERβ (41,42), SRC-
1 (45,46), and SIM1 (43,44) and regulate a variety of target genes. Of note, ARNT has 
also been shown to form homodimers and bind to E-box DNA to regulate transcription of 
genes, but more research is needed into this aspect (53,268,269). The two most well 
studied ARNT pathways are the hypoxia HIF and the “dioxin” AhR cascades. This 
section of the review will focus of the function of ARNT with AhR, since that is the 
focus the latter half of this dissertation and since the function of ARNT with HIFα is 
described under the Hypoxia Inducible Factors section.  
Aryl Hydrocarbon Receptor 
  Polycyclic aromatic hydrocarbons (PAHs) and polyhalogenated aromatic 
hydrocarbons (dioxins) are generated from industrial processes when substances are 
burnt, such as coal, oil and gasoline. These compounds contaminate our environment and 
are taken up by animals via diet, skin contact or inhalation leading to serious health risks, 
including, but not limited to, cancer (reviewed in (270)). Recently, PAHs have even been 
identified as contaminants in a variety of processed foods, such as beverages, meats and 
dairy products (271). These chemicals act as ligands for Aryl Hydrocarbon Receptor 
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(AhR) with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin) being one of the most 
potent ligands and one of the most well studied (272).  
More than 30 years ago, AhR was one of the first bHLH-PAS transcription factors 
to be identified due to its ability to regulate cytochrome P4501A1 (CYP1A1) (273). A 
schematic representation of canonical AhR/ARNT signaling is show in Figure 8. Prior to 
ligand binding, AhR is retained in the cytoplasm bound to a chaperone complex 
consisting of HSP90, HSP90 co-chaperone p23 and XAP2 (47-50). A ligand binding to 
cytoplasmic AhR results in exposure of the NLS and a PKC phosphorylation site (51). 
Upon PKC phosphorylation, AhR translocates into the nucleus, dimerizes with ARNT 
and binds to xenobiotic response elements (XREs also referred to as dioxin response 
elements) with the sequence 5’-RCGTG-3’ (R = T/G) in the promoter of a variety of 
genes (Table 4) (51,52). In fact, a large-scale genome wide analysis of AhR target genes 
has been performed, identifying around 600 putative target genes (274). Intriguingly, 
Spry2 was found to be among the top 400 promoters upregulated by AhR when the cells 
are treated with dioxin. The signal is terminated when the cis-acting nuclear export signal 
results in AhR being shuttled out of the nucleus and then degraded by the proteosome 
(275-277). 
 It has been well accepted that induction of AhR transcription by a variety of 
pollutants leads to the transcription of enzymes, such as the CYP450’s that mediate the 
toxic effects of the pollutants (278). In addition, AhR mediates the carcinogenic effects of 
these compounds. This was demonstrated by the tumor promoting effect of PAHs being 





Figure 8: Schematic of canonical AhR activation.  
Cytosolic AhR is bound to a chaperone complex of Hsp90, XAP2 and p23. Upon ligand 
binding, AhR translocates into the nucleus where it dissociates from the chaperone 
complex and dimerizes with ARNT. The dimer binds XRE’s in the promoter of a variety 
of Phase I and Phase II metabolic enzymes. AhR being exported from the nucleus and 





AhR/ARNT Target Gene Reference 





Aldehyde dehydrogenase 3 (289) 
Phase II Metabolism Enzymes 









Table 4: AhR/ARNT Target Genes. Table shows some of the well-characterized target 





tumors when exposed to benzo[a]pyrene, but tumor formation was inhibited when ARNT 
or AhR was knocked out (280,294). Alternatively, AhR can promote tumor progression 
by upregulating genes involved in proliferation or the immune system (reviewed in 
(295)). 
For many years, it was believed that the sole purpose of AhR/ARNT was to 
respond to environmental contaminants and induce the transcription of metabolic 
enzymes. However, if this were the sole purpose of AhR/ARNT, then it would be 
expected that knocking out AhR in a mouse model would have no phenotype. Although 
AhR knockout mice are resistant to dioxin toxicity, they do have a phenotype of defective 
vascular and liver development and cardiac hypertrophy, suggesting an endogenous 
ligand for AhR exists (296-298). Recently, a few low affinity endogenous ligands have 
been identified (Table 5). Intriguingly, it was observed that UV light exposed culture 
media activated AhR (299). It was discovered it was due to tryptophan being converted 
into 6-formlindolo(3,2-b)carbazole (FICZ). Not only is FICZ an ideal substrate for 
CYP1A1, 1A2, and 1B1 (299,300), but also FICZ binds to AhR with the highest affinity 
of any known ligands and therefore induces its own clearance (299,300). This provided a 
new avenue of research into AhR/ARNT physiological relevance.  
Crosstalk between AhR and HIF 
Intriguingly, there has been evidence of crosstalk between AhR and HIF 
signaling. Specifically, many groups have shown that hypoxia reduces the transcriptional 
activity of AhR (301-308). Fewer groups have reported dioxin/dioxin-like compounds 
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 (uM to mM affinity) 
High-Affinity AhR Ligands  

















Table 5: List of Known AhR ligands.  





that ARNT is limiting, meaning there are not enough ARNT subunits to activate 
transcription for both AhR and HIF simultaneously, which is supported by a recent study 
showing overexpression of ARNT reversed the reduction of AhR transcriptional activity 
by hypoxia (303). This would be of particular interest when investigating regulation of 
ARNT protein levels. A protein or interaction that could reduce ARNT protein levels 
would further limit either/both HIF- and AhR- mediated transcriptional regulation of a 
variety of genes. Alternatively, a protein or interaction that elevated ARNT protein levels 
would allow both HIF and AhR to regulate transcription of their respective target genes 
simultaneously and alleviate the competition between these two factors for the limited 
amounts of ARNT. However, other studies have suggested that ARNT is not rate limiting 
and overexpression does not rescue the reduction in AhR activity (308,311). These 
differences could be cell type specific since overexpression of ARNT in hepatoma cell 
lines, but not breast cancer cells, rescued the reduction in AhR activity, but more cell 
lines need to be investigated (303,308). 
Instead of ARNT being limiting, it was proposed that hypoxia depletes a cofactor 
required for AhR activity, such as BRCA, a AhR co-regulator (308). In fact, the two 
pathways, HIF and AhR, utilize many of the same cofactors such as CBP (312), SRC-1-3, 
and TRIP230 (313). Alternatively, hypoxia may cause the induction of inhibitors of AhR 
causing a reduction in AhR transcriptional activity (314). Whatever the mechanism, there 
clearly exists crosstalk between AhR and hypoxic signaling. 
Regulation of ARNT mRNA and protein levels 
 Despite the fact AhR signaling and regulation has been studied for over 40 years, 
mechanisms that regulate ARNT expression or protein levels remain largely unknown. 
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Many reviews cite ARNT protein levels as being constitutively expressed and localized 
to the nucleus (315-318). However, recently some reports have suggested that ARNT 
levels are regulated by a variety of factors.  
 A few groups have shown that miR’s target ARNT mRNA reducing ARNT 
levels. Previous research has shown that ARNT mRNA can be targeted by miR-24 in 
human liver-derived cells (319) Additionally, two studies have shown that miR-107 
targets ARNT mRNA in colon cancer cells reducing HIF1 transcriptional activity and 
tumor angiogenesis (57,320). Another study showed that targeting of ARNT by miR-107 
also inhibits endothelial progenitor cell differentiation (321). Yet another study showed 
miR-221, which is often upregulated in HCC, targets ARNT mRNA and provides a 
partial explanation for the pro-proliferative actions of miR-221 (322). 
  In terms of regulation of ARNT protein levels, early on, it was reported that 
ARNT mRNA and protein levels were upregulated by hypoxia (28). Since then a few 
groups have reproduced the hypoxic regulation of ARNT protein levels in mouse 
fibroblast L929, mouse hepatoma Hepa1 (323), human prostate cancer PC3 (324), human 
melanoma 518A2 (325), and human breast cancer MCF7 (326) cell lines, but this is often 
not accompanied by an increase in ARNT mRNA levels. One group found that this 
upregulation was dependent upon HIF1α, thereby preventing ARNT from becoming 
limiting in hypoxia (325). However, another report provided contradictory results of 
ARNT not being regulated by hypoxia (327), and the overall consensus is that ARNT 
protein and mRNA levels are not regulated by hypoxia. This leads to the conclusions that 
perhaps the regulation of ARNT by hypoxia is cell type specific, and further research is 
needed to deduce its relevance and mechanism of upregulation in hypoxia. 
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One study showed that treating tumor cells with curcumin, a component of 
turmeric, resulted in enhanced ubiquitylation and proteosomal degradation of ARNT and 
consequently down-regulation HIF1 target genes (328). The ability of curcumin to reduce 
HIF1 target genes provides a possibly explanation for the anti-cancer actions of 
curcumin. The authors were unable to identify an ubiquitin ligase responsible for the 
enhanced ubiquitylation from curcumin treatment (328). In fact, to our knowledge no one 
has identified any ubiquitin ligase capable of ubiquitylating ARNT, and this should be a 
key area of future studies on ARNT. 
Another study found that estrogen receptor β (ERβ) also reduced HIF1 
transcriptional activity via downregulation of ARNT (329). Yet again, this resulted in the 
down regulation of the HIF1 target genes and an inhibition of breast cancer progression 
(329). Interestingly, the regulation of ARNT by ERβ provides a possible mechanism for 
the previously documented tumor suppressive functions of ERβ (330). Similar to the 
study with curcumin above, the authors showed that the ubiquitylation and proteosomal 
degradation of ARNT was enhanced, but did not attempt to identify the ubiquitin ligase 
responsible (329). In addition to ARNT ubiquitylation, one study has show that ARNT is 
SUMOylated (331). SUMOylation of ARNT on lysine 245 prevented its association with 
PML and reduced it transcriptional activity (331). 
ARNT in Cancer 
 The role ARNT plays in tumor progression is sorely understudied despite the fact 
the impact of HIF1α and AhR in cancer has been very well studied. Additionally, 
whether ARNT promotes or inhibits tumor growth has been controversial. The role of 
ARNT as a tumor promoter would be in agreement with its function as the partner for 
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HIF1α and AhR, both of which have been shown to promote tumor formation and 
progression (as discussed above under HIF in cancer and Aryl Hydrocarbon Receptor, 
respectively). ARNT has been shown to promote HCC growth and metastasis (53). 
Additionally, in normoxia, ARNT, via binding Sp1 and c-Jun, regulates the transcription 
of EGF-induced p21WAF/CIP1, COX-2 and 12(S)-lipoxygenase contributing to 
tumorigenesis (54,55). The same group also showed that ARNT regulates the 
transcription of multidrug resistance 1 (MDR1), which would confer drug resistance to 
cancer cells (56). Furthermore, reduction of ARNT enhanced cisplatin-induced cell death 
in both cisplatin sensitive and resistant cell lines (56).  
Most recently, the Chen group also suggested that ARNT plays a tumor-
promoting role in the early stages of tumor growth, which is in agreement with an earlier 
study by the Hankinson group (57,58) and the studies described above. However, in later 
stages of tumor growth, the Chen group shows that ARNT transitions to having a tumor 
suppressive role by having a negative impact on tumor migration and invasion (57). 
Specifically, ARNT protein levels were reduced in late stage CRC and a reduction in 
ARNT levels resulted in enhanced cancer cell migration and invasion via elevation in 
fibronectin, N-cadherin and integrin β1 (57). Of importance, the authors noted that 
chemotherapeutic drugs reduced ARNT levels (57). Overall, ARNT has a tumor 
promoting function whether bound to HIF1α, AhR or Sp1, but perhaps in late stage 
tumors, ARNT would have a tumor suppressive effect. More studies into this 
phenomenon are needed, but it is possible targeting ARNT in cancer may have varying 
effects depending on the tumor stage.  
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To conclude, ARNT by dimerizing with many transcription factors is at the center 
of a large transcription-signaling network. Despite this, regulation of ARNT levels and 
impact ARNT has in cancer has been sorely understudied. 
In light of this previous research emphasizing the seemingly opposite effects 
HIFα and Spry2 have on cellular processes and cancers, we investigated if Spry2 
regulated the levels HIFα. During this investigation, we also monitored if Spry2 regulated 
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The α-subunits of hypoxia inducible factors (HIF1α and HIF2α) promote 
transcription of genes that regulate glycolysis and cell survival and growth. Sprouty2 
(Spry2) is a modulator of receptor tyrosine kinase signaling and inhibits cell proliferation 
by a number of different mechanisms. Because of the seemingly opposite actions of HIFα 
subunits and Spry2 on cellular processes, we investigated whether Spry2 regulates the 
levels of HIF1α and HIF2α proteins. In cell lines from different types of tumors in which 
the decreased levels of Spry2 protein have been associated with poor prognosis, silencing 
of Spry2 elevated HIF1α protein levels. Increase in HIF1α and HIF2α protein levels due 
to silencing of Spry2 also upregulated HIFα target genes. Using HIF1α as a prototype, we 
show that Spry2 enhances the ubiquitylation and proteosomal degradation of HIF1α by a 
pVHL dependent mechanism. Spry2 also exists in a complex with HIF1α. Since Spry2 
can also associate with pVHL, using a mutant form of Spry2 (3P/3A-Spry2) that binds 
HIF1α, but not pVHL, we show that WT-Spry2 but not the 3P/3A-Spry2 decreases 
HIF1α protein levels. In accordance, expression of WT-Spry2, but not 3P/3A-Spry2 
results in a decrease in HIF1α-sensitive glucose uptake. Together our data suggest that 
Spry2 acts as a scaffold, to bring more pVHL/associated E3 ligase in proximity of HIF1α
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and increase its ubiquitylation and degradation. This represents a novel action of Spry2 in 
modulating biological processes regulated by HIFα subunits.  
 
INTRODUCTION 
The four Sprouty proteins (Spry1 – Spry4), which are products of different genes, 
regulate downstream signaling from certain receptor tyrosine kinases (RTK) and, 
therefore, play a major role in development (13,88,332-334). Because cell proliferation 
processes in normal development and tumor growth overlap, some of the Spry proteins, 
such as Spry1, Spry2, and Spry4, also regulate tumor growth (14,15,17,18,20,21,335-
339). Among the four isoforms, Spry2 is ubiquitously expressed and well studied in 
cancer. In cancers of the liver, lung, breast and prostate, Spry2 levels are decreased (14-
21,143). The decrease in Spry2 levels in these cancers has been correlated to poor patient 
prognosis and shorter survival of patients implicating Spry2 as a tumor suppressor. 
Therefore, a number of studies have investigated mechanisms that regulate the expression 
of Spry2 as well as how it modulates signaling via RTKs (6-8,12,116,169). At the post-
translational level, Spry2 has been shown to be ubiquitylated and targeted for 
proteosomal degradation by c-Cbl (108,113), Siah2 (119), Nedd4-1 (103) and pVHL 
associated E3 ligase (121). Interestingly, in some patient-derived hepatocellular 
carcinomas, when Spry2 levels were decreased, the levels of Nedd4-1 were elevated (18).  
It is now well established that as tumors proliferate rapidly prior to angiogenesis, 
the oxygen from the nearby vasculature cannot diffuse throughout the entire tumor 
resulting in the formation of a hypoxic environment (see (22) for review). Cells adapt to 




an increase in the levels of the transcription factors, hypoxia inducible factors (HIFs) 
(23,24,26-28). HIFs are heterodimers composed of one of three alpha subunits (HIF1α, 
HIF2α, HIF3α) and a beta subunit (HIF1β). The role of HIF3α in hypoxic gene regulation 
is not well understood, but a splice variant of HIF3α may function as an inhibitor of gene 
transcription during hypoxia (340,341). In normoxia, HIF1α and HIF2α are degraded by 
a well-characterized proteosomal mechanism (see (342,343) for review). Prolyl 
Hydroxylase Domain proteins (PHDs) bind to the HIFα subunits and hydroxylate two 
proline residues on HIFα (29,30). These hydroxy-prolyl residues serve as the docking site 
for von Hippel-Lindau protein (pVHL) and its associated E3 ubiquitin ligase resulting in 
the ubiquitylation and subsequent proteosomal degradation of HIFα subunits (31-34). 
Because the hydroxylation reaction requires oxygen, in hypoxia the activity of the PHDs 
is attenuated and therefore, the hydroxylation, ubiquitylation and degradation of HIFα 
subunits is inhibited. This permits the accumulation of HIFα protein levels and 
consequently, enhances their ability to regulate transcription of genes such as those that 
regulate proliferation, angiogenesis, drug metabolism and glycolysis to promote tumor 
survival and growth (reviewed in (35-37)).  
Because of the anti-proliferative and tumor suppressor actions of Spry2, we 
investigated whether Spry2 alters the levels of HIFα subunits and/or their ability to alter 
transcription of their target genes. Herein we report the novel ability of endogenous 
Spry2 to promote the degradation of HIF1α and HIF2α resulting in a decrease in the 
expression of the genes that the two HIFs regulate. With HIF1α as the prototype of the 
two HIFα proteins (HIF1α and HIF2α), we demonstrate that Spry2 enhances the 




also show that Spry2 exists in a complex with HIF1α. Because we previously reported 
that Spry2 is capable of binding to pVHL (121), we hypothesized that Spry2, by binding 
with HIF1α, increases the amount of pVHL in the vicinity of HIF1α and promotes its 
degradation through a pVHL dependent mechanism. Indeed, our studies show that when 
pVHL is silenced, Spry2 cannot alter HIF1α protein levels. Additionally, a mutant form 
of Spry2 that does not bind to pVHL does not decrease HIF1α protein levels. In 
agreement, wild-type (WT) Spry2 inhibits HIF1α-sensitive glucose uptake whereas the 
mutant form of Spry2 that does not associate with pVHL does not alter glucose uptake. 
 
EXPERIMENTAL PROCEDURES 
Chemicals and Reagents 
Cycloheximide (CHX) and N-ethylmaleimide (NEM) were purchased from Sigma 
Chemical Co. (St. Louis, MO). MG132 was purchased from Selleck Chem (Houston, 
TX). Bortezomib was purchased from LC labs (Woburn, MA). All primers, probes and 
siRNAs were synthesized by Integrated DNA Technologies Inc. (Coralville, IA). The 
sequences of the various siRNAs used are described in Table 6. Antibodies used for 
different applications and their dilutions are listed in Table 6. 
DNA Constructs 
The cloning of human Spry2 cDNA in to the pHM6-HA-vector is described 
elsewhere (93). pHM6-HA-3P/3A-Spry2 was generated using site directed mutagenesis 
of the wild type pHM6-HA-Spry2 to mutate prolines 18, 144, and 160 (121). The cDNA 
of HIF1α was purchased from Origene and subcloned into pcDNA3 vector using HindIII 





siRNA Targets siRNA Sense (5’-3’) siRNA Anti-Sense(5’-3’) 
Spry2 1 GAUCAGAUCAGAGCCAUCCGAAACACC GGUGUUUCGGAUGGCUCUGAUCUGAUC 
Spry2 2 CACUCCUUACAUUUGCACUUGCCACAG GUGGCAAGUGCAAAUGUAAGGAGTG 
Mut Spry2 GGAGUUUCGCAUGGCUAUGAUCUGCUC GAGCAGAUCAUAGCCAUGCGAAACUCC 
HIF1  CAAAGUUAAAGCAUCAGGUUCCUCUU GAAGGAACCUGAUGCUUUAACUUTG 
HIF2  GCAGGAUUCCAUUUCCGUUUCUAAGUU CUUAGAAACGGAAAUGGAAUCCUGC 
Control (for HIF1/2 ) GUCAGCAGAACAAAAGUAGTT TTCAGUCGUCUUGGUUUUCAUC 
pVHL 1 ACUAUGAAACAGUCCAGGCUACUCCAU GGAGUAGCCUGGACUGUUUCAUAGT 








Rabbit Sigma, St. Louis, MO S1444 092M4796 WB - 1:1k O/N 4°C 
IP - 3µg Ab/500µg total 
protein 
Spry2 (ICC) Rabbit Rockland, Limerick, PA 600-401-E68 
 
n/a 1:400 O/N 4°C 
HIF1  (WB) Rabbit Abcam, Cambridge, England Ab51608 GR185326-12 1:2k O/N 4°C 
HIF1  
(WB/ICC) 
Mouse BD Transduction Laboratories, 
Franklin Lakes, NJ 
610959 4073775 WB - 1:1k O/N 4°C 
ICC - 1:50 O/N 4°C 
HIF1  (IP) Mouse Novus Biologicals, Littleton, CO NB100-105 Al-1 2µg Ab/150µg total protein 
HIF2  Goat R and D Systems, Minneapolis, 
MN 
AF2886 VEA0312021 1:1k O/N 4°C 
pVHL (WB) Rabbit Cell Signaling, Danvers, MA 2738S 2 1:2k O/N 4°C 
pVHL (IP) Mouse BD Transduction Laboratories, 
Franklin Lakes, NJ 
556347 5044733 3µg Ab/250µg total protein 
Total AKT Rabbit Cell Signaling, Danvers, MA 9272S 13 1:5k1hr RT 
Phospho-
AKT S473 
Mouse Cell Signaling, Danvers, MA 4051S 13 1:1k O/N 4°C 
Tubulin Mouse Iowa State University E7 n/a 1:5k 1hr RT 




Mouse Cell Signaling, Danvers, MA 9106S 30 1:1k O/N 4°C 
Actin Mouse MP Biomedicals, LLC, Solon, OH 691001 Q1642 1:10k 1hr RT 
PHD1 Rabbit Novus Biologicals, Littleton, CO NB100-310SS A7 1:5k 1hr RT 
PHD2 Rabbit Abcam, Cambridge, England Ab4561-100 701327 1:8k 1hr RT 
PHD3 Rabbit Novus Biologicals, Littleton, CO NB100-139 n/a 1:1k O/N 4°C 
HA-HRP Mouse Roche Life Science, Indianapolis, 
IN 
12013819001 n/a 1:10k 1hr RT 
FLAG-M2 (IP) Mouse Sigma, St. Louis, MO F4049 070M6058 3µg Ab/100µg total protein 
FLAG-HRP Mouse Sigma, St. Louis, MO A8592 059K6059 1:10k 1hr RT 
 
Table 6: Sequences for siRNAs and information about antibodies used.  
(A) Sense and anti-sense sequences for all siRNAs used. (B) List of antibodies with 





University Chicago. pGL2-Pfkfb3/-3566 was kindly provided by Ramon Bartrons, 
University of Barcelona. pCMV-3x- FLAG-ubiquitin was kindly provided by Dr. 
Adriano Marchese, Loyola University Chicago. The cloning of FLAG-Spry2 is described 
previously (103). FLAG-Spry1, FLAG-Spry3, and FLAG-Spry4 were generous gifts 
from Dr. Graeme Guy, Institute of Molecular and Cell Biology, Singapore. All constructs 
were verified by sequencing. 
Cell Culture 
HuH7 and Hep3B cells were kindly provided by Dr. Basabi Rana, University of 
Illinois at Chicago. HuH7 cells were cultured in DMEM F12 50/50 supplemented with 
HEPES (10 mM), 10% FBS, penicillin (100 units/mL), and streptomycin (100 µg/mL). 
Hep3B cells were cultured in MEM supplemented with HEPES (10 mM), sodium 
pyruvate (1 mM), MEM non-essential amino acid solution (1X), 10% FBS, penicillin 
(100 units/mL), and streptomycin (100 µg/mL). HEK293T cells were kindly provided by 
Dr. Jody Martin, Loyola University Chicago. HeLa cells were kindly gifted by the late 
Dr. Jill Lahti, St. Jude Children’s Research Hospital, Memphis, TN. HEK293T and HeLa 
cells were cultured in high glucose containing DMEM supplemented with 10% FBS, 
penicillin (100 units/mL), and streptomycin (100 µg/mL). Dr. Ajay Rana, University of 
Illinois at Chicago, kindly provided MDA-MB-231 and MCF7 cells. MDA-MB-231 were 
cultured in RMPI 1640 supplemented with 10% FBS, penicillin (100 units/mL), and 
streptomycin (100 µg/mL).  MCF7 cells were cultured in MEM supplemented with 0.01 
mg/mL human recombinant insulin, 10% FBS, penicillin (100 units/mL), and 




Loyola University Chicago cells were cultured in F-12K supplemented with 10% FBS, 
penicillin (100 units/mL), and streptomycin (100 µg/mL).  
Cells were maintained under normoxic conditions (21% O2) in a water-jacket CO2 
incubator (Thermo Fischer Scientific, Waltham, MA) at 37°C, 5% CO2. To split cells, the 
media in a 10-cm dish was aspirated off and the dish was washed with 10 mL of PBS 
(w/o magnesium and calcium). Trypsin (1 mL) was added to the dish and incubated for 
about 3 minutes at 37°C. Media (5 mL) was added and cells were counted and plated for 
experiments as described or split into multiple 10-cm dishes for maintenance with a total 
final volume of 10 mL/dish. Cells were maintained under hypoxic conditions (3% O2) in 
a Coy Hypoxic Chamber (Grass Lake, MI) at 37°C, 5% CO2. Media used for hypoxic 
experiments was pre-equilibrated under hypoxia for 16 h.  
Silencing of Endogenous Spry2 in a variety of cell lines 
Cells (150,000-250,000/35-mm dish) were plated. Next day, media in the dishes 
was changed to 800 µL fresh media. OptiMEM (200 µL/dish) was incubated with Trans-
IT TKO (Mirus Bio LLC, Madison, WI) transfection reagent (6 µL/dish). The mixture 
was divided into two equal aliquots and 20nM 27-mer (control) mutant Spry2 siRNA 
containing three ribonucleotide substitutions of the Spry2 siRNA or Spry2 siRNA duplex 
(2 µL/dish) was added. The mixture was incubated at room temperature for 20 minutes 
before being added drop wise to the dishes. The cells were placed in hypoxia the next day 
and the media was changed to pre-equilibrated hypoxic media (1 mL). Cell lysates were 
collected after either 8 or 24 hours in laemmli sample buffer composed of 125 mM Tris-






A protein determination was performed on samples using a bovine serum albumin 
standard curve and Pierce 660nm Protein Assay Reagent. An aliquot of each sample (15-
40µg depending on the experiment) was loaded into an acrylamide gel. The gel was run 
at 120-160V for 1-2 hours in running buffer composed of 25 mM Tris, pH 8.3, 192 mM 
Glycine and 0.1% SDS. The proteins were transferred from the gel onto a nitrocellulose 
membrane at 100-115V for 1 hour at 4°C in transfer buffer composed of 25 mM Tris, pH 
8.3, 192 mM Glycine, and 20% (v/v) methanol. The membrane was stained with ponceau 
to ensure an efficient transfer and then blocked in 5% milk in PBST for 30 mins. Primary 
antibody was diluted as shown in Table 6 in either 5% BSA or milk in PBST and 
incubated on the membrane either for 1 h room temperature or overnight at 4°C. The 
membrane was washed once in PBST for 10 minutes. Secondary antibodies conjugated to 
horseradish peroxidase (HRP) were diluted 1:7000 in 5% milk and incubated for 1 h 
room temperature. The membrane was washed 3 times in PBST 10 mins each. Either pico 
or dura chemiluminescent substrate (Thermo Fisher) was applied to the membrane, and 
visualization of the bands was obtained using film and an auto developer or a ChemiDoc 
(BioRad). 
Isolating RNA, cDNA Synthesis and quantitative Real Time Polymerase Chain 
Reaction (qRT-PCR) 
HuH7 cells were plated (250,000/35-mm dish or 80,000/well in a 12-well plate) 
and transfected the following day with control (40 nM), Spry2 (20 nM + control (for 
HIF1/2α) 20 nM), Spry2 (20 nM) + HIF1α (20 nM), or Spry2 (20 nM) + HIF2α (20 nM) 




hours in hypoxia, the cells were lysed in 500 µL of TRIzol (Life Technologies, 
Carlsbad, CA) for a 12-well plate. Either 100 µL of chloroform or 50µL of 1-bromo-3-
chloropropane was added to each sample, shaken vigorously, and incubated at room 
temperature for 3 minutes. The samples were centrifuged at 12,000 x g for 15 minutes to 
separate the two phases. The top aqueous phase was carefully removed, pipetted into a 
new tube, and mixed with 250 µL 100% isopropanol and 1 µL GlycoBlue (Life 
Technologies, Carlsbad, CA) to aid in precipitation of RNA. The samples were incubated 
for 10 minutes at room temperature and then centrifuged at 12,000 x g for 10 minutes. 
The supernatant was removed and the pellet was washed with 70% ethanol in RNase free 
water. The samples were centrifuged again at 8,000 x g for 10 minutes, pellets were air 
dried and then dissolved in 50 µL nuclease free water. The RNA was re-precipitated with 
5 µL sodium acetate and 150 µL 100% ethanol overnight to remove impurities. The next 
day the samples with centrifuged at 12,000 x g for 10 minutes. The pellets were washed 
with 100% ethanol with a centrifugation of 8,000 x g for 5 minutes and then air dried. 
The pellets were resuspended in 30-40 µL of nuclease free water and quantified. All RNA 
used had a 260/280 ratio above 1.8 and a 260/230 ratio above 1.9. Total RNA was 
reverse transcribed into cDNA using the SuperScript® VILO cDNA Synthesis Kit (Life 
Technologies, Carlsbad, CA) by mixing the volume of cDNA that equals 500 ng, 3 µL 
5X reaction mix, 1.5 µL 10X enzyme mix, and a volume of water to bring the final 
volume to 15 µL. The tubes are then put into the CFX96 Touch (BioRAD) and incubated 
through the following protocol: 25°C 10 mins, 42°C for 1 h, and 85°C for 5 mins. 




Master Mix with Rox (Roche, Indianapolis, IN) (10 µL master mix, 1 µL primer/probe, 
3 µL cDNA, 6 µL water) or FastStart Universal SYBR Master mix with Rox (Roche, 
Indianapolis, IN)(10 µL master mix, 0.6 µL forward primer, 0.6 µL reverse primer, 3 µL 
cDNA, 5.8 µL water). All primers and probes with their calculated efficiencies are listed 
in Tables 7A and 7B. The plate was run on a CFX96 touch Real Time PCR Detection 
System (BioRAD). The run settings were as follows: 95°C for 10 minutes, (95°C for 10s, 
57/60/62°C (depending on primers) for 30s) * 40 cycles. The cycle threshold (CT) was 
calculated using a single threshold. Three housekeeping genes were used: 18S Ribosomal 
RNA (RN18S1), Hypoxanthine phosphoriosyltransferase (HPRT) and Ribosomal protein, 
large, P0 (RPLP0). The average was taken for the CT’s of the control siRNA transfected 
cells for all housekeeping genes and genes of interest (GOI). The fold change of each 
housekeeping gene and GOI was calculated by taking the efficiency (E) of the gene to the 
power of the difference of the experimental CT and the average CT of control CT. (fold 
change = E^(CTexp-average(CTcontrol) The geometric mean was taken of three 
housekeeping genes. To calculate the relative mRNA amount of each GOI, the fold 
change of the GOI was divided by the geometric mean of the housekeeping genes. 
(Relative mRNA amount = fold change(GOI)/geomean(fold change(RN18S1, HPRT, 
RPLP0)) 
Luciferase Assays  
HuH7 cells were plated (50,000/24-well plate) and the following day co-
transfected using Trans-IT TKO (Mirus Bio LLC, Madison, WI) with control siRNA or 
siRNAs against Spry2, Spry2+HIF1α, Spry2+HIF2α or Spry2+HIF1α+HIF2α (as 




Table 7: Sequences for primers and primers/probe for qRT-PCR.  
Sequences for qRT-PCR (A) primers/probe and (B) primers shown along with the 
temperature they were used at and the efficiency of the (A) primers/probe and (B) 











GLUT-1 TCATCGTGGCTGAACTCTTC GATGAAGACGTAGGGACCAC 60 2.031 
EPO TGGGAGCCCAGAAGGAAGCCA TGGTCATCTGTCCCCTGTCCTGC 62 2.0376 
RPLP0 GCAGCATCTACAACCCTGAA CAGACAGACACTGGCAACAT 57 1.99 
HPRT CGAGATGTGATGAAGGAGATGG TTGATGTAATCCAGCAGGTCAG 60 2.045 
 
Target 





PGK1 GCTTCTGGGAACAAGGTTAAAG TCAATGATGCTTTTGGCACTGCTCACCTGTGGCAGATTGACTCCTAC 62 2.042 
SPRY2 TGCTCGGAAGTTGGTCTAAAG TTGCACCAACCCCTCTCCCTT CACATCTGAACTCCGTGATCG 62 2.023 
HIF1  AACATAAAGTCTGCAACATGGAAG TACGTGAATGTGGCCTGTGCAGT TTTGATGGGTGAGGAATGGG 57 2.16 
HIF2  CCCATGTCTCCACCTTCAAG CGAGCCCCAAAACCCTTTGCAG GGCTTGCTCTTCATACTCCAG 57 2.027 








incubated in normoxia or hypoxia (3% O2) for 24 hours. The cells were lysed in 100 
µL Passive Lysis Buffer (Promega, Madison, WI) and pipetted into a 96-well plate. 
Luciferase assays were performed using the Promega Dual Luciferase Kit.  First, 100 µL 
of luciferase assay reagent II was added to the plate and then read on a PHERAStar FS 
plate reader (BMG labtech, Cary, NC) using the luminescence function. Next, 100 µL of 
the Stop and Glo® reagent was added to the plate and it was read again to obtain the 
renilla luminescence. Relative luminescence was calculated by dividing the luciferase 
luminescence by the renilla luminescence.  
Stability of HIF1α  
HuH7 cells (250,000/35-mm dish) were plated and the following day transfected 
with 20 nM each of control or Spry2 siRNAs as stated above. The cells were treated with 
vehicle (DMSO) or bortezomib (50 nM) for 16 hours. Then the cells were placed in 
hypoxia in media containing fresh vehicle (DMSO) or bortezomib. Eight hours later 
cycloheximide (200 µM) was added. The cells were lysed after 0, 5, or 10 minutes in 
Laemmli sample buffer. HIF1α, Spry2, ERK1/2 and Actin levels were monitored using 
western blotting.  
Ubiquitylation assays  
HEK293T cells (300,000/35-mm dish) were plated and the following day 
transfected using Trans-IT TKO (Mirus Bio LLC, Madison, WI) with 1.25µg of pJX40- 
FLAG-Ubiquitin and 625ng of pcDNA3-HIF1α along with either control or Spry2 
siRNA. The following day cells were placed in hypoxia for 12 hours and 25µM MG132 
was added for an additional 4 hours. The cells were lysed in denaturing lysis buffer (50 




sodium deoxycholate with the following protease inhibitors: 50 mM NaF, 5mM β 
Glycerol phosphate, 1mM Sodium orthovanadate, 150 nM Aprotinin, 1.5 mM Pepstatin 
A, 25 µM MG132, 4.7 mM Leupeptin, 6.6 mM Benzamidine, 8.3 mM Sodium 
pyrophosphate, 5 mM NEM, 0.1mM Phenylmethylsulfonyl fluoride, pH 7.4). The 
samples were sonicated twice for 10 seconds on ice and centrifuged at 15,000 X g for 15 
mins. Lysate (100µg) was diluted one to ten with lysis buffer without SDS and incubated 
with 3µg of anti-FLAG-M2 or mouse IgG for 1 hour. Protein G beads (Roche, 
Indianapolis, IN) (20µL slurry) were incubated with the lysate for 2 hours.  The beads 
were washed three times with lysis buffer with 0.1% SDS. Heating in Laemmli sample 
buffer eluted the bound proteins, which were then separated by SDS-PAGE and HIF1α 
and FLAG-ubiquitin were detected by Western analysis. 
Co-immunoprecipitation (co-IP) of Endogenous Spry2 and HIF1α 
HuH7 cells (800,000/60-mm dish) were plated and the following day exposed to 
hypoxia for 8 hours with the proteosomal inhibitor MG132 (25 µM) treatment during the 
last 4 hours. Cells were washed twice with ice-cold PBS, lysed in lysis buffer (as 
described above except with 1% Triton X100 instead of SDS, NP40, and sodium 
deoxycholate) and rotated for 30 min at 4°C. Lysates were centrifuged at 15,000 x g for 
15 min, and 500 µg of protein was rotated with 3 µg of anti-N-terminal Spry2 antibody 
overnight at 4°C. The next day the lysates were incubated rotating with 30 µL slurry of 
protein G beads (Roche, Indianapolis, IN) for 2 hours at 4°C. The beads were washed 
three times in lysis buffer and then heated to 95°C for 10 min in Laemmli buffer to 
collect bound proteins, which were analyzed for HIF1α and Spry2 by Western blotting. 




HuH7 cells were plated in an 8-well chamber slide and the following day 
transfected with 20 nM each of control or HIF1α siRNAs as stated above. The cells were 
placed in hypoxia the next day for 8 hours and fixed with 3.7% formaldehyde in PIPES 
pH 6.8 for 10 min at room temp (RT), washed, permeabilized with 0.1% triton X100 for 
10 min and blocked with 10% normal goat serum for 1h at RT (ICC) or the PLA kit 
(Sigma, St. Louis, MO) blocking solution for 30 mins at 37°C (PLA). Rabbit Spry2 
(Rockland, Limerick, PA) (1:400 dilution) and mouse HIF1α (BD, Franklin Lake, NJ) 
(1:50 dilution) were incubated overnight 4°C. For ICC, the secondary antibodies were 
goat anti-rabbit conjugated to Alexa Fluor 488 or goat anti-mouse conjugated to Alexa 
Fluor 594 (ThermoFisher, Grand Island, NY) (1:500 dilution). For PLA (Sigma, St. Louis, 
MO), the chambers were washed 5 times 3 minutes each with wash buffer A. A ligation 
reaction was prepared with 14 µL/well of the 5X ligation mixture, 54.25 µL/well water, 
and 1.75 µL/well of ligase since the minimum volume to cover a well in a chamber slide 
is 70 µL. The slide was incubated at 37°C for 30 minutes. The slide was washed four 
times 3 minutes each with wash buffer A. An amplification reaction was prepared with 
14 µL/well of 5X amplification stock, 55.125 µL/well of water, 0.875 µL/well of the 
polymerase. The slide was incubated at 37°C for 100 minutes. The slide was washed 4 
times 5 minutes each in wash buffer B and once more in wash buffer B diluted 1 to 100. 
The chambers were removed and the slide was dried and cover slipped with the DAPI 
containing mounting media provided. Confocal images were obtained with a TCS SP5 
laser scanning confocal microscope (Leica, Exton, PA, USA) equipped with DMI6000 
inverted microscope with blue diode (405 nm), Argon (458/476/488/496/514 nm), diode 




blue (numerical aperture: 1.4 oil immersion) objective lens. The software used to 
capture the images was Leica Application Suite Advanced Fluorescence (LAS AF). For 
ICC, 5 fields were taken for each condition. For PLA, 10-15 fields were taken of each 
condition and PLA puncta were quantified using NIH ImageJ64 Software using the 
“analyze particles” function. The 3X zoomed insets were generated using “Zoom in 
images and stacks” macro by Gilles Carpentier. 
Co-IP of HIF1α with pVHL  
HuH7 cells (650,000/600-mm dish) were plated and next day transfected with 
20nM control or Spry2 siRNA as stated above. The following day the cells were exposed 
to hypoxia for 8 hours with the proteosomal inhibitor MG132 (10 µM) treatment during 
the last 4 hours. Immunoprecipitation of pVHL was performed using the buffer described 
for “Ubiquitylation Assays” except the buffer contained 0.1% SDS instead of 1% SDS. 
The samples were centrifuged at 15,000 rpm for 15 mins and 250 µg of protein was 
rotated with 3 µg of anti-pVHL (BD, Franklin Lakes, NJ) bound bead slurry (15 µL/IP) 
(Roche, Indianapolis, IN) overnight at 4°C. The next the beads were washed three times 
with the buffer diluted 1:1 with PBS. The bound proteins were eluted in Laemmli buffer 
and analyzed using Western blotting for HIF1α and pVHL. 
Co-IP of WT-Spry2 and 3P/3A Spry2 with HIF1α  
HEK293T (500,000 cells/ 60 mm dish) cells plated and the next day cells were 
transfected with 750 ng of pHM6-vector, pHM6-WT-HA-Spry2 or pHM6-3P/3A-HA-
Spry2 along with 750 ng pcDNA3-HIF1α with TransIT-2020 (Mirus Bio LLC, Madison, 
WI). The media on the dishes was changed to 3 mL fresh media. For each dish, 400 µL of 




2020 for this experiment). The mixture was divided between three tubes (400µL per 
tube) and the appropriate amount of DNA was added to each tube to equal 750 ng. The 
mixture was incubated at room temperature for 20 minutes and then added drop wise to 
each dish. Next day, cells were incubated in hypoxia for 16 hours. Immunoprecipitation 
protocol was modified from the two-step lysis method in (344). Protein G bead slurry 
(Roche, Indianapolis, IN) was incubated overnight at 4°C with 2 µg of antibody (anti-
HIF1α (Novus Biologicals, Littleton, CO) or mouse IgG (Sigma Chemical Co., St. Louis, 
MO) in PBS with 0.5% CHAPS and 5% BSA. Next day, cells were lysed in 500µl of 
Triton X-100 hypotonic buffer (described in (344) with the addition of protease and 
phosphatase inhibitors stated above). The samples were sonicated twice at 15% power for 
10 seconds. NaCl was added to each tube to a final concentration of 420 mM and the 
samples were incubated on ice for 1 hour. The samples were sonicated again as 
previously stated and centrifuged at 10,000 X g for 10 minutes. The supernatant (150 µg) 
was incubated with antibody bound beads (either mouse IgG or HIF1α) for 2 hours. The 
samples were washed three times in the hypotonic buffer with 150 mM NaCl. The final 
wash was removed and the bound proteins were eluted off the beads by heating in 
Laemmli sample buffer. 
pVHL silencing 
 HuH7 cells were plated (250,000/35-mm dish) and transfected using Trans-IT 
TKO with 20 nM each of control or Spry2 siRNA along with 40 nM each of control or 
one of two pVHL siRNAs (pVHL siRNA 1 or 4) as described above. The next day cells 
were incubated in hypoxia for 8 hours. The cells were lysed in Laemmli sample buffer 




Expression of wild-type (WT) Spry2 and Spry2 P18A/P144A/P160A (3P/3A) 
mutant Spry2  
HEK293T cells were plated (250,000/35-mm dish) and transfected the next day 
using TransIT-2020 transfection reagent (Mirus Bio LLC, Madison WI) with 250 ng of 
pHM6-vector, pHM6-WT-HA-Spry2 or pHM6-3P/3A-HA-Spry2 as described under 
“Co-IP of WT-Spry2 and 3P/3A Spry2 with HIF1α”. After 24 hours, the cells were placed 
in hypoxia for 16 hours. The cells were lysed in Laemmli sample buffer and analyzed for 
HIF1α, HA-Spry2, Actin, ERK1/2, pAKT S473, total AKT, PHD1, PHD2, PHD3 and 
pVHL levels using Western blotting. 
Glucose Uptake Assays  
HeLa or HuH7 cells (40,000/well of 24-well plate) were plated and the following 
day transfected with 20 nM each of control or HIF1α siRNA and 200 ng each of either 
pHM6-vector, pHM6-WT-HA-Spry2, or pHM6-3P/3A-HA-Spry2 using TransIT-
HeLaMONSTER (Mirus) (HeLa) or TransIT-X2 (Mirus) (HuH7). Quadruplicate sets of 
wells for each condition were transfected. Next day, the cells were placed in the hypoxic 
chamber and the media changed to pre-equilibrated hypoxic media. After 24 hours, the 
cells were washed with Krebs Ringer HEPES Buffer (KRH) (modified from Cold Spring 
Harbor Protocols) and then incubated in KRH with 100 µM [3H]-2-deoxy-D-glucose (0.5 
µCi/well) for 10 minutes. One set of duplicate wells was incubated with an additional 20 
mM 2-deoxy-D-glucose to compete with [3H]-2-deoxy-D-glucose and determine specific 
glucose uptake. The cells were then washed three times in ice-cold KRH and lysed in 0.5 
M NaOH with 0.1% triton X100. An aliquot (10 µL) of the lysate from each sample was 




scintillation vial. Each well was washed once with 300 µl of KRH that was also 
transferred to the scintillation vials for counting after mixing with 5 mL of scintillation 
fluid. The vials were counted on a Beckman Coulter scintillation counter. Data were 
calculated to represent picomoles of [3H]-2-deoxy-D-glucose uptake/ µg of total protein. 
To determine the HIF1α-specific glucose uptake, the average of the HIF1α siRNA 
transfected samples was subtracted from the control siRNA transfected samples. 
Statistical Analysis  
All data are represented as mean ± standard error of the mean (SEM). Data was 
analyzed as indicated in figure legends with two-tailed unpaired t-tests, one-way analysis 
of variance (ANOVA), or Two-way ANOVA; p<0.05 was considered significant, n.s, not 






Endogenous Spry2 regulates HIF1α and HIF2α protein levels  
 Since previous studies have suggested that Spry2 plays a critical role in the 
regulation of hepatocellular, prostate, breast, and lung carcinomas, we utilized HuH7 
cells that are derived from a human hepatocellular carcinoma (14-21,143). In these cells, 
the siRNA-mediated silencing of endogenous Spry2 resulted in a 2.5-fold elevation of 
endogenous HIF1α protein levels (Fig. 9A). As established by numerous studies, HIF1α 
levels are not detectable in normoxia. However, once the cells are exposed to hypoxia, 
HIF1α protein levels are elevated (Fig. 9A). It is also important to note that as reported in 
our earlier report (121), Spry2 levels are also elevated by hypoxia (Fig. 9A). The increase 
in HIF1α protein levels upon silencing of endogenous Spry2 is not accompanied by a 
change in HIF1α mRNA levels (Fig. 9B). Like HIF1α, endogenous HIF2α protein levels 
in HuH7 cells were also increased by hypoxia and further elevated by 2-fold upon 
silencing of Spry2 (Fig. 9C) without any changes in HIF2α mRNA levels (Fig. 9D). A 
second Spry2 siRNA targeting a different sequence in the mRNA also elevated HIF1α 
and HIF2α protein levels in HuH7 cells (Fig. 10A). Together, these findings suggest that 
Spry2 alters HIF1α and HIF2α protein levels post-transcriptionally.  
The generality of our findings is exemplified by the observations that silencing of 
Spry2 with two different siRNAs results in an elevation of HIF1α protein levels in the 
following panel of cell lines derived from tumors in which Spry2 plays a crucial role: 
breast cancer derived cell lines (MCF7 and MDA-MB-231), lung cancer cell line (A549) 





Figure 9: Silencing of Spry2 increases HIF1α and HIF2α protein amounts without 
altering their mRNA levels.  
HuH7 cells transfected with control (Cntrl) siRNA or siRNA targeting Spry2 were 
cultured in normoxia (N) (21%O2) or hypoxia (H) (3% O2). Representative western blots 
probed for (A) HIF1α, (C) HIF2α (images from same blot), Spry2 and Actin (loading 
control) are shown. Graphs in lower panels show mean ± SEM of densitometric analysis 
of (A) HIF1α or (B) HIF2α normalized to actin from 3 (A) or 4 (C) independent 
experiments. Transcript levels of HIF1α (B), HIF2α (D) and Spry2 were monitored using 
qRT-PCR and relative levels were calculated as described in Experimental Procedures. 
Graphs are mean ± SEM from 3 independent experiments. Statistical significance was 
assessed using unpaired Student t-tests (A & C).  
  

























































































HEK293T cells also elevated HIF1α levels (WCL blot in Fig. 12B). Additionally, 
ectopic expression Spry2 decreased HIF1α protein levels in HEK293T (Fig. 14B) and 
HeLa cells (Figs. 10C, 10D & 14C). Moreover, expression of the other isoforms of Spry 
(Spry1, Spry3, and Spry4) also decreased HIF1α protein levels (Fig. 10D). These 
findings suggest that all isoforms of Spry proteins regulate HIF1α protein levels. 
However, to elucidate the mechanisms and impact of the regulation of HIFα protein 
levels, herein we have focused on Spry2 as a prototypic member of this family. 
Spry2 regulates the ability of HIF1α and HIF2α to modulate the transcription of their 
target genes  
HIF1α and HIF2α form heterodimers with HIF1β and act as transcription factors 
to regulate a variety of genes including those that regulate glycolysis 
(182,250,255,260,345-347). To determine if the ability of HIF1α and HIF2α to function 
as transcription factors was altered upon silencing of endogenous Spry2, mRNA levels of 
HIF1α- and HIF2α- regulated genes were monitored using quantitative RT-PCR. As 
examples of HIF1α regulated genes, we monitored the mRNA levels of the glucose 
transporter GLUT1 and the glycolytic enzyme phosphoglycerate kinase 1 (PGK-1). 
Consistent with the changes in protein levels of HIF1α, Spry2 silencing resulted in a 
significant elevation of GLUT1 and PGK-1 mRNA levels (Figs. 11A & 11B). The 
silencing of HIF1α, but not HIF2α, abolished the ability of siRNA against Spry2 to 
elevate GLUT1 and PGK-1 mRNA levels demonstrating that silencing of Spry2 mediated 






Figure 10: Two siRNAs against Spry2 enhance HIF1α protein levels in a variety of 
cell lines and ectopic expression of all Spry isoforms decreases HIF1α protein levels. 
(A) HuH7 cells transfected with control (Cntrl) siRNA or two different siRNAs targeting 
Spry2 were cultured in hypoxia (H) (3% O2). Western blot probed for HIF1α, HIF2α, 
Spry2 and Actin (loading control) is shown. (B) MCF7, MDA-MB-231, A549, and 
Hep3B cells transfected with control (-) or one of two different Spry2 siRNAs (1 & 2) 
were cultured in hypoxia (3% O2). A representative blot probed for HIF1α, Spry2, and 
Actin is shown. Graph shows mean ± variances of densitometric analysis of HIF1α 
normalized to Actin for 2 independent experiments. (C) Control or HA-Spry2 expressing 
HeLa cells were cultured in normoxia (N) (21% O2) or hypoxia (H) (3% O2). 
Representative blot probed for HIF1α, HA-Spry2 and ERK1/2 (loading) is shown. Graph 
below shows mean ± SEM of densitometric analysis of HIF1α normalized to Actin from 
4 independent experiments. Statistical significance was assessed by unpaired Student t-
test. (D) HeLa cells transfected with empty vector or vector constructs expressing Spry1, 
Spry2, Spry3 and Spry4 were placed in hypoxia (H) (3% O2) for 24 hours. Western blot 
























































































As a second approach to monitor the ability of Spry2 to modulate HIF1α-
elicited transcription, we transfected HuH7 cells with a luciferase reporter plasmid 
comprised of the phosphofructose kinase (PFK) promoter fused to a luciferase reporter 
gene (PFK-Luc) and a renilla luciferase plasmid as a control for transfection efficiency. 
Transcription of the PFK gene and the PFK promoter-Luc construct is regulated by 
HIF1α, but not by HIF2α (250). In these cells, the ability of HIF1α to regulate 
transcription, as measured by luciferase activity, was elevated by 2.5-fold by hypoxia 
(Fig. 11C). Moreover, silencing of Spry2 further elevated luciferase activity by 63% (Fig. 
11C). Silencing of HIF1α, but not HIF2α, abolished the ability of Spry2 targeting siRNA 
to enhance luciferase activity (Fig. 11C) demonstrating that silencing of Spry2 enhances 
the transcription of PFK-Luc via changes in HIF1α levels. These data (Figs. 11A-11C) 
also show that, as reported by others (182,250,345,347), the expression of GLUT1, PGK-
1, and PFK-Luc are regulated by HIF1α and not HIF2α. 
  Recently, erythropoietin (EPO) was identified as a HIF2α responsive gene 
(348,349). Therefore, to determine if the enhanced HIF2α levels observed upon silencing 
of Spry2 (Fig. 9B) also altered the transcription of the HIF2α responsive EPO gene, we 
monitored EPO mRNA levels in HuH7 cells. Akin to the findings with GLUT1 and 
PGK-1 for HIF1α, the silencing of Spry2 elevated EPO mRNA levels and the silencing of 
HIF2α, but not HIF1α, obliterated the ability of the siRNA against Spry2 to elevate EPO 
mRNA levels (Fig. 11D). The efficient silencing of the Spry2, HIF1α and HIF2α 
expression by the different siRNAs for the qRT-PCR data is shown in Figs. 11E-11G. 
Overall, the data presented thus far demonstrate that Spry2 decreases HIF1α and HIF2α 





Figure 11: Spry2 silencing enhances the transcript levels of HIF1α- and HIF2α- 
regulated genes and activity of the PFK-Luc reporter. 
 HuH7 cells were transfected with control siRNA or siRNAs against Spry2, 
Spry2+HIF1α, Spry2+HIF2α, or Spry2+HIF1α+HIF2α and cultured in hypoxia (3% O2). 
Transcript levels of GLUT-1 (A), PGK-1 (B), EPO (D), Spry2 (E), HIF1α (F) and HIF2α 
(G) were monitored using qRT-PCR and relative levels were calculated as described in 
Experimental Procedures. (C) HuH7 cells were transfected with the same siRNAs as 
described for (A, B, & D) along with pGL2-Pfkfb3/-3566 and pRG-TK (as control) and 
cultured in normoxia (21%O2) or hypoxia (3% O2) for 24 hours. Luciferase assays were 
performed as described in Experimental Procedures. Data shown are the mean ± SEM, 
from 4 (B & D-G), 3 (A) or at least 3 (C) independent experiments. Statistical 
significance was assessed by one-way ANOVA with Tukey’s multiple comparisons (A, B 



















































































































































expression is silenced the elevation in their protein levels increases the transcription of 
their respective target genes. Hence, endogenous Spry2 regulates the endogenous HIFα 
protein content and the transcription of their target genes. 
Spry2 regulates the stability and ubiquitylation of HIF1α  
The lack of any changes in mRNA levels of HIF1α or HIF2α when expression of 
Spry2 is silenced in the face of a 2- to 2.5- fold increases in the levels of the two proteins 
(Figs. 9A & 9C) would suggest that Spry2 regulates HIF1α and HIF2α post-
translationally. The post-translational regulation of HIF1α and HIF2α involves very 
similar mechanisms comprising of hydroxylation of two prolyl residues that serve as the 
binding site for von Hippel-Lindau protein (pVHL) and associated E3 ligase (see 
(342,343) for review). Therefore, using HIF1α as a prototypic member, we first examined 
whether Spry2 altered the stability of HIF1α protein. Essentially, HuH7 cells transfected 
with control siRNA or siRNA against Spry2 were treated with the protein translation 
inhibitor cycloheximide (CHX) and the levels of HIF1α were monitored at different 
times. As shown in Figure 12A, silencing of Spry2 increased the half-life of HIF1α from 
4.3 mins to 7.1 mins. The major degradation pathway for HIF1α involves ubiquitylation 
followed by proteosomal degradation and treatment of cells expressing endogenous 
Spry2 (i.e. Ctrl siRNA in Fig. 12A right panel) with the proteosomal inhibitor bortezomib 
stabilized HIF1α suggesting that Spry2 enhances the proteosomal degradation of HIF1α.  
Next, we directly determined whether Spry2 altered the ubiquitylation of HIF1α. 
For this purpose, we utilized HEK293T cells because the transfection efficiency of HuH7 
cells with FLAG-ubiquitin was very low. HEK293T cells were transfected with FLAG-




lysate (WCL) shows efficient silencing of Spry2 and equal expression of FLAG-Ub 
(Fig. 12B left panel). Immunoprecipitation of cell lysates under denaturing conditions 
with non-specific IgG or anti-FLAG antibody showed that the anti-FLAG antibody 
immunoprecipitates similar amounts of total FLAG-tagged ubiquitylated proteins from 
cells treated with control siRNA and siRNA against Spry2 (Fig. 12B middle panel). 
Probing the immunoprecipitates for HIF1α assessed the amount of ubiquitylated HIF1α 
in each sample. When Spry2 was silenced, the amount of ubiquitylated HIF1α was 
approximately 50% lower than that in control siRNA transfected cells (Fig. 12B middle 
and bar graph on the right). These data (Fig. 12) demonstrate that endogenous Spry2 
increases the ubiquitylation of HIF1α and targets it for proteosomal degradation. 
Spry2 exists in a complex with HIF1α and regulates HIF1α through pVHL dependent 
mechanism  
To identify the mechanism by which Spry2 regulates HIF1α ubiquitylation and 
degradation, we determined if endogenous Spry2 and HIF1α exist in the same complex. 
In hypoxic HuH7 cells treated with the proteosomal inhibitor MG132, 
immunoprecipitates of Spry2 contained endogenous HIF1α (Fig. 13A). Additionally, by 
immunocytochemistry, we also observed the co-localization of Spry2 and HIF1α, and this 
co-localization was markedly decreased upon silencing of HIF1α (Fig. 13B). The co-
localization of Spry2 and HIF1α within intact cells was further confirmed using the 
proximity ligation assay (PLA) that permits detection of interacting proteins within intact 
cells (350). As shown in Figure 13C, the PLA approach also showed that Spry2 and 




Figure 12: Spry2 decreases the stability of HIF1α by enhancing the ubiquitylation 
and proteosomal degradation of HIF1α.  
(A) HuH7 cells transfected with control (Cntrl) siRNA or siRNA targeting Spry2 were 
treated with vehicle (DMSO) or bortezomib for 24 hours and cultured in hypoxia (3% O2) 
for the last 8 hours. Cycloheximide (CHX) (200 µM) was added and cells were lysed at 
the indicated times. Representative western blot probed for HIF1α, Spry2, Actin and 
ERK1/2 are shown. Graph shows mean ± SEM of densitometric analysis of HIF1α 
normalized to the average of Actin and ERK1/2 from 5 independent experiments. Half-
lives are listed in legend; n.d., not determinable in time frame measured. Statistical 
significance was assessed by unpaired Student t-test. (B) HEK293T cells were transfected 
with constructs of HIF1α and FLAG-tagged Ubiquitin along with either control (Cntrl) or 
Spry2 siRNAs. Cells were cultured in hypoxia (3% O2) for 16 hours and MG132 (25 µM) 
was added in during the last 4 hours of incubation. All FLAG-tagged ubiquitylated 
proteins were immunoprecipitated (IP) and the amount of ubiquitylated HIF1α was 




as control. Whole cell lysates (WCL) were analyzed for HIF1α, Spry2, FLAG-tagged 
Ubiquitin and Actin (loading). Graph shows mean ± SEM of densitometric analysis of 
ubiquitylated HIF1α divided by total immunoprecipitated FLAG-tagged ubiquitylated 
proteins from 3 independent experiments. Statistical significance was assessed by 






silenced. Interestingly, the data in Figures 13B and 13C show that Spry2 and HIF1α 
interact in the nucleus. While the localization of Spry2 in cytoplasm and membrane 
ruffles has been previously reported (92,95), this is the first demonstration of Spry2 being 
present in the nucleus. Overall, using three different approaches, the data in Figure 13 
demonstrates that endogenous Spry2 and HIF1α exist in a complex. 
Previous work from our lab has shown that Spry2 is also hydroxylated by PHDs 
and can bind to pVHL (121). With this in mind and the data demonstrating the existence 
of endogenous Spry2 in a complex with HIF1α (Fig. 13), we postulated that Spry2 by 
associating with HIF1α brings more pVHL in proximity of HIF1α, and therefore, 
enhances the degradation of HIF1α. In order to investigate the involvement of pVHL in 
the ability of Spry2 to regulate HIF1α, HuH7 cells were transfected with two different 
siRNAs targeting pVHL and the effect of Spry2 silencing on HIF1α protein was 
monitored. Indeed, as shown previously (Fig. 9A), silencing of Spry2 resulted in a 
significant increase in HIF1α protein levels without altering pVHL protein levels (Fig. 
14A). However, once pVHL is silenced with either of the two pVHL targeting siRNAs, 
the silencing of Spry2 no longer affected HIF1α protein levels (Fig. 14A). These data 
suggest that Spry2 regulates HIF1α in a pVHL dependent mechanism. 
To further investigate the contribution of pVHL in the ability of Spry2 to regulate 
HIF1α, we utilized a mutant Spry2 that cannot bind pVHL. Previously, using proteomic 
analyses we showed that P18, P144 and P160 on Spry2 are hydroxylated (121). The 
substitution of these three Pro residues to Ala abolished the ability of Spry2 to bind 










 (A & B) HuH7 cells incubated in hypoxia (3% O2) for 8 hours were treated with 
MG132 (25 µM) during the last 4 hours of the incubation. (A) Spry2 was 
immunoprecipitated (IP) and the co-immunoprecipitation of HIF1α was monitored; 
nonspecific rabbit IgG was used in control immunoprecipitations. A representative blot 
from 3 independent experiments is shown. Whole cell lysates (WCL) were analyzed for 
HIF1α and Spry2. (B) Immunocytochemistry was performed as described under 
Experimental Procedures to stain for Spry2 (green) and HIF1α (red). Images shown are 
X126 magnification. White bar (bottom left) is the scale for 20 µm. (C) HuH7 cells were 
incubated in hypoxia (3% O2) for 8 hours. A PLA reaction was performed as described 
under Experimental Procedures to look at Spry2 and HIF1α interaction. Images shown 
are X63 magnification and the inset (top left) is X3 greater. White bar (bottom right) is 
scale for 100 µm. Controls included PLA secondary antibodies (Secondary only) alone 
and complete PLA assay without Spry2 antibody (Omit one Primary). Graph shows mean 
± variance of the quantified puncta divided by the number of cells in the field normalized 
to control siRNA transfected cells from 2 independent experiments in which 10-15 fields 





To determine if the 3P/3A-Spry2 could alter HIF1α protein levels, HEK293T 
cells were transfected with empty vector, wild-type (WT)-Spry2, or 3P/3A-Spry2 and 
HIF1α levels were monitored. As expected and alluded to earlier, the expression of WT-
Spry2 resulted in a 50% reduction in HIF1α protein levels compared to empty vector 
transfected cells (Fig. 14B). Intriguingly, the expression of 3P/3A-Spry2, which cannot 
bind pVHL, had no significant effect on HIF1α protein levels. Similar results were 
observed in HeLa cells stably expressing no Spry2, WT-Spry2, or 3P/3A-Spry2 (Fig. 
14C). Once again, cells expressing WT-Spry2 had a 50% reduction in HIF1α protein 
levels while the expression of 3P/3A-Spry2 had no significant effect on HIF1α levels 
when compared to cells not expressing Spry2 (Fig. 14C). These data provide further 
evidence that Spry2 regulates HIF1α in a pVHL dependent manner since when Spry2 
cannot bind pVHL, it cannot alter HIF1α protein levels 
We reasoned that if Spry2 was bringing more pVHL in proximity of HIF1α, then 
in immunoprecipitates of pVHL the amount of HIF1α in the presence of siRNA against 
Spry2 should be diminished. Indeed, when Spry2 was silenced in HuH7 cells, 
immunoprecipitates of pVHL contained approximately 50% less HIF1α (Fig. 14D). It is 
of note that the protein levels of PHD1, PHD2, PHD3, and pVHL were not significantly 
altered by the expression of WT-Spry2 or 3P/3A-Spry2 compared to empty vector 
transfected cells (Fig. 15A). 
3P/3A-Spry2 can associate with HIF1α and inhibit the phosphorylation of AKT  
To address the possibility that the mutation of the three proline residues in 3P/3A-
Spry2 abrogated its ability of to associate with HIF1α and, therefore, abolished its ability 






Figure 14: Spry2 enhances the degradation of HIF1α in a pVHL dependent manner. 
(A) HuH7 were transfected with control (Cntrl) or Spry2 siRNAs along with control (-) 
or one of the two pVHL siRNAs (1 or 4) and cultured in hypoxia (3% O2) for 8 hours. 
Representative western blots probed for HIF1α, Spry2, pVHL and Actin (loading) are 
shown. Graph below shows mean ± SEM of densitometric analysis of HIF1α normalized 
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vector or vector constructs to express WT-Spry2 or 3P/3A-Spry2 were cultured in 
hypoxia (3% O2) for 16 hours. Representative western blots probed for HIF1α, HA-
Spry2, Actin and ERK1/2 are shown. Graph below shows mean ± SEM of densitometric 
analysis of HIF1α normalized to the average of Actin and ERK1/2 from 4 independent 
experiments. (C) Control and HA-Spry2 (either WT-Spry2 or 3P/3A-Spry2) expressing 
HeLa cells were cultured in hypoxia for 24 hours. Representative western blots probed 
for HIF1α, HA-Spry2 and Tubulin (loading control) are shown. Graph below shows 
mean ± SEM of densitometric analysis of HIF1α normalized to Tubulin from 4 
independent experiments. (D) HuH7 cells transfected with control or Spry2 siRNA were 
incubated in hypoxia (3% O2) for 8 hours. pVHL was immunoprecipitated (IP) and the 
co-immunoprecipitation of HIF1α was monitored. Graph below shows mean ± SEM of 
densitometric analysis of HIF1α normalized to pVHL immunoprecipitated from 4 
independent experiments. Statistical significance was assessed by (A, C & D) unpaired 





HEK293T cells were transfected with HIF1α and either WT-Spry2 or 3P/3A-Spry2 
and placed in hypoxia. The WCL indicates equal amounts of the two Spry2 constructs 
were transfected into the cells (Fig. 15B). Both WT-Spry2 and 3P/3A-Spry2 co-
immunoprecipitated with HIF1α (Fig. 15B). Hence, substitution of the three prolines on 
Spry2 with alanines does not alter the ability of Spry2 to associate with HIF1α. Spry2 has 
been shown to inhibit the downstream signaling processes such as phosphorylation and 
activation of ERK1/2 and AKT (6-8,12,116,169). Therefore, we also determined if the 
3P/3A-Spry2 retained its ability to modulate downstream signaling such as 
phosphorylation of AKT. Using the HEK293T cell lysate from experiments described in 
Figure 14B, the levels of phosphorylation of AKT (pAKT) on Ser 473 were monitored. 
As expected from our previous findings (126), the expression of WT-Spry2 reduced 
pAKT by more than 50%. Likewise, 3P/3A-Spry2 also reduced pAKT levels to a similar 
extent (Fig. 15C). Thus, 3P/3A-Spry2 retains its ability to inhibit the phosphorylation of 
AKT. Taken together, these data indicate that 3P/3A-Spry2 only lacks the ability to bind 
to pVHL (121) and alter HIF1α levels (Fig. 14B & 14C) but retains its other functions 
such as binding to HIF1α and inhibiting AKT phosphorylation (Fig. 15B & 15C). 
WT-Spry2, but not 3P/3A-Spry2 regulates HIF1α-sensitive glucose uptake 
Since 3P/3A-Spry2 does not alter HIF1α protein levels, we reasoned that a 
biological function that is regulated by HIF1α would be susceptible to modulation by 
WT-Spry2 but not 3P/3A-Spry2. In this context, it is well established that HIF1α 
regulates the expression of certain glucose transporters such as GLUT1 and GLUT3 and 






Figure 15: 3P/3A-Spry2 interacts with HIF1α and inhibits phosphorylation of AKT 
to similar extent as WT-Spry2.  
(A) HEK293T lysates from Figure 14B were used to monitor the levels of pVHL, PHD1, 
PHD2, PHD3, Spry2, Actin and ERK1/2 by Western analysis. A representative blot is 
shown and the graph shows mean ± SEM of densitometric analysis of protein of interest 
normalized to the average of Actin and ERK1/2 from 4 independent experiments. (B) 
HEK293T cells transfected with vector constructs to express HIF1α and either WT-Spry2 






















































































































immunoprecipitated (IP) and the co-immunoprecipitation of Spry2 was monitored; 
immunoprecipitation with nonspecific IgG was used a control. A representative blot from 
3 independent experiments is shown. Whole cell lysates (WCL) were probed for HIF1α, 
HA-Spry2 and Actin (loading). (C) HEK293T lysates from Figure 14B were used to 
probe for phospho-AKT S473, HA-Spry2 and Actin (loading) are shown. Graph below 
shows mean ± SEM of densitometric analysis of pAKT normalized to Actin from 4 
independent experiments. Statistical significance was assessed by a one-way ANOVA 






(347,351). Therefore, in HuH7 and HeLa cells, we monitored HIF1α-sensitive glucose 
uptake after transfecting either WT- or 3P/3A-Spry2. As shown in Figure 16A, [3H]-2-
deoxy-D-glucose uptake in HeLa cells was linear over time and silencing of HIF1α 
decreases [3H]-2-deoxy-D-glucose uptake by 31%. Moreover, the addition of unlabeled 
2-deoxy-D-glucose markedly inhibited [3H]-2-deoxy-D-glucose uptake in the presence 
and absence of HIF1α demonstrating the specificity of glucose uptake via glucose 
transporters (Fig. 16A). The HIF1α-sensitive glucose uptake was significantly inhibited 
(61%) by WT-Spry2 but was not affected by 3P/3A-Spry2 (Fig. 16B). Similarly in HuH7 
cells, WT-Spry2 reduced HIF1α-sensitive [3H]-2-deoxy-D-glucose uptake by 73% while 
3P/3A-Spry2 did not affect it (Fig. 16C). These findings are consistent with the 
observations that WT-Spry2, but not 3P/3A-Spry2 regulates HIF1α protein content in 






Figure 16: WT-Spry2, but not 3P/3A-Spry2, reduces HIF1α-sensitive [3H]-2-deoxy-
D-glucose uptake.  
























































































































Cntrl siRNA + 20mM 2-DG





















































(A) HeLa cells transfected with control (Cntrl) (Closed circle) or HIF1α-specific 
siRNA (Closed square) were cultured in hypoxia for 24 hours. [3H]-2-deoxy-D-glucose 
(100 µM) uptake was monitored over the time course shown following the protocol 
described in Experimental Procedures. Samples treated in an identical manner but with 
excess unlabeled 2-deoxy-D-glucose (20 mM) were used a control to demonstrate 
specificity (open circle and square). Cells were lysed and the amount of radioactivity was 
measured in a scintillation counter and a protein determination was performed on the 
lysates. Data are presented as picomoles of [3H]-2-deoxy-D-glucose uptake per µg of 
protein. (B) HeLa and (C) HuH7 cells were transfected with empty vector or vector 
constructs to express WT-Spry2 or 3P/3A-Spry2 along with control (Cntrl) or HIF1α-
specific siRNA. [3H]-2-deoxy-D-glucose uptake over 10 minutes was monitored. HIF1α-
sensitive uptake was calculated by subtracting the [3H]-2-deoxy-D-glucose uptake from 
HIF1α siRNA transfected cells from the uptake in control siRNA transfected cells. Graph 
shows mean ± SEM of picomoles of HIF1α-sensitive [3H]-2-deoxy-D-glucose per µg of 
protein from 3 independent experiments. (C) Representative western shows efficiency of 
HIF1α silencing and equal expression of WT-Spry2 and 3P/3A-Spry2. Statistical 
significance was assessed by (B) one-way ANOVA with Dunnett’s multiple comparisons 







Sprouty proteins, especially Spry2, working via a number of different 
mechanisms have been shown to modulate signaling downstream of receptor tyrosine 
kinases to inhibit cell proliferation and migration (6,12,89,352). Consistent with these 
findings, several studies have shown that Spry2 levels are decreased in different forms of 
cancer including those of the breast, liver, prostate and lung, suggesting a potential role 
of Spry2 as a tumor suppressor (14-21,143). Because decreased protein levels of Spry2 in 
hepatocellular carcinomas has been associated with poor patient survival and prognosis, it 
has been suggested that Spry2 levels could be utilized as a prognostic marker (142). On 
the other hand, the role of HIFα subunits, in particular HIF1α, is now well established in 
promoting tumor survival, growth and metastasis. Specifically, HIF1α by augmenting the 
transcription of genes encoding for glucose transporters, GLUT1 and GLUT3, as well as 
several glycolytic enzymes, provides tumors with a growth advantage in hypoxia 
(182,250,255,260,345-347). Hence, while Spry2 may have tumor suppressor functions, 
HIFα subunits, especially HIF1α, act as tumor promoters (reviewed in (35-37)). In this 
study, using HIF1α as a prototype of HIFα subunits, we have uncovered a novel 
mechanism for regulation of HIFα protein levels by Spry2. Our findings, for the first 
time, demonstrate that endogenous Spry2 regulates HIF1α protein levels in a variety of 
different cell types derived from breast (MCF7, MDA-MB-231), liver (HuH7, Hep3B), 
and lung (A549) cancer in which Spry2 plays a critical role (Fig. 9A, 10A & 10B). 
Additionally silencing of Spry2 in HEK293T or its ectopic expression in these cells and 
HeLa cells regulates HIF1α protein levels (Fig. 14B & 14C). These observations 




HIF1α and HIF2α protein levels (Figs. 9A & 9C) and augments their ability to 
regulate their respective target genes; GLUT1, PGK-1 and PFK for HIF1α and EPO for 
HIF2α (Figs. 11A-D). Consistently, the overexpression of Spry2 or other Spry isoforms 
(Spry1, Spry3, and Spry4) decrease HIF1α levels demonstrating the ability of different 
Spry isoforms to modulate HIF1α levels (Fig. 10D). Hence, the findings described in this 
study are also applicable to the other Spry isoforms.  
It is well established that pVHL/associated E3 ligase degrades HIF1α and HIF2α 
under normoxic conditions via a process that involves their hydroxylation by PHDs 
(29,30). In hypoxia, the lack of free molecular oxygen reduces, but does not completely 
inhibit, activities of the PHDs (124,353). This results in a reduction of pVHL/associated 
E3 ligase binding to HIFα subunits and therefore, a decrease in their ubiquitylation and 
degradation in hypoxia (reviewed in (342,343)). Herein, we demonstrate that Spry2 
decreases the amount of HIF1α by increasing its ubiquitylation and degradation even in 
hypoxic conditions and the proteosomal inhibitor, bortezomib, stabilized HIF1α in the 
presence of endogenous Spry2 suggesting that Spry2 enhances the proteosomal 
degradation of HIF1α (Fig. 12). This process requires pVHL since silencing of pVHL 
abrogated the ability of Spry2 to regulate HIF1α (Fig. 14A).  
Furthermore, for the reasons described below, our data suggest that Spry2, which 
we have previously shown to bind pVHL (121), exists in a complex with HIF1α and 
thereby brings more pVHL in the proximity of HIF1α to permit its ubiquitylation and 
degradation. First, using three different approaches, we demonstrate that Spry2 and 
HIF1α exist in a complex (Fig. 13). Second, the silencing of pVHL expression abrogates 




Spry2 decreases HIF1α levels, but not 3P/3A-Spry2 that does not bind pVHL (121) 
(Figs. 14A-C). Notably, 3P/3A-Spry2 is as effective as WT-Spry2 at attenuating AKT 
activation (Fig. 15C) and associating with HIF1α (Fig. 15B). Thus, 3P/3A-Spry2 does not 
lose all of its biological functions. Third, immunoprecipitates of pVHL from HuH7 cells 
in which Spry2 has been silenced contain approximately 50% less HIF1α (Fig. 14D). All 
of this evidence strongly supports the notion that Spry2 by interacting with both pVHL 
and HIF1α brings more pVHL in proximity of HIF1α and, thereby enhances HIF1α 
ubiquitylation and degradation. The latter is supported by our data that show that 
silencing of Spry2 diminishes the ubiquitylation of HIF1α (Fig. 12B). Consistent with our 
proposal that Spry2 acts as a scaffold to bring more pVHL/associated E3 ligase in 
proximity of HIF1α, unlike WT-Spry2, the 3P/3A-Spry2 that does not bind pVHL also 
does not inhibit HIF1α-sensitive glucose transport in HeLa and HuH7 cells (Fig. 16). The 
paradigm we propose fits well with the function of Spry2 as a scaffolding protein, which 
by interacting with other proteins regulates different signaling pathways and biological 
functions (6-8,12,116,169). 
One of the interesting and novel observations by immunocytochemistry and PLA 
(Fig. 13B & 13C) from our studies is the nuclear localization of Spry2 with HIF1α. 
Although others and we have shown cytoplasmic and membrane localization of Spry2 
(92,95), to date its nuclear localization has not been reported. Notably, Spry2 does not 
have a nuclear localization sequence and how it enters the nucleus is not known. 
However, as clearly shown here, it can interact with nuclear proteins such as HIF1α and 
perhaps other nuclear proteins not yet identified. This adds a novel dimension by which 




While increasing HIF stability by inhibiting pVHL has been shown previously 
(354-356), only one study, aside from the current study, has shown that HIF1α 
degradation by pVHL can be enhanced in hypoxia. Specifically, that report showed that 
SSAT2 binding to pVHL stabilized the interactions between pVHL and elongin C and 
enhanced the ability of pVHL to degrade HIF1α (222). Likewise, it has also been shown 
that recruitment of PHDs in proximity of HIF1α can enhance its degradation in hypoxia. 
Osteosarcoma amplified 9 (OS-9) and mitogen activated protein kinase organize 1 
(MORG1) by associating with PHDs and bringing them in proximity of HIF1α enhances 
the hydroxylation and therefore degradation of HIF1α in hypoxia (217,357). Furthermore, 
by a mechanism similar to what we have shown here, HIF1α degradation is enhanced by 
p53 interacting with HIF1α and bringing the E3 ubiquitin ligase MDM2 in proximity of 
HIF1α (358). 
Reports in the literature suggest that AKT and ERK can regulate HIF1α 
translation, protein levels and activity ((207,359-362) & see review (318)). The role of 
AKT regulation of HIF1α appears to be cell type specific and not critical for HIF1α 
stabilization in hypoxia (363). Nevertheless, the ability of Spry2 to inhibit ERK and AKT 
activation could provide a possible mechanism by which Spry2 regulates HIF1α protein 
levels. However, we have shown that both WT-Spry2 and 3P/3A-Spry2 inhibit the 
phosphorylation of AKT (Fig. 15C), but only WT-Spry2 decreases HIF1α protein levels 
suggesting AKT activity has no role in the ability of Spry2 to regulate HIF1α (Figs. 14B 
& 14C). Likewise, under the same conditions as those in Figure 9, silencing of Sprouty2 
in HuH7 cells did not alter ERK1/2 phosphorylation status suggesting that ERK1/2 do 




Liu et al. (360) demonstrated that microRNA-21 (miR-21) elevated HIF1α 
levels due to modest increases in AKT and ERK1/2 activation. However, miR-21 also 
decreases the expression of Spry2 (149). Hence, in light of our findings, one could argue 
that in the studies of Liu et al. (360) miR21-mediated decrease in Spry2 contributes to the 
elevation in HIF1α protein levels. 
Our findings that silencing of endogenous Spry2 elevates the transcription of 
HIF1α responsive genes (Figs. 11A-C) and that Spry2 also inhibits HIF1α-sensitive 
glucose uptake (Fig. 16) implicate Spry2 as a regulator of glycolysis. In this context, 
Wang et al. showed that expression of a dominant negative Spry2 with AKT resulted in 
increased membrane levels of GLUT1 and GLUT4 as well as an increase in the 
glycolysis master regulator pyruvate kinase M2 (PKM2) (156). However, that study did 
not delineate the mechanism by which Spry2 upregulated PKM2. Given our findings in 
this report and the fact that PKM2 transcription and expression are elevated by HIF1α 
(257), it is tempting to speculate the upregulation of PKM2, GLUT1 and GLUT4 by 
dominant negative Spry2 is due to an elevation of HIF1α levels because dominant 
negative Spry2 would ablate the ability of endogenous Spry2 to decrease HIF1α levels.  
In summary, we showed that Spry2 acts as a scaffold that complexes with HIF1α 
and pVHL elevating the local concentrations of pVHL to ubiquitylate HIF1α in hypoxia 
and target it for degradation. The regulation of HIF1α levels by Spry2 also translates into 
regulation of HIF1α responsive genes and glucose uptake. Thus, Spry2 also inhibits the 
expression of glycolytic genes and HIF1α-sensitive glucose uptake. Since glucose uptake 
and glycolysis are critical in providing survival advantage and promotion of cancer, our 




protein levels and gene transcription. As a corollary, when Spry2 is decreased or lost 
in certain forms of cancer, the transcription of HIF1α regulated genes would be elevated 
therefore, further promoting the progression of the cancer. Overall, these findings reveal 
a novel mode of action for Spry2 in regulating cellular signaling and biological functions 





SPRY2 REGULATES ARYL HYDROCARBON RECEPTOR NUCLEAR 
TRANSLOCATOR (ARNT) PROTEIN LEVELS AS WELL AS THE mRNA 
AMOUNTS OF GENES REGULATED BY ARNT.  
 
ABSTRACT 
 The regulation of the dimerization partners for Aryl Hydrocarbon Receptor 
Nuclear Translocator (ARNT), Aryl Hydrocarbon Receptor (AhR) and Hypoxia 
Inducible Factor α (HIFα), have been well studied for years. However, few studies have 
investigated the regulation of ARNT. Sprouty2 (Spry2) is a modulator of receptor 
tyrosine kinase signaling. As we have shown previously, Spry2 regulates the protein 
levels of HIF1α in a pVHL dependent manner. This led us to investigate if Spry2 
regulated the levels of the other half of the HIF transcription factor, ARNT. Indeed, 
silencing Spry2 elevated ARNT protein levels in human hepatoma cell lines, HuH7 and 
Hep3B, and lung cancer cell line A549. Additionally, Spry2 decreases the stability of 
ARNT via enhanced proteosomal degradation and associates with ARNT. Since no 
ubiquitin ligase capable of targeting ARNT has been identified, we began by 
investigating the ubiquitin ligases known to associate with Spry2. While we found no 
evidence for the involvement of c-Cbl and pVHL in regulating ARNT protein levels, 
Nedd4-1 appears to be an E3 ubiquitin ligase that regulates ARNT protein. Thus, when 
Nedd4-1 expression was silenced, ARNT levels were enhanced and the elevation of 
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ARNT protein levels when Spry2 expression is silenced are attenuated. These findings 
suggest that Spry2 by interacting with both ARNT and Nedd4-1 regulates ARNT in a 
Nedd4-1 dependent manner. To determine a functional impact, we monitored mRNA 
levels of the ARNT/AhR regulated gene cytochrome P450 1A1 (CYP1A1). In both 
hypoxia and normoxia, silencing Spry2 elevated CYP1A1 mRNA levels. Taken together, 
these data suggest that Spry2 via Nedd4-1 enhances the proteosomal degradation of 
ARNT decreasing the mRNA levels of ARNT/AhR regulated genes. 
 
INTRODUCTION 
 Sprouty (Spry) proteins act as modulators of Receptor Tyrosine Kinase (RTK) 
signaling via scaffolding regulatory proteins or sequestering key signaling components 
(13,88,332-334). There are four mammalian Sprouty isoforms (Spry1-Spry4) that are 
transcribed from four different genes (3,13). Among the four isoforms, Spry2 is 
ubiquitously expressed and one of the most well studied isoforms making it the focus of 
our studies. Since RTK signaling plays a critical role in developmental processes and 
tumor growth and survival, the impact of Spry2 in these processes has been investigated 
due to the ability of Spry2 to regulate RTK signaling. As discussed in Chapter II and III, 
previous research has shown that patient prognosis is poor when Spry2 levels are lost or 
decreased in cancers of the breast, liver, prostate and lung (14-21,143). This has 
implicated Spry2 as a tumor suppressor. 
 Aryl hydrocarbon receptor nuclear translocator (ARNT) (also known as Hypoxia 
Inducible Factor 1β (HIF1β)) is the central axis in gene transcription networks that 
regulate a variety of physiological processes such as hypoxic signaling (27), xenobiotic 
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responses (40) and neuronal development (364). ARNT is a member of the beta helix-
loop-helix Per ARNT Sim (bHLH-PAS) family of transcription factors ((264) and 
discussed in Chapter II) and is the dimerization partner for a variety of transcription 
factors such as hypoxia inducible factors (HIFs) (27), aryl hydrocarbon receptor (AhR) 
(40), SRC-1 (45,46), single-minded homolog 1 (SIM1) (43,44), and estrogen receptor α 
and β (ERα & ERβ) (41,42).   
While the regulation of the dimerization partners for ARNT, HIFα and AhR, have 
been very well studied in relation to a variety of cellular processes and diseases, the 
regulation of ARNT is sorely understudied. To date, the only studies on ARNT regulation 
have shown that ARNT mRNA levels can be regulated by microRNAs (57,319-322) and 
proteosomal degradation of ARNT protein is enhanced either by ERβ via an unknown 
mechanism (329) or curcumin via an oxidative stress dependent mechanism (328,365). 
Neither of these studies identified an ubiquitin ligase capable of targeting ARNT. Also, 
one study showed that ARNT is SUMOylated reducing its transcriptional activity (331).  
Although HIF1α and AhR have been shown to play a tumor-promoting role 
(22,38,39,279,280,366,367), the role of ARNT in cancer has been controversial. In 
agreement with ARNT being the binding partner for HIF1α and AhR, a few studies have 
shown that ARNT plays a tumor-promoting role (53-56). Recently, it has been proposed 
that ARNT plays a tumor-promoting role in the initial stages of tumor growth, but in later 
stages of tumor growth ARNT plays a tumor suppressive role by inhibiting migration and 
invasion (57,58). Despite ARNT having a crucial role as the central axis to many 
transcriptional pathways, the regulation of ARNT and impact of ARNT in cancer is still 
unclear highlighting the need to investigate mechanisms that regulate ARNT levels. 
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Previously, we showed that Spry2 enhances HIF1α ubiquitylation and 
proteosomal degradation in hypoxia via acting as a scaffold to bring more von Hippel-
Lindau protein (pVHL) and its associated E3 ubiquitin ligase in proximity to HIF1α 
(Chapter III). This prompted us to hypothesize that Spry2 enhanced the degradation of 
the other half of the HIF transcription factor, ARNT. We have shown that silencing Spry2 
elevates ARNT protein levels in the hepatoma cell lines HuH7 and Hep3B, as well as in 
the lung cancer cell line A549. Intriguingly, this regulation appears to be cell type 
specific since we did not observe Spry2 silencing significantly elevating ARNT protein 
levels in breast cancer cell lines MCF7 and MD-MBA-231. We also show that Spry2 
decreases the stability of ARNT protein via enhanced proteosomal degradation and that 
Spry2 and ARNT are in a complex. 
As stated earlier, there has been limited research on how ARNT protein is 
regulated and to date no ubiquitin ligase capable of ubiquitylating ARNT has been 
identified. Therefore, as a starting point, we investigated if any of the ubiquitin ligases 
that Spry2 has been shown to interact with are responsible for ARNT regulation. Spry2 
has been shown to associate with and be ubiquitylated and targeted for proteosomal 
degradation by c-Cbl (108,113), Siah2 (119), Nedd4-1 (103) and pVHL/associated E3 
ligase (121). While c-Cbl and pVHL silencing did not alter ARNT protein levels or the 
regulation of ARNT by Spry2, the silencing of Nedd4-1 elevates ARNT protein levels, as 
well as attenuates the increase in ARNT protein levels when Spry2 was silenced.  
As a functional read out of the changes in ARNT protein levels upon silencing of 
Spry2, we investigated if silencing of Spry2 alters the mRNA levels of one of the genes 
that ARNT regulates. ARNT via dimerization with AhR can regulate the transcription of 
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a variety of metabolic enzymes in response to environmental pollutants or endogenous 
ligands (293). We show that Spry2 silencing results in an elevation in the ARNT and 
AhR regulated metabolic enzyme cytochrome p450 1A1 (CYP1A1) mRNA levels in both 
normoxia, hypoxia and under AhR activation by the ligand β-naphthoflavone (BNF). In 
conclusion, we have shown Spry2 regulates ARNT levels via a Nedd4-1 dependent 
mechanism, which would have a large impact in a variety of processes by causing 
changes in the genes ARNT regulates. 
 
EXPERIMENTAL PROCEDURES 
Many experimental procedures for this chapter are the same as in Chapter III and are 
indicated as such. Any exceptions are denoted. 
 Chemical and Reagents 
 Cycloheximide (CHX), N-ethylmaleimide (NEM), and β-naphthoflavone (BNF) 
were purchased from Sigma Chemical Co. (St. Louis, MO). MG132 was purchased from 
Selleck Chem (Houston, TX). All primers, probes and siRNAs were synthesized by 
Integrated DNA Technologies Inc. (Coralville, IA). The sequences for control for Spry2, 
two Spry2, and two pVHL siRNAs are listed in Table 6 in Chapter III. The sequences of 
the siRNAs for ARNT, c-Cbl, and Nedd4-1 are listed in Table 8A.  The antibodies for 
Spry2, Actin, ERK1/2, Tubulin, pVHL, and HA-tag and dilutions used are listed in Table 
6 in Chapter III. The antibodies for ARNT, c-Cbl, and Nedd4-1 and dilutions used are 





Table 8: Sequences for siRNAs, information about antibodies used and sequences 
for primers and primer/probes for qRT-PCR. 
(A) Sense and anti-sense sequences for siRNAs used that are unique to this chapter. (B) 
List of antibodies with species antibody was raised in, company purchased from, catalog 
number, lot number, and dilution used with incubation conditions. (C) Sequences for 
either the primer/probe (ARNT) or primers (CYP1A1) used for qRT-PCR along with the 




siRNA Sense (5’-3’) siRNA Anti-Sense (5’-3’) 
ARNT CAGGTTAAGACAAACGACAACGACG GUCCAAUUCUGUUUGCUGUUGCUGCUG 
c-Cbl  GGACCAGUGAGUUGGGAGUUAUUAC GUAAUAACUCCCAACUCACUGGUCCUC 




Antibody Species Company Catalog # Lot  Dilution 
ARNT Mouse BD Transduction 
Laboratories 
 Franklin Lake, NJ 
611078 2146892 1:2000  
1 hr RT 
ARNT  Rabbit  Cell Signaling, 
Danvers, MA 
3718S 1 1:2000 1 
 hr RT 
c-Cbl Rabbit Santa Cruz 
Santa Cruz, CA 
Sc-170 H0607 1:1000  
O/N 4°C 
Nedd4 Rabbit Millipore 
Billerica, MA 










ARNT AGAATGTGTATGGGCTCAAGG TCCTGCATCTGTTCCTCACAAAGCTC GGTTCCCCATCCTTTACAGAG 57 1.99 




 DNA Constructs 
 All DNA constructs used in this chapter are described in Chapter III. 
Cell Culture 
 The conditions for the maintenance of HuH7, Hep3B, A549, MCF7, MD-MBA-
231, and HEK293T cells lines used are described in Chapter III. 
 Silencing of Endogenous Spry2 in a variety of cell lines and Western Blotting 
 The conditions for silencing Spry2 and the procedure for Western blotting were 
identical to those described in Chapter III. 
 Isolating RNA, cDNA Synthesis, and quantitative Real Time Polymerase Chain 
Reaction (qRT-PCR) 
 HuH7 cells were plated (80,000/ well in a 12-well plate) and transfected the next 
day with control (40 nM), Spry2 (20 nM + control for ARNT (20 nM)), or Spry2 (20 nM) 
+ ARNT (20 nM) siRNAs for part A or two controls (control for Spry2 (20 nM) + control 
for ARNT (20 nM)), Spry2 (20 nM) + control for ARNT (20 nM), control for Spry2 (20 
nM) + ARNT (20 nM), or Spry2 (20 nM) + ARNT (20nM) for part B. Triplicate samples 
for each condition were generated. The cells were then placed in either normoxia or 
hypoxia for 24 hours or treated with vehicle (0.5% DMSO) or BNF (5 µM) for 16 hours. 
As described in Chapter III, RNA was isolated, converted to cDNA and qRT-PCR 
performed. The formula to calculate the relative fold change in mRNA is described in 
Chapter III, along with the sequences and efficiencies for the three housekeeping genes 
used (RPLP0, RN18S1 and HPRT) (Table 7). The primers and probe for ARNT and the 
primers for CYP1A1 with their annealing temperatures and calculated efficiencies are 
listed in the Table 8C on previous page. 
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 Stability of ARNT and MG132 treatment 
 HuH7 cells (250,000/35-mm dish) were transfected with 20nM of control or 
Spry2 siRNAs as described in Silencing of Endogenous Spry2 in a variety of cell lines in 
Chapter III. The cells were incubated in hypoxia for 24 hours and in the last 4 hours the 
cells were treated with CHX (50 µM). The cells were lysed in Laemmli sample buffer 
after 0, 1, 2 or 3 hours after CHX addition. ARNT, Spry2 and Actin were monitored 
using Western blotting. 
 For MG132 treatment, the cells plated and transfected as described above. After 
18 hours of hypoxia, the cells were treated in hypoxia with MG132 (25 µM) for 2 hours 
prior to the addition of CHX. The cells were lysed after 0 or 4 hours of CHX treatment 
and monitored for ARNT, Spry2 and Actin by Western blotting. 
 Coimmunoprecipitation of Spry2 and ARNT 
 HuH7 cells (80,000/60-mm dish) were incubated in normoxia or hypoxia for 24 
hours with MG132 (25 µM) treatment for the last four hours. The cells were lysed in a 
buffer containing 50mM Tris HCl, 150mM NaCl, 1mM EDTA, 1mM EGTA, 0.5% 
NP40, 1% Triton X100 and 5mM NEM with phosphatase (Cat. No. P5726, Sigma) and 
protease inhibitor cocktails (Cat. No P8340, Sigma). The cells were centrifuged at 12,000 
x g for 20 minutes. A protein determination was performed on the supernatant. Control 
rabbit IgG or anti-ARNT antibodies (4 µg) were incubated overnight at 4°C with 500 µg 
total protein. The next day the lysate was incubated with protein G beads (Roche, 
Indianapolis, IN) for 2 hours prior to washing four times with the lysis buffer without 
NEM. The beads were boiled in Laemmli sample buffer to elute the bound proteins. 
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Western blotting was performed to monitored the immunoprecipitation of ARNT and the 
co-immunoprecipitation of Spry2. 
 pVHL silencing and expression of WT-Spry2 and 3P/3A-Spry2 
 The description of the method for generating these samples is described in 
Chapter III. The same samples were also probed for ARNT via Western blotting. 
 Silencing c-Cbl and Nedd4-1 
 HEK293T (150,000/35-mm dish) were plated and transfected with 20nM each of 
control or Spry2 siRNAs or 20 nM each of control or c-Cbl siRNAs with TransIT TKO  
(Mirus Bio LLC, Madison, WI) as described previously. The cells were then incubated in 
normoxia or hypoxia for 24 hours prior to being lysed and monitored for ARNT, c-Cbl, 
Spry2, and Actin via Western blotting.  
HuH7 (150,000/35-mm dish) were plated and transfected with 20 nM each of 
control or Spry2 siRNAs along with 40 nM each of control or Nedd4-1 siRNAs with 
TransIT TKO (Mirus Bio LLC, Madison, WI) as described previously. The cells were 
then either incubated in normoxia or hypoxia (3% O2) for 24 hours or treated with vehicle 
(0.5% DMSO) or BNF (5 µM) for 16 hours. The levels of ARNT, Nedd4-1, Spry2, 






Endogenous Spry2 regulates ARNT protein levels in normoxia and hypoxia.  
ARNT functions as the dimerization partner for a variety of transcription factors. 
Three well-studied dimerization partners for ARNT are HIF1α and HIF2α in hypoxia and 
AhR in both hypoxia and normoxia. Therefore, the ability of Spry2 to regulate ARNT 
protein levels was monitored in both hypoxia and normoxia. In the human hepatoma cell 
line HuH7, siRNA-mediated silencing of Spry2 resulted in a 2.3- and 3.7-fold increase in 
ARNT protein levels in normoxia and hypoxia, respectively (Fig. 17A). Interestingly, 
ARNT protein levels were reduced by hypoxia (Fig. 17A). The mRNA levels of ARNT 
were also elevated by about 40% when the expression of endogenous Spry2 was silenced 
(shown later in Fig. 24A & 24B, left panels). Thus, the elevation in ARNT protein levels 
due to silencing of Spry2 may result from changes in transcription, mRNA stability or 
post-translational changes. However, since Spry2, as discussed in Chapter III, has been 
shown to regulate the stability of proteins by acting as a scaffold, we focused on the 
hypothesis that Spry2 regulates ARNT protein levels via post-translational mechanisms. 
The increase in ARNT protein levels upon silencing of Spry2 expression was also 
observed in two other cells lines, the hepatoma cell line Hep3B and the lung cancer cell 
line A549 (Fig. 17B & 17C). To demonstrate elevation in ARNT protein levels is not an 
off target effect of one particular siRNA, we tested a second siRNA against Spry2 in 
Hep3B and A549. This second siRNA against Spry2 also elevated ARNT protein levels 
(Figs. 17B & 17C). The regulation of ARNT by Spry2 was not observed in two breast 
cancer cell lines, MCF7 and MDA-MB-231, suggesting that the regulation of ARNT by 
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Figure 17: Silencing Spry2 elevates ARNT protein levels in a variety of cell lines. 
HuH7 cells transfected with control or Spry2 siRNAs were incubated in hypoxia (3% O2) 
or normoxia. (A) The protein levels of ARNT, Spry2, and Actin (loading) were 
monitored by Western blotting. (A) Graph below shows mean ± SEM of densitometric 
analysis of ARNT normalized to Actin for 3 independent experiments. Statistical 
significance was assessed by unpaired Student t-test. (B) Hep3B or (C) A549 cells were 
transfected with control or one of two different Spry2 siRNAs. The cells were then 
incubated in hypoxia and the levels of ARNT, Spry2 or Actin (loading) were monitored 
via Western blotting. Graphs below show mean ± variance for two independent 
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Figure 18: Spry2 does not regulate ARNT protein levels in two breast cancer cell 
lines. 
MCF7 and MBA-MD-231 cells transfected with control or one of two different Spry2 
siRNAs were placed in hypoxia (3% O2). The levels of ARNT, Spry2 and Actin (loading) 
were monitored using Western blotting. Graphs below show the mean ± variance of 
densitometric analysis of ARNT normalized to Actin for 2 independent experiments for 




Overall, these data suggest that in some cell lines silencing Spry2 results in an elevation 
in ARNT protein levels. 
Spry2 destabilizes ARNT protein levels via enhancing the proteosomal degradation in 
hypoxia.  
 Although ARNT plays an important role in mediating the biological actions of 
HIFs and AhR, its regulation is an area that is greatly understudied. As stated earlier we 
focused on the post-translational regulation of ARNT, therefore as a starting point we 
examined whether Spry2 regulated the protein stability of ARNT. HuH7 cells transfected 
with control or Spry2 targeting siRNAs were placed in hypoxia and treated with the 
protein translation inhibitor cycloheximide (CHX). The protein levels of ARNT were 
monitored over three hours by Western blot analyses and the half-life of ARNT with and 
without silencing of Spry2 was calculated. Silencing Spry2 more than doubled the half-
life of ARNT from 1.9 hours in control siRNA transfected cells to 4.3 hours in Spry2 
siRNA transfected cells (Fig. 19A). These data suggest that endogenous Spry2 decreases 
the half-life of ARNT protein. 
Since it was previously reported that ARNT could be degraded by the proteosome 
(328,329,365), we investigated whether pretreatment with the proteosomal inhibitor 
MG132 would prevent Spry2 from destabilizing ARNT. For this purpose HuH7 cells 
were treated as described for Figure 19A, except that 2 hours prior to the addition of 
CHX, the cells were pretreated with vehicle or MG132 and the protein levels of ARNT 
were monitored at 0 and 4 hours after CHX. In cells transfected with control siRNA, 
approximately 75% of the ARNT protein degraded after 4 hours of CHX treatment (Fig. 
19B). On the other hand, silencing of Spry2 stabilized ARNT protein, such that only 50% 
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Figure 19: Spry2 decreases the stability of ARNT by enhancing the proteosomal 
degradation.  
(A) HuH7 cells transfected with control or Spry2 siRNA were placed in hypoxia for 24 
hours. The cells were treated with cycloheximide (CHX) (50 µM) and lysed at the 
indicated time points. The levels of ARNT, Spry2, and Actin proteins (loading) were 
monitored by Western blot analyses. Graph below shows the mean ± SEM of the 
densitometric analysis of ARNT normalized to Actin on a semi-log scale for three 
independent experiments. (B) HuH7 cells transfected with control or Spry2 siRNAs 
were incubated in hypoxia for 18 hours. While in hypoxia, the cells were treated with 
MG132 (25 µM) for 2 hours prior to the addition of CHX (50 µM). The cells were 
lysed after 0 or 4 hours of CHX treatment and the levels of ARNT, Spry2, ERK 1/2 
(loading), and Actin (loading) were monitored using Western blot analyses. Graph to 
the right shows quantification of data from 4 independent experiments as the percent 
decrease in ARNT ± SEM after 4 hours of CHX treatment. Statistical significance was 
assessed using unpaired Student t-test. 
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of the ARNT protein was degraded (Fig. 19B). In stark contrast, pretreatment of HuH7 
cells with MG132 abrogated the degradation of ARNT whether or not the endogenous 
Spry2 expression was silenced (Fig. 19B). Together these data suggest that Spry2 
enhanced the proteosomal degradation of ARNT in hypoxia. 
Spry2 interacts with ARNT  
 Since Spry2 apparently regulates the stability of ARNT via a proteosomal 
degradation mechanism (Fig. 19B) and because Spry2 associates with at least four 
ubiquitin E3 ligases (c-Cbl (108,113,118,169), SIAH2 (119), Nedd4-1 (103), 
pVHL/associated E3 ligase (121)), we propose that Spry2 by interacting with ARNT 
brings one of the E3 ubiquitin ligases associated with Spry2 in the vicinity of ARNT to 
permit its ubiquitylation and proteosomal degradation. To begin investigating this 
postulation, we examined whether Spry2 and ARNT exist in the same complex. HuH7 
cells were placed in normoxia or hypoxia for 24 hours and 4 hours prior to lysing the 
cells, the proteosomal inhibitor MG132 was added to the dishes. As Figure 20 shows, 
Spry2 coimmunoprecipitated with ARNT in both normoxia and hypoxia suggesting the 
two proteins exist in the same complex by either direct or indirect interactions. 
Furthermore, these data suggest that the interaction is not dependent upon hypoxia.  
Regulation ARNT protein levels by Spry2 are not mediated via pVHL or c-Cbl 
 To date, no ubiquitin ligase capable of ubiquitylating ARNT has been identified. 
Therefore to identify the possible E3 ubiquitin ligase involved in the regulation of ARNT 
by Spry2, we began by investigating the E3 ubiquitin ligases that have been shown to 
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Figure 20: Spry2 and ARNT interact in HuH7 cells.  
HuH7 cells were placed in normoxia or hypoxia for 24 hours. An immunoprecipitation 
(IP) was performed with control IgG or anti-ARNT antibodies. The presence of Spry2 
coimmunoprecipitating with ARNT was monitored using Western blotting. The blot is 
representative of 2 experiments. 
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pVHL/associated E3 ligase is capable of degrading HIFα, the other half of the HIF 
heterodimer, we began by investigating whether pVHL and associated E3 ubiquitin ligase 
was involved in the ability of Spry2 to degrade ARNT. For this purpose in HuH7 cells 
were transfected with control or Spry2 siRNAs along with control or one of two different 
pVHL siRNAs. Western blotting was used to monitor ARNT protein levels. In agreement 
with what was shown in Figure 17, silencing Spry2 elevated ARNT protein levels by 2-
fold (Fig. 21A). In the presence of two different siRNAs against pVHL, ARNT protein 
levels were still elevated 1.6- and 1.9- fold when Spry2 expression was silenced (Fig. 
21A). These data suggest that Spry2-mediated regulation of ARNT does not involve 
pVHL. To confirm that pVHL was not involved in Spry2-mediated regulation of ARNT, 
we utilized the 3P/3A-Spry2 mutant that does not bind pVHL described in Chapter III 
under “Spry2 exists in a complex with HIF1α and regulates HIF1α through a pVHL 
dependent mechanism” (page 82). HEK293T cells transfected with vector, WT-Spry2 or 
3P/3A-Spry2 were placed in hypoxia and ARNT protein levels were monitored. The 
expression of either WT-Spry2 or 3P/3A-Spry2 resulted in about a 40% reduction in 
ARNT protein levels demonstrating that whether or not Spry2 was able to associate with 
pVHL did not alter the ability of Spry2 to regulate ARNT protein levels (Figure 21B). 
Together these data (Fig. 21) eliminated pVHL as a candidate E3 ubiquitin ligase 
involved in Spry2-mediated regulation of ARNT. 
 Next, we investigated if c-Cbl was involved by transfecting HEK293T cells with 
control or Spry2 siRNAs along with a c-Cbl siRNA. The cells were incubated in both 
normoxia and hypoxia. Once again similar to what was shown in Figures 17A and 21A, 
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Figure 21: Spry2 does not regulate ARNT protein levels via pVHL. 
(A) HuH7 cells were transfected with control or Spry2 siRNAs along with control (-) or 
one of two pVHL siRNAs (1 or 4). The cells were incubated in hypoxia (3% O2) and the 
levels of ARNT, Spry2, pVHL, and Actin (loading) were monitored using Western blot 
analyses. Graph to the right shows the densitometric analysis of ARNT normalized to 
Actin from 4 independent experiments. (B) HEK293T cells transfected with empty vector 
or vector constructs WT-Spry2 or 3P/3A-Spry2 were placed in hypoxia. The levels of 
ARNT, HA-Spry2, and Actin (loading) were monitored using Western blotting. Graph to 
the right is the densitometric analysis of ARNT normalized to Actin for 4 independent 
experiments. Statistical significance was assessed using a one-way ANOVA. (A) & (B) 
These are the same samples as in Figure 14 in the HIF chapter. 
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normoxia and hypoxia (Fig. 22). Intriguingly, when c-Cbl was silenced, ARNT protein 
levels were decreased and Spry2 silencing elevated ARNT protein levels even further by 
almost 3-fold in both normoxia and hypoxia (Fig. 22). These data suggest that c-Cbl is 
not involved in the ability of Spry2 to regulate ARNT protein levels. 
Spry2 enhances the degradation of ARNT in a Nedd4-1 dependent manner. 
Next, we investigated whether the HECT-domain containing E3 ubiquitin ligase 
Nedd4-1 that associates with Spry2 is involved in the regulation of ARNT protein levels 
(103). HuH7 cells were transfected with control and Spry2 siRNAs along with control 
and Nedd4-1 siRNAs and then incubated in normoxia and hypoxia. Consistent with what 
was shown before, silencing of Spry2 expression elevated ARNT protein levels by 2-fold 
(Fig. 23A). Interestingly, silencing of Nedd4-1 expression alone, in both normoxia and 
hypoxia, also elevated ARNT protein levels by 50% (Fig. 23A). Importantly, the 
silencing of Spry2 expression in the presence of a siRNA against Nedd4-1 only elevated 
ARNT protein levels 40%, a difference that is not significant when compared to the 
silencing of Spry2 alone (Fig. 23A). This residual (40%) increase may be attributed to the 
fact that the expression of Nedd4-1 was not completely silenced as monitored by Western 
analyses (Figs. 23A). These data suggest that Nedd4-1, which associates with Spry2, is 
the E3 ubiquitin ligase that regulates ARNT ubiquitylation and proteosomal degradation. 
 As stated earlier, ARNT heterodimerizes with AhR. AhR is a cytosolic protein 
that upon binding to its ligand translocates into the nucleus and dimerizes with ARNT to 
regulate the transcription of metabolic genes. One known ligand for AhR is β-
naphthoflavone (BNF). Therefore, we investigated whether Spry2 and Nedd4-1 could  
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Figure 22: ARNT protein levels are not regulated by c-Cbl.  
HEK293T cells transfected with control or Spry2 siRNAs along with control or c-Cbl 
siRNAs were incubated in normoxia or hypoxia (3% O2). The protein levels of ARNT, 
c-Cbl, Spry2, and Actin (loading) were monitored by Western blotting. Graphs below 
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Figure 23:  Spry2 regulates ARNT protein levels via Nedd4-1.  
(A) HuH7 cells transfected with control or Spry2 siRNAs along with control or Nedd4-
1 siRNAs were incubated in normoxia or hypoxia for 24 hours. The levels of ARNT, 
Spry2, Nedd4-1, and Tubulin (loading) were monitored using Western blotting. Graphs 
below show the mean ± SEM of the densitometric analysis of ARNT normalized to the 
average of tubulin for 3 (Nor) or 2 (Hyp) independent experiments. (B) HuH7 cells 
transfected as in (A) were treated with vehicle (DMSO) or BNF (5 µM) for 16 hours. 
The levels of ARNT, Spry2, Nedd4-1, Actin (loading), Tubulin (loading), and ERK1/2 
(loading) were monitored using Western blotting. Graphs below show the mean ± 
variance of the densitometric analysis of ARNT normalized to the average of three 
loading controls for 2 independent experiments. 
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regulate ARNT protein levels after 16 hours of treatment with the AhR ligand, BNF. 
HuH7 cells were transfected as described for Figure 23A, and the next day the cells were 
treated with DMSO vehicle or 5 µM BNF. In vehicle treated cells, as described above for 
Figure 23A, ARNT protein levels were elevated upon silencing of Spry2 and/or Nedd4-1 
(Fig. 23B). As in Figure 23A, when Nedd4-1 expression was silenced the increase in 
ARNT levels with Spry2 silencing was attenuated (Fig 23B). In BNF-treated cells, the 
changes in ARNT levels were in the same direction as those in vehicle treated control 
cells, but the effects were dampened (Fig. 23B). Notably, these experiments were 
performed with a single, high concentration of BNF and experiments with either lower 
concentrations of BNF or a shorter treatment time would be necessary to more 
definitively determine whether Spry2 silencing influences ARNT protein levels in the 
presence of a ligand of AhR.  
Spry2 silencing enhanced the mRNA levels of the ARNT regulated gene CYP1A1 
 As previously stated, ARNT via dimerization with a ligand bound AhR can 
regulate the transcription of metabolic enzymes such as CYP450’s. To determine if Spry2 
affected the function of ARNT, the mRNA levels of the AhR/ARNT regulated gene 
CYP1A1 were monitored. Previous research has indicated there is competition between 
AhR and HIFα for ARNT as a dimerization partner in hypoxia (301-308). Therefore, we 
monitored CYP1A1 mRNA levels in hypoxia without BNF treatment. HuH7 cells 
transfected with control, Spry2 or ARNT siRNAs were incubated in hypoxia for 8 hours, 
mRNA was isolated, converted to cDNA and the relative amount of CYP1A1 mRNA was 
monitored by qRT-PCR. Consistent with our observations that Spry2 silencing enhanced 
ARNT protein levels, when Spry2 was silenced CYP1A1 mRNA was also elevated 1.5-
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fold and silencing ARNT along with Spry2 markedly reduced CYP1A1 mRNA levels 
(Fig. 24A). As indicated earlier, ARNT mRNA levels were also elevated 1.4-fold by 
Spry2 silencing in hypoxia (Fig. 24A). Nevertheless, CYP1A1 mRNA is elevated upon 
silencing of Spry2 whether it is due to an increase in ARNT protein or mRNA levels. 
 To determine if Spry2 was capable of altering CYP1A1 levels when AhR was 
activated by a ligand, BNF, HuH7 cells transfected with control siRNA or siRNA against 
Spry2 were then treated with vehicle (DMSO) or BNF (5 µM) for 16 hours. In order to 
determine the role of ARNT in changes in CYP1A1 levels, ARNT expression was also 
silenced with or without simultaneous silencing of Spry2 in the presence of BNF. In 
vehicle treated cells, Spry2 silencing elevated CYP1A1 mRNA 1.7-fold (Fig. 24B). 
Treatment with BNF elevated CYP1A1 mRNA levels more than 15-fold and Spry2 
silencing increased CYP1A1 mRNA levels even further to 21-fold over control (Fig. 
24B). ARNT silencing greatly reduced CYP1A1 mRNA levels indicating that the 
elevations in CYP1A1 mRNA levels with BNF treatment are due to ARNT. Moreover, 
the finding that silencing of ARNT attenuated changes in CYP1A1 upon silencing of 
Spry2 expression demonstrate that the Spry2 siRNA mediated changes in CYP1A1 are 



































































































Figure 24: Spry2 silencing results in elevation of the ARNT-regulated gene 
CYP1A1. 
(A) HuH7 cells transfected with control, Spry2 or Spry2 and ARNT siRNAs were placed 
in hypoxia (3% O2) for 8 hours. (B) HuH7 cells transfected with control or Spry2 siRNAs 
along with control or ARNT siRNAs were treated with vehicle (DMSO) or BNF (5 µM). 
RNA was isolated, converted to cDNA and the mRNA levels were monitored by qRT-
PCR. The relative amount of each gene was calculated as described in the Experimental 
Procedures in Chapter III. (A) Graph shows mean ± SEM for 3-5 independent 





 Endogenous Spry2 is capable of decreasing ARNT protein levels in both 
normoxia and hypoxia (Fig. 17) indicating the mechanism of Spry2-mediated degradation 
is not hypoxia or HIF dependent. Intriguingly, ARNT protein levels were actually slightly 
reduced in hypoxia contradicting previous studies that have shown ARNT levels are 
elevated in some cell lines (28,323-326). Spry2 regulation of ARNT also seemed to be 
cell type specific since elevation in ARNT protein levels with Spry2 silencing was 
observed in hepatoma cells HuH7 and Hep3B, a lung cancer cell line A549 and 
HEK293T cells, but not in two breast cancer cell lines MCF7 and MD-MBA-231 (Fig. 
17B, 17C, & 18). Currently, there is no obvious reason for this cell specific regulation 
and could be the focus of future studies. 
 The experiments in this study delineated a novel mechanism whereby Spry2 
enhanced the proteosomal degradation of ARNT via a Nedd4-1 dependent mechanism. 
First, the protein stability of ARNT was enhanced by Spry2 silencing demonstrated by 
the doubling of the half-life of ARNT (Fig. 19A). Furthermore, the pretreatment with 
proteosomal inhibitor MG132 prevented this Spry2-mediated enhanced degradation of 
ARNT suggesting Spry2 was enhancing the proteosomal degradation of ARNT (Fig. 
19B). Importantly, Spry2 and ARNT exist in a complex (Fig. 20). Finally, the silencing 
of Nedd4-1, but not pVHL or c-Cbl, not only enhanced ARNT protein levels, but also 
attenuated the increase in ARNT protein levels with Spry2 silencing (Figs. 21, 22, & 23). 
This regulation was observed in both normoxia and hypoxia (Fig. 23A). The fact that 
Spry2 can regulate ARNT in both normoxia and hypoxia has more broad implications for 
all of the dimerization partners for ARNT including HIF, AhR, SIM, and ER.  
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Since ARNT can dimerize with AhR to regulate the expression of xenobiotic 
metabolism genes, we also investigated if Nedd4-1 and Spry2 could regulate ARNT 
protein levels under conditions when AhR is activated by one of its ligands, BNF. With 5 
µM BNF treatment for 16 hours, the changes in ARNT protein levels with Nedd4-1 
silencing were diminished (Fig. 23B). Perhaps treating cells with such a high 
concentration of BNF for 16 hours caused signaling pathways to be disrupted. One 
publication found the half maximal effective concentration (EC50) of BNF for AhR to be 
1.4 µM meaning our treatment is 3.5 times the EC50 (368). Repeating this experiments 
with a lower, more physiological relevant concentration of BNF may provide similar 
results to those observed with normoxia, hypoxia and DMSO treatment. 
While no report to date has identified Nedd4-1 as an ubiquitin ligase for ARNT, 
one publication showed that curcumin enhances the ubiquitylation and proteosomal 
degradation of ARNT via a reactive oxygen species dependent mechanism (328,365). 
Interestingly, one study found that treatment of mice with curcumin increased Nedd4 
expression in the kidneys (369), while another study found that Nedd4-1 is upregulated 
by oxidative stress in neuronal tissues (370). It is tempting to speculate that curcumin 
perhaps via oxidative stress upregulates Nedd4-1 and enhances the degradation of ARNT. 
Nevertheless, future studies should be aimed at examining whether Nedd4-1 can 
ubiquitylate ARNT. 
ARNT functions as the dimerization partner for HIF1α to regulate hypoxic gene 
induction (27) and AhR to regulate induction of genes that regulate xenobiotic 
metabolism (40). Since in Chapter 3 we already investigated the regulation of 
ARNT/HIF1α dimer actions on HIF- target genes, we focused on the AhR/ARNT dimer 
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and transcription of its target genes. AhR/ARNT dimers have a xenobiotic-dependent role 
in promoting the transcription of the phase I and phase II metabolic enzymes and 
xenobiotic-independent roles in perinatal growth, fertility, hepatic and vascular 
development, and hematopoiesis (296,371-375). To activate xenobiotic-induced 
transcription of metabolic enzymes, xenobiotic ligands, which can be environmental 
pollutants, such as BNF, dioxin, or polyaromatic hydrocarbons, bind to AhR causing it to 
translocate into the nucleus where AhR binds to ARNT (47-51) (see schematic Fig. 8). 
One group of metabolic enzymes Ahr/ARNT dimers induce the transcription of is 
cytochrome P450 CYP1 comprising of CYP1A1, CYP1B1, and CYP1A2 (282-287). 
These CYP1 enzymes metabolize the ligands into active compounds that have been 
shown to form DNA adducts and have toxic and carcinogenic effects (376).  
We investigated if the elevation in ARNT protein levels with Spry2 silencing 
would result in the elevation of ARNT/AhR dependent gene CYP1A1, a phase I 
metabolic enzyme. Indeed, in hypoxia the silencing of Spry2 resulted in an elevation in 
CYP1A1 levels (Fig. 24A). It is interesting that in hypoxia, without AhR activation by a 
ligand, changes in ARNT protein levels are reflected in changes in the genes ARNT 
regulates. There has been a somewhat controversial speculation that in hypoxia there is a 
competition for ARNT by HIF1α, HIF2α and AhR (301-308). If ARNT is limiting, then 
when Spry2 is silenced the increase in ARNT protein levels allows for more subunits of 
ARNT to be bound to AhR and regulate metabolic enzyme transcription.  
As stated previously, many environmental pollutants we encounter every day 
induce the transcription of CYP1A1 by acting as ligands for AhR, therefore we 
investigated if Spry2 could alter the mRNA levels of CYP1A1 when AhR was activated 
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by BNF, an AhR ligand. In normoxic, DMSO treated cells silencing Spry2 elevated 
CYP1A1 levels by 70% (Fig. 24B), which is in agreement with the 66% induction of 
ARNT protein levels we observed under the same conditions in Figure 20B (left panel). 
As expected, treatment with BNF greatly elevated CYP1A1 mRNA levels more than 15-
fold and silencing Spry2 elevated them even further suggesting that Spry2 is able to 
regulate ARNT protein levels under BNF treatment (Fig. 24B). However, it would still be 
prudent to repeat this experiments with lower BNF concentrations as discussed above. 
Nevertheless, the fact that Spry2 silencing increases CYP1A1 mRNA levels even in the 
absence of ligand for AhR, suggests that Spry2 expression would reduce CYP1A1 
enzyme levels, thereby reducing the activation of pollutants and their toxic effects.  
It is also important to note the mRNA levels of genes regulated by the other 
dimerization partners for ARNT, such as SIM (43,44) and ER (41,42), may be altered by 
Spry2 decreasing ARNT protein levels. In fact, the role of ARNT in ER signaling has 
been well studied. First, there is ligand-dependent reciprocal inhibition of ER and AhR 
transcriptional activities meaning estrogen inhibits AhR dependent genes and vice versa 
(377-379). Second, AhR and ARNT have been implicated as part of an E3-ubiquitin 
ligase complex that targets ER for proteosomal degradation (380). Third, ARNT and ER 
have been shown to interact (41,377). Therefore, future studies could investigate the 
impact Spry2 has on ER signaling especially with respect to the ability of Spry2 to 
regulate ARNT. 
While the main focus of this study was on the post-translational regulation of 
ARNT by Spry2, a significant increase in ARNT mRNA with Spry2 silencing was 
observed (Fig. 24A & 24B, right panels). Future research into how this regulation is 
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occurring is needed, but this does not take away from the fact that Spry2 is regulating the 
protein levels of ARNT as well. By treating cells with CHX, as shown in Figure 19, the 
differences in transcriptional regulation of ARNT are eliminated and the half-life of 
ARNT was enhanced by Spry2 silencing. 
In conclusion, Spry2 via a Nedd4-1 dependent mechanism enhances the 
proteosomal degradation of ARNT. We propose that by interacting with ARNT and 
Nedd4-1, Spry2 brings more Nedd4-1 in proximity to ARNT enhancing the degradation 
of ARNT. The elevation in ARNT protein levels with Spry2 silencing are also reflected 
in the elevation of the ARNT/AhR regulated gene CYP1A1.  
To expand upon the translational impact of the mechanism unveiled in this 
dissertation, when Spry2 is lost in certain forms of cancer (14-21), ARNT protein levels 
would be elevated. This, together with the concomitant increase in HIFα protein levels 
(Chapter 3), would result in an increase in ARNT/AhR and ARNT/HIFα gene 
transcription, which has been shown to be tumor promoting (22,38,39,279,280,366,367). 
The ability of Spry2 to decrease ARNT protein levels would provide an additional way 
by which Spry2 functions as a tumor suppressor, aside from inhibiting RTK signaling. 
Additionally, since we are constantly encountering AhR ligands in the form of 
environmental pollutants or endogenous ligands, such as the tryptophan derivative 6-
formylindolo[3,2-b]carbazole (FICZ), it is possible that the loss of Spry2 elevating 
ARNT protein levels allows for the ligand activated AhR to induce the transcription of 
more CYP1 enzymes, resulting in a tumor initiating process. Previous research has shown 
the induction of CYP1 enzymes, as would occur with loss of Spry2, causes an increase in 
the metabolism of compounds into the active form, therefore promoting the formation of 
137 
 
DNA adducts and cancer formation (376). Furthermore, recently AhR has been shown to 
promote cancer stem cell formation (reviewed in (381)). To conclude, future studies 
should determine if ARNT levels are increased when Spry2 is lost in cancer and if this is 






OVERALL CONCLUSIONS AND FUTURE DIRECTIONS  
The studies in this dissertation have identified a new mode of action for Spry2 in 
the regulation of proteins and their biological actions. Specifically, Spry2 enhances the 
ubiquitylation and degradation of proteins by associating with both the target protein and 
the E3 ubiquitin ligase that ubiquitylates the target protein. Although Spry2 has been 
demonstrated to be a regulator of different biological processes such as cell proliferation, 
migration and apoptosis (reviewed in (101,382)), the concept that Spry2 can regulate the 
stability of proteins by forming a complex of the substrate and E3 ligase via its 
scaffolding properties has previously neither been examined nor reported. Thus, the 
findings presented in this dissertation are not only novel, but establish a new paradigm by 
which Spry2 exerts its actions on regulating biological processes ranging from glucose 
uptake to expression of CYP1A1 that regulates xenobiotic metabolism. Herein, we 
demonstrate that among the four E3 ubiquitin ligases that Spry2 has been shown to 
associate with, pVHL/associated E3 ligase regulates the stability of HIF1α whereas 
Nedd4-1 regulates the stability of the HIF1α/HIF2α dimerization partner ARNT (a.k.a. 
HIF1β) as shown in the proposed model (Fig. 25). Notably, these two ubiquitin E3 
ligases that we have identified in the regulation of HIF1a and ARNT were discovered in 





Figure 25: Schematic of Proposed Mechanisms of Regulation of HIF1α and ARNT 
by Spry2. 
The studies from this dissertation demonstrate that Spry2 enhances the proteosomal 
degradation of HIF1α by increasing the amount of pVHL in proximity of HIF1α. 
Additionally, our studies show that Spry2 regulates ARNT in a Nedd4-1-dependent 
manner. Therefore, we propose the following mechanisms to suggest how Spry2 is 
interacting with HIF1α/pVHL and ARNT/Nedd4-1 whereby Spry2 acts as a scaffold and 
substrate recognition component for the ubiquitin ligases. 
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bases for the actions of Spry2 on two key proteins that regulate not only changes in gene 
expression related to hypoxia but also xenobiotic metabolism genes. 
The mechanism in Figure 25 represents possible complexes that would result 
from Spry2 scaffolding the relevant ubiquitin ligases and ARNT or HIF1α. However, 
there are alternatives to the proposed mechanism. For instance, Spry2 and HIF1a or 
ARNT may not directly associate with Spry2 and there could be intermediary proteins 
that form the complex. Nevertheless, our data, especially with the proximity ligation 
assay that demonstrates that HIF1a and Spry2 are co-localized in a complex, along with 
the data presented with forms of Spry2 that do not associate with the E3 ligases serve as 
compelling argument for the model we propose. Although, we have not deduced the 
stoichiometry of the interactions between Spry2 and ARNT, it should be noted that Spry2 
has been suggested to undergo oligomerization (170). Therefore, it is possible that there 
are multiple Spry2 protein molecules that are bound to both the ubiquitin ligase and 
HIF1α or ARNT in the complex. Currently, the determination of stoichiometry of 
associations is not possible since we do not know the number of Spry2 molecules that 
form the purported oligomers in-vivo. Not withstanding a knowledge of the stoichiometry 
of interactions, our work has determined that Spry2 enhances the degradation of HIF1α 
and ARNT in a pVHL and Nedd4-1 –dependent manner, respectively. 
The studies in my dissertation showing that Spry2 enhances the degradation of 
two proteins via two different ubiquitin ligases incites an intriguing idea that Spry2 is 
perhaps functioning as a component in ubiquitin ligase complexes. The covalent 
attachment of ubiquitin to proteins is a highly conserved mechanism that is tightly 
regulated due to the fact that ubiquitylation has been shown to alter the stability, 
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localization and function of proteins (reviewed in (383)). Since Spry2 clearly lacks any of 
the canonical domains associated with being an ubiquitin ligase, we would postulate 
Spry2 is acting a scaffold and/or substrate recognition component for ubiquitin ligases. 
Previous research has shown that proteins aid in the ubiquitylation process without being 
ubiquitin ligases. In fact, this has been shown for ARNT/AhR whereby ARNT/AhR act 
as a scaffold and substrate recognition component for E3 ubiquitin complexes that targets 
ERα, ERβ, androgen receptor, β-catenin and AhR itself (380,384). Thus, future research 
should investigate if Spry2 alters the ability of the four ubiquitin ligases Spry2 is known 
to associate with to target other proteins or if the enzyme kinetics for these ubiquitin 
ligases are altered by Spry2.  
Spry2, by decreasing the protein levels of ARNT and HIF1α by a mechanism that 
includes scaffolding of ubiquitin ligases that target HIF1α or ARNT for ubiquitylation 
and proteosomal degradation implicates Spry2 as a regulator of two novel biological 
processes. First, the negative regulation by Spry2 of HIF1a protein levels, and, therefore 
of processes such as glucose uptake as well as, the reduced expression of glycolytic 
enzyme genes reported herein, for the first time demonstrates a role of Spry2 in 
regulating intermediary metabolism, which is of notable relevance since glucose uptake 
and glycolysis are upregulated in tumors and Spry2 has been denoted as a “tumor 
suppressor”. Thus, some of the tumor suppressing functions of Spry2 may be due to these 
newly unraveled actions of Spry2. The regulation of glucose uptake by Spry2 is also of 
relevance in diabetes since previous research has shown that glycolysis is elevated in the 
liver of mice with type 2 diabetes and Chinese and Japanese populations with genetic 
variants of Spry2 are susceptible to type 2 diabetes (385-387). 
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Given the previous research and data in this dissertation, in the future it would be 
intriguing to monitor the real time glycolytic profile of the different cell types with and 
without Spry2 in normoxia and hypoxia. This could be achieved using Seahorse XF 
technology. These studies would provide deeper insights into the role of Spry2 in normal 
cell metabolism, as well as, in pathologies such as cancer and type 2 diabetes. 
Consequently, future studies should investigate how the mechanisms described in this 
dissertation involving Spry2 altering glycolysis are involved in type 2 diabetes and 
cancer. 
Second, Spry2 has been implicated as a regulator of xenobiotic metabolism due to 
the fact that Spry2 via decreasing ARNT protein levels would reduce the levels and 
activity of the drug metabolism enzymes such as CYP1A1, 1A2, and 1B1 (282,287,388). 
This provides yet another mechanism by which Spry2 acts as a tumor suppressor since 
the CYP1 enzymes have been shown to generate carcinogens by metabolizing various 
substances into active carcinogens thereby promoting tumor formation (373). Hence, 
future studies should investigate if mice with liver specific Spry2 knock out are more 
susceptible to tumor formation when exposed to carcinogens such as dioxin. 
Further focusing on the impact of Spry2 in cancer, studies investigating the effect 
of loss of Spry2 in different cancers via generation of conditional organ specific Spry2 
knockout mice would be beneficial to determine all pathways Spry2 impacts in cancer. 
For example, while excellent studies have been performed investigating the role a 
dominant negative Spry2Y55F hydrodynamically injected into the livers of mice had on 
HCC formation and progression, future studies should be aimed at investigating the effect 
of complete Spry2 knockout in the liver of mice and the impact on HCC tumor formation 
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(17,18,156). Moreover, HIF1α transcriptional activity in these tumors could then be 
monitored using bioluminescent imaging and a hydrodynamic injection of a luciferase 
construct that is transcriptionally regulated by HREs. Such experiments would further 
validate the findings in this dissertation in an in vivo model. To investigate a more global 
impact of the loss of Spry2, high throughput techniques such as RNA sequencing could 
be employed in conjunction with proteomic data in normal and tumor derived cells with 
and without Spry2 silencing, to then superimpose these data on established signaling 
networks to identify the signaling nodes that Spry2 regulates since these nodes can be 
targets for drugs. This would be a three dimensional approach of systems pharmacology 
and involve computational modeling and bioinformatics expertise.  
Another fairly novel finding from the studies in this dissertation is that the 
proximity ligation assays and immunocytochemistry studies demonstrated that Spry2 
exists in the nucleus in HuH7 cells. Spry2 localization in the nucleus has also been shown 
in cardiomyocytes and neurons, but not in other cell types suggesting Spry2 localizing to 
the nucleus may be cell type dependent (104,149). Future studies should focus on the 
mechanism by which Spry2 enters the nucleus and what the function of Spry2 is in the 
nucleus. By Spry2 being localized to the nucleus, it would suggest that Spry2 would be 
able to regulate a new population of nuclear proteins such as transcription factors or act 
as a co-activator or repressor. This is a totally uncharted area of research. 
As described previously, the regulation of ARNT and HIF1α by Spry2 would 
have implications in tumorigenesis since the loss of Spry2 expression, as it has been 
shown for specific cancers, would, in theory, result in higher HIF1α and ARNT proteins 
levels which would promote tumor growth and survival. However, there are other 
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processes and pathologies in which this mechanism of Spry2-mediated regulation of 
HIF1α and ARNT may also play a role in pathologies such as in ischemic stroke. Very 
recently, a publication showed that Spry2 and Spry4 silencing has a neuroprotective 
effect by stimulating astrogliosis therefore reducing ischemic brain injury (389). With my 
dissertation work in mind, it is possible another way Spry2 silencing is having a 
neuroprotective affect is via upregulation of HIF1 and transcription of HIF1 target genes 
which has previously been shown to possibly have a neuroprotective effect in ischemic 
stroke (reviewed in (390)). It is of note that it is controversial whether HIF1 has a 
beneficial or detrimental affect in ischemic stroke (390). In addition, it would be 
interesting to see if Spry2-mediated regulation of HIF1 occurred in other non-cancerous 
cells. For instance, in T cells where recently Spry2 levels were shown to be elevated in 
HIV-specific T cells resulting in decreased T cell polyfunctionality (391). Since the 
mouse isoform of HIF1 has been shown to be upregulated in T cells and the impact HIF1 
has in HIV has not been well studied, it would be interesting to see if HIF1 plays a role in 
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